OHI Healthcare Properties Limited Partnership 10-Q3 Nov 202020 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Oct. 28, 2020
Document And Entity Information [Line Items]
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Entity Registrant Name	OMEGA HEALTHCARE INVESTORS, INC.
Entity Central Index Key	0000888491
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	MD
Entity File Number	1-11316
Entity Tax Identification Number	38-3041398
Entity Common Stock Shares Outstanding		227,003,999
Amendment Flag	false
Document Fiscal Period Focus	Q3
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Address, Address Line One	303 International Circle, Suite 200
Entity Address, City or Town	Hunt Valley
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21030
City Area Code	410
Local Phone Number	427-1700
Title of 12(b) Security	Common Stock
Trading Symbol	OHI
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Omega OP
Document And Entity Information [Line Items]
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Entity Registrant Name	OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP
Entity Central Index Key	0001639315
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity File Number	333-203447-11
Entity Tax Identification Number	36-4796206
Amendment Flag	false
Document Fiscal Period Focus	Q3
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Address, Address Line One	303 International Circle, Suite 200
Entity Address, City or Town	Hunt Valley
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21030
City Area Code	410
Local Phone Number	427-1700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Real estate properties
Real estate investments	$ 8,779,962	$ 8,985,994
Less accumulated depreciation	(1,974,038)	(1,787,425)
Real estate investments - net	6,805,924	7,198,569
Investments in direct financing leases - net	10,858	11,488
Mortgage notes receivable - net	892,539	773,563
Total	7,709,321	7,983,620
Other investments - net	464,503	419,228
Investments in unconsolidated joint ventures	196,214	199,884
Assets held for sale - net	35,921	4,922
Total investments	8,405,959	8,607,654
Cash and cash equivalents	35,951	24,117
Restricted cash	4,164	9,263
Contractual receivables - net	10,757	27,122
Other receivables and lease inducements	226,413	381,091
Goodwill	644,084	644,415
Other assets	71,261	102,462
Total assets	9,398,589	9,796,124
LIABILITIES AND EQUITY
Revolving line of credit	170,667	125,000
Term loans - net	802,334	804,738
Secured borrowings	371,351	389,680
Senior notes and other unsecured borrowings - net	3,828,609	3,816,722
Accrued expenses and other liabilities	277,596	312,040
Deferred income taxes	9,618	11,350
Total liabilities	5,460,175	5,459,530
Equity:
Common stock $.10 par value authorized - 350,000 shares, issued and outstanding - 226,980 shares as of September 30, 2020 and 226,631 as of December 31, 2019	22,698	22,663
Common stock - additional paid-in capital	6,001,092	5,992,733
Cumulative net earnings	2,533,339	2,463,436
Cumulative dividends paid	(4,763,468)	(4,303,546)
Accumulated other comprehensive loss	(49,101)	(39,858)
Total stockholders' equity	3,744,560	4,135,428
Noncontrolling interest	193,854	201,166
Total equity	3,938,414	4,336,594
Owners' Equity:
Total liabilities and equity	9,398,589	9,796,124
Omega OP
Real estate properties
Real estate investments	8,779,962	8,985,994
Less accumulated depreciation	(1,974,038)	(1,787,425)
Real estate investments - net	6,805,924	7,198,569
Investments in direct financing leases - net	10,858	11,488
Mortgage notes receivable - net	892,539	773,563
Total	7,709,321	7,983,620
Other investments - net	464,503	419,228
Investments in unconsolidated joint ventures	196,214	199,884
Assets held for sale - net	35,921	4,922
Total investments	8,405,959	8,607,654
Cash and cash equivalents	35,951	24,117
Restricted cash	4,164	9,263
Contractual receivables - net	10,757	27,122
Other receivables and lease inducements	226,413	381,091
Goodwill	644,084	644,415
Other assets	71,261	102,462
Total assets	9,398,589	9,796,124
LIABILITIES AND EQUITY
Term loans - net	74,837	74,763
Secured borrowings	371,351	389,680
Accrued expenses and other liabilities	219,958	245,406
Deferred income taxes	9,618	11,350
Intercompany loans payable	4,784,411	4,738,331
Total liabilities	5,460,175	5,459,530
Owners' Equity:
General partners' equity	3,744,560	4,135,428
Limited partners' equity	193,647	200,950
Total owners' equity	3,938,207	4,336,378
Noncontrolling interest	207	216
Total equity	3,938,414	4,336,594
Total liabilities and equity	$ 9,398,589	$ 9,796,124

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares shares in Thousands	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized	350,000	350,000
Common stock, shares issued	226,980	226,631
Common stock, shares outstanding	226,980	226,631

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue
Rental income	$ 83,226	$ 202,470	$ 526,258	$ 589,464
Income from direct financing leases	258	258	775	777
Mortgage interest income	24,013	19,796	65,378	56,762
Other investment income	11,286	9,989	32,870	33,036
Miscellaneous income	394	682	3,315	2,123
Total operating revenues	119,177	233,195	628,596	682,162
Expenses
Depreciation and amortization	81,072	76,696	247,301	221,185
General and administrative	14,812	13,762	44,704	43,770
Real estate taxes	2,127	3,921	9,448	11,833
Acquisition and merger related costs	36	887	62	5,072
Impairment on real estate properties	28,105	3,836	43,732	9,545
(Recovery) impairment on direct financing leases	(324)		(1,076)	7,700
Provision for credit losses	32,076		33,577
Total operating expenses	157,904	99,102	377,748	299,105
Other operating (loss) income
(Loss) gain on assets sold - net	(749)	53,067	13,932	52,803
Operating (loss) income	(39,476)	187,160	264,780	435,860
Other income (expense)
Interest income and other - net	(82)	(25)	(675)	121
Interest expense	(51,800)	(49,878)	(157,332)	(146,358)
Interest - amortization of deferred financing costs	(2,462)	(2,277)	(7,384)	(6,753)
Interest - refinancing costs	(896)		(896)
Realized gain (loss) on foreign exchange	19	23	(50)	(146)
Total other expense	(55,221)	(52,157)	(166,337)	(153,136)
(Loss) income before income tax expense and income from unconsolidated joint ventures	(94,697)	135,003	98,443	282,724
Income tax expense	(763)	(483)	(2,626)	(1,951)
Income from unconsolidated joint ventures	1,692	8,428	4,654	10,028
Net (loss) income	(93,768)	142,948	100,471	290,801
Net loss (income) attributable to noncontrolling interest	2,477	(4,208)	(2,540)	(9,218)
Net (loss) income available to common stockholders/owners	$ (91,291)	$ 138,740	$ 97,931	$ 281,583
Basic:
Net (loss) income available to common stockholders	$ (0.40)	$ 0.64	$ 0.43	$ 1.33
Diluted:
Net (loss) income	$ (0.40)	$ 0.63	$ 0.43	$ 1.32
Omega OP
Revenue
Rental income	$ 83,226	$ 202,470	$ 526,258	$ 589,464
Income from direct financing leases	258	258	775	777
Mortgage interest income	24,013	19,796	65,378	56,762
Other investment income	11,286	9,989	32,870	33,036
Miscellaneous income	394	682	3,315	2,123
Total operating revenues	119,177	233,195	628,596	682,162
Expenses
Depreciation and amortization	81,072	76,696	247,301	221,185
General and administrative	14,812	13,762	44,704	43,770
Real estate taxes	2,127	3,921	9,448	11,833
Acquisition and merger related costs	36	887	62	5,072
Impairment on real estate properties	28,105	3,836	43,732	9,545
(Recovery) impairment on direct financing leases	(324)		(1,076)	7,700
Provision for credit losses	32,076		33,577
Total operating expenses	157,904	99,102	377,748	299,105
Other operating (loss) income
(Loss) gain on assets sold - net	(749)	53,067	13,932	52,803
Operating (loss) income	(39,476)	187,160	264,780	435,860
Other income (expense)
Interest income and other - net	(82)	(25)	(675)	121
Interest expense	(51,800)	(49,878)	(157,332)	(146,358)
Interest - amortization of deferred financing costs	(2,462)	(2,277)	(7,384)	(6,753)
Interest - refinancing costs	(896)		(896)
Realized gain (loss) on foreign exchange	19	23	(50)	(146)
Total other expense	(55,221)	(52,157)	(166,337)	(153,136)
(Loss) income before income tax expense and income from unconsolidated joint ventures	(94,697)	135,003	98,443	282,724
Income tax expense	(763)	(483)	(2,626)	(1,951)
Income from unconsolidated joint ventures	1,692	8,428	4,654	10,028
Net (loss) income	(93,768)	142,948	100,471	290,801
Net loss (income) attributable to noncontrolling interest	3	9	9	9
Net (loss) income available to common stockholders/owners	$ (93,765)	$ 142,957	$ 100,480	$ 290,810
Net income available to Omega OP Unit holders:
Net (loss) income available to owners'	$ (0.40)	$ 0.64	$ 0.43	$ 1.33
Diluted:
Net (loss) income	$ (0.40)	$ 0.63	$ 0.43	$ 1.32

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net (loss) income	$ (93,768)	$ 142,948	$ 100,471	$ 290,801
Other comprehensive income (loss):
Foreign currency translation	11,874	(7,952)	(7,869)	(9,243)
Cash flow hedges	5,723	169	(1,608)	(7,918)
Total other comprehensive income (loss)	17,597	(7,783)	(9,477)	(17,161)
Comprehensive (loss) income	(76,171)	135,165	90,994	273,640
Comprehensive loss (income) attributable to noncontrolling interest	2,014	(3,978)	(2,306)	(8,677)
Comprehensive (loss) income attributable to common stockholders	(74,157)	131,187	88,688	264,963
Omega OP
Net (loss) income	(93,768)	142,948	100,471	290,801
Other comprehensive income (loss):
Foreign currency translation	11,874	(7,952)	(7,869)	(9,243)
Cash flow hedges	5,723	169	(1,608)	(7,918)
Total other comprehensive income (loss)	17,597	(7,783)	(9,477)	(17,161)
Comprehensive (loss) income	(76,171)	135,165	90,994	273,640
Comprehensive loss (income) attributable to noncontrolling interest	3	9	9	9
Comprehensive (loss) income attributable to common stockholders	$ (76,168)	$ 135,174	$ 91,003	$ 273,649

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Omega OPTotal Stockholders' Equity [Member]	Omega OPAccumulated Other Comprehensive Loss	Omega OPNoncontrolling Interest	Omega OP	Total Stockholders' Equity [Member]Scenario, Previously Reported [Member]	Total Stockholders' Equity [Member]Restatement Adjustment [Member]	Total Stockholders' Equity [Member]	Common StockScenario, Previously Reported [Member]	Common StockRestatement Adjustment [Member]	Common Stock	Additional Paid-in CapitalScenario, Previously Reported [Member]	Additional Paid-in CapitalRestatement Adjustment [Member]	Additional Paid-in Capital	Cumulative Net EarningsScenario, Previously Reported [Member]	Cumulative Net EarningsRestatement Adjustment [Member]	Cumulative Net Earnings	Cumulative DividendsScenario, Previously Reported [Member]	Cumulative DividendsRestatement Adjustment [Member]	Cumulative Dividends	Accumulated Other Comprehensive LossScenario, Previously Reported [Member]	Accumulated Other Comprehensive LossRestatement Adjustment [Member]	Accumulated Other Comprehensive Loss	Noncontrolling InterestScenario, Previously Reported [Member]	Noncontrolling InterestRestatement Adjustment [Member]	Noncontrolling Interest	Scenario, Previously Reported [Member]	Restatement Adjustment [Member]	Total
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Cumulative effect of accounting change (see Note 1)	$ (8,490)			$ (8,490)		$ (8,198)			$ 0			$ 0			$ (8,198)			$ 0			$ 0			$ (292)			$ (8,490)
Balance, beginning, adjusted							$ 3,436,243			$ 20,235			$ 5,074,544			$ 2,122,313			$ (3,739,197)			$ (41,652)			$ 319,751			$ 3,755,994
Beginning balance at Dec. 31, 2018					$ 3,444,441			$ 20,235			$ 5,074,544			$ 2,130,511			$ (3,739,197)			$ (41,652)			$ 320,043			$ 3,764,484
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Grant of restricted stock to company directors							0			2			(2)			0			0			0			0			0
Stock-based compensation expense							11,031			0			11,031			0			0			0			0			11,031
Vesting/exercising of equity compensation plan, net of tax withholdings							(3,610)			13			(3,623)			0			0			0			0			(3,610)
Dividend reinvestment plan and stock purchase plan							91,845			248			91,597			0			0			0			0			91,845
Deferred compensation directors							164			0			164			0			0			0			0			164
Equity Program							107,044			307			106,737			0			0			0			0			107,044
Issuance of common stock - merger-related							281,628			748			280,880			0			0			0			0			281,628
Common dividends declared							(417,416)			0			0			0			(417,416)			0			0			(417,416)
Vesting/exercising of Omega OP Units							(4,429)			0			(4,429)			0			0			0			4,429			0
Conversion and redemption of Omega OP Units to common stock							114,522			294			114,228			0			0			0			(114,522)			0
Omega OP Units distributions							0			0			0			0			0			0			(17,086)			(17,086)
Noncontrolling interest - consolidated joint venture			$ 228	228			0			0			0			0			0			0			228			228
Comprehensive income:
Foreign currency translation	(9,243)			(9,243)			(8,970)			0			0			0			0			(8,970)			(273)			(9,243)
Cash flow hedges	(7,918)			(7,918)			(7,650)			0			0			0			0			(7,650)			(268)			(7,918)
Net (loss) income	290,810		(9)	290,801			281,583			0			0			281,583			0			0			9,218			290,801
Total comprehensive income				273,640																								273,640
Balance , ending at Sep. 30, 2019		$ (60,801)					3,881,985			21,847			5,671,127			2,403,896			(4,156,613)			(58,272)			201,477			4,083,462
Beginning balance at Jun. 30, 2019					3,802,971			21,608			5,580,042			2,265,156			(4,013,116)			(50,719)			249,535			4,052,506
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Stock-based compensation expense							2,921			0			2,921			0			0			0			0			2,921
Vesting/exercising of equity compensation plan, net of tax withholdings							(653)			2			(655)			0			0			0			0			(653)
Dividend reinvestment plan and stock purchase plan							37,742			100			37,642			0			0			0			0			37,742
Deferred compensation directors							56			0			56			0			0			0			0			56
Equity Program							4,175			12			4,163			0			0			0			0			4,175
Common dividends declared							(143,497)			0			0			0			(143,497)			0			0			(143,497)
Vesting/exercising of Omega OP Units							(2,029)			0			(2,029)			0			0			0			2,029			0
Conversion and redemption of Omega OP Units to common stock							49,112			125			48,987			0			0			0			(49,112)			0
Omega OP Units distributions							0			0			0			0			0			0			(4,953)			(4,953)
Comprehensive income:
Foreign currency translation	(7,952)			(7,952)			(7,718)			0			0			0			0			(7,718)			(234)			(7,952)
Cash flow hedges	169			169			165			0			0			0			0			165			4			169
Net (loss) income	142,957		(9)	142,948			138,740			0			0			138,740			0			0			4,208			142,948
Total comprehensive income				135,165																								135,165
Balance , ending at Sep. 30, 2019		(60,801)					3,881,985			21,847			5,671,127			2,403,896			(4,156,613)			(58,272)			201,477			4,083,462
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Cumulative effect of accounting change (see Note 1)	(28,785)			(28,785)		$ (28,028)			$ 0			$ 0			$ (28,028)			$ 0			$ 0			$ (757)			$ (28,785)
Balance, beginning, adjusted							4,107,400			22,663			5,992,733			2,435,408			(4,303,546)			(39,858)			200,409			4,307,809
Beginning balance at Dec. 31, 2019					$ 4,135,428			$ 22,663			$ 5,992,733			$ 2,463,436			$ (4,303,546)			$ (39,858)			$ 201,166			$ 4,336,594		4,336,594
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Grant of restricted stock to company directors							0			1			(1)			0			0			0			0			0
Stock-based compensation expense							14,380			0			14,380			0			0			0			0			14,380
Vesting/exercising of equity compensation plan, net of tax withholdings							(4,148)			16			(4,164)			0			0			0			0			(4,148)
Dividend reinvestment plan and stock purchase plan							3,747			9			3,738			0			0			0			0			3,747
Deferred compensation directors							179			0			179			0			0			0			0			179
Equity Program							1,788			5			1,783			0			0			0			0			1,788
Common dividends declared							(459,922)			0			0			0			(459,922)			0			0			(459,922)
Vesting/exercising of Omega OP Units							(8,788)			0			(8,788)			0			0			0			8,788			0
Conversion and redemption of Omega OP Units to common stock							1,236			4			1,232			0			0			0			(1,236)			0
Omega OP Units distributions							0			0			0			0			0			0			(16,413)			(16,413)
Comprehensive income:
Foreign currency translation	(7,869)			(7,869)			(7,674)			0			0			0			0			(7,674)			(195)			(7,869)
Cash flow hedges	(1,608)			(1,608)			(1,569)			0			0			0			0			(1,569)			(39)			(1,608)
Net (loss) income	100,480		(9)	100,471			97,931			0			0			97,931			0			0			2,540			100,471
Total comprehensive income				90,994																								90,994
Balance , ending at Sep. 30, 2020		(51,364)					3,744,560			22,698			6,001,092			2,533,339			(4,763,468)			(49,101)			193,854			3,938,414
Beginning balance at Jun. 30, 2020							3,970,233			22,694			5,999,972			2,624,630			(4,610,828)			(66,235)			197,159			4,167,392
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Stock-based compensation expense							5,122			0			5,122			0			0			0			0			5,122
Vesting/exercising of equity compensation plan, net of tax withholdings							(779)			3			(782)			0			0			0			0			(779)
Deferred compensation directors							61			0			61			0			0			0			0			61
Equity Program							(9)			0			(9)			0			0			0			0			(9)
Common dividends declared							(152,640)			0			0			0			(152,640)			0			0			(152,640)
Vesting/exercising of Omega OP Units							(3,355)			0			(3,355)			0			0			0			3,355			0
Conversion and redemption of Omega OP Units to common stock							84			1			83			0			0			0			(84)			0
Omega OP Units distributions							0			0			0			0			0			0			(4,562)			(4,562)
Comprehensive income:
Foreign currency translation	11,874			11,874			11,561			0			0			0			0			11,561			313			11,874
Cash flow hedges	5,723			5,723			5,573			0			0			0			0			5,573			150			5,723
Net (loss) income	$ (93,765)		$ (3)	(93,768)			(91,291)			0			0			(91,291)			0			0			(2,477)			(93,768)
Total comprehensive income				$ (76,171)																								(76,171)
Balance , ending at Sep. 30, 2020		$ (51,364)					$ 3,744,560			$ 22,698			$ 6,001,092			$ 2,533,339			$ (4,763,468)			$ (49,101)			$ 193,854			$ 3,938,414

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Dividend per Common Share	$ 0.67	$ 0.66	$ 2.01	$ 1.98

CONSOLIDATED STATEMENTS OF CH_3

CONSOLIDATED STATEMENTS OF CHANGES IN OWNERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total Stockholders' Equity [Member]Omega OP	Total Stockholders' Equity [Member]Restatement Adjustment [Member]	Total Stockholders' Equity [Member]	Noncontrolling InterestOmega OP	Noncontrolling InterestRestatement Adjustment [Member]	Noncontrolling Interest	General PartnerOmega OP	Limited PartnerOmega OP	Omega OP	Restatement Adjustment [Member]	Total
Increase (Decrease) in Partners' Capital [Roll Forward]
Cumulative effect of accounting change	$ (8,490)	$ (8,198)			$ (292)		$ (8,198)	$ (292)	$ (8,490)	$ (8,490)
Partners' Capital, Adjusted Balance, Total	3,755,994						$ 3,436,243	$ 319,751	$ 3,755,994
Balance (in units)							202,346	8,714	211,060
Balance, beginning at Dec. 31, 2018	3,764,484						$ 3,444,441	$ 320,043	$ 3,764,484
Balance (in units) at Dec. 31, 2018							202,346	8,714	211,060
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions from partners	602,624						$ 602,624		$ 602,624
Contributions from partners (in units)							16,132		16,132
Distributions to partners	(434,502)						$ (417,416)	$ (17,086)	$ (434,502)
Vesting/exercising of Omega OP Units							(4,429)	$ 4,429
Vesting/exercising of Omega OP Units (in units)								119	119
Noncontrolling interest - consolidated joint venture			$ 0	$ 228		$ 228			$ 228		$ 228
Omega OP Unit conversions	(114,522)							$ (114,522)	$ (114,522)
Omega OP Unit conversions (in units)								(2,946)	(2,946)
Comprehensive income:
Foreign currency translation	(9,243)		(8,970)			(273)	(8,970)	$ (273)	$ (9,243)		(9,243)
Cash flow hedges	(7,918)		(7,650)			(268)	(7,650)	(268)	(7,918)		(7,918)
Net income (loss)	290,810		281,583	(9)		9,218	281,583	9,227	290,801		290,801
Total comprehensive income									273,640		273,640
Balance, ending at Sep. 30, 2019	4,083,243			219			$ 3,881,985	$ 201,258	$ 4,083,462
Balance (in units) at Sep. 30, 2019							218,478	5,887	224,365
Balance, beginning at Jun. 30, 2019	4,052,278			228			$ 3,802,971	$ 249,307	$ 4,052,506
Balance (in units) at Jun. 30, 2019							216,089	7,080	223,169
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions from partners	93,353						$ 93,353		$ 93,353
Contributions from partners (in units)							2,389		2,389
Distributions to partners	(148,450)						$ (143,497)	$ (4,953)	$ (148,450)
Vesting/exercising of Omega OP Units							(2,029)	$ 2,029
Vesting/exercising of Omega OP Units (in units)								56	56
Omega OP Unit conversions	(49,112)							$ (49,112)	$ (49,112)
Omega OP Unit conversions (in units)								(1,249)	(1,249)
Comprehensive income:
Foreign currency translation	(7,952)		(7,718)			(234)	(7,718)	$ (234)	$ (7,952)		(7,952)
Cash flow hedges	169		165			4	165	4	169		169
Net income (loss)	142,957		138,740	(9)		4,208	138,740	4,217	142,948		142,948
Total comprehensive income									135,165		135,165
Balance, ending at Sep. 30, 2019	4,083,243			219			$ 3,881,985	$ 201,258	$ 4,083,462
Balance (in units) at Sep. 30, 2019							218,478	5,887	224,365
Increase (Decrease) in Partners' Capital [Roll Forward]
Cumulative effect of accounting change	(28,785)	$ (28,028)			$ (757)		$ (28,028)	$ (757)	$ (28,785)	$ (28,785)
Partners' Capital, Adjusted Balance, Total	4,307,593			216			$ 4,107,400	$ 200,193	$ 4,307,809
Balance (in units)							226,631	5,931	232,562
Balance, beginning at Dec. 31, 2019	4,336,378			216			$ 4,135,428	$ 200,950	$ 4,336,594
Balance (in units) at Dec. 31, 2019							226,631	5,931	232,562
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions from partners	17,182						$ 17,182		$ 17,182
Contributions from partners (in units)							349		349
Distributions to partners	(476,335)						$ (459,922)	$ (16,413)	$ (476,335)
Vesting/exercising of Omega OP Units							(8,788)	$ 8,788
Vesting/exercising of Omega OP Units (in units)								282	282
Omega OP Unit conversions	(1,236)							$ (1,236)	$ (1,236)
Omega OP Unit conversions (in units)								(38)	(38)
Comprehensive income:
Foreign currency translation	(7,869)		(7,674)			(195)	(7,674)	$ (195)	$ (7,869)		(7,869)
Cash flow hedges	(1,608)		(1,569)			(39)	(1,569)	(39)	(1,608)		(1,608)
Net income (loss)	100,480		97,931	(9)		2,540	97,931	2,549	100,471		100,471
Total comprehensive income									90,994		90,994
Balance, ending at Sep. 30, 2020	3,938,207			207			$ 3,744,560	$ 193,647	$ 3,938,414
Balance (in units) at Sep. 30, 2020							226,980	6,175	233,155
Balance, beginning at Jun. 30, 2020	4,167,182			210			$ 3,970,233	$ 196,949	$ 4,167,392
Balance (in units) at Jun. 30, 2020							226,943	6,068	233,011
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions from partners	4,479						$ 4,479		$ 4,479
Contributions from partners (in units)							37		37
Distributions to partners	(157,202)						$ (152,640)	$ (4,562)	$ (157,202)
Vesting/exercising of Omega OP Units							(3,355)	$ 3,355
Vesting/exercising of Omega OP Units (in units)								110	110
Omega OP Unit conversions	(84)							$ (84)	$ (84)
Omega OP Unit conversions (in units)								(3)	(3)
Comprehensive income:
Foreign currency translation	11,874		11,561			313	11,561	$ 313	$ 11,874		11,874
Cash flow hedges	5,723		5,573			150	5,573	150	5,723		5,723
Net income (loss)	(93,765)		$ (91,291)	(3)		$ (2,477)	(91,291)	(2,474)	(93,768)		(93,768)
Total comprehensive income									(76,171)		$ (76,171)
Balance, ending at Sep. 30, 2020	$ 3,938,207			$ 207			$ 3,744,560	$ 193,647	$ 3,938,414
Balance (in units) at Sep. 30, 2020							226,980	6,175	233,155

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net (loss) income	$ 100,471	$ 290,801
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	247,301	221,185
Impairment on real estate properties	47,210	13,220
(Recovery) impairment on direct financing leases	(1,076)	7,700
Provision for credit losses	33,577
Provision for rental income	144,502	10,970
Interest - amortization of deferred financing costs	7,384	6,753
Accretion of direct financing leases	18	6
Stock-based compensation expense	14,380	11,519
Gain on assets sold - net	(13,932)	(52,803)
Amortization of acquired in-place leases - net	(8,460)	(4,673)
Effective yield receivable on mortgage notes	(433)	(258)
Interest paid-in-kind	(5,789)	(5,269)
Loss from unconsolidated joint ventures	153
Change in operating assets and liabilities - net:
Contractual receivables	5,359	(156)
Straight-line rent receivables	(16,112)	(35,592)
Lease inducements	(23,391)	(27,353)
Other operating assets and liabilities	(20,265)	(30,295)
Net cash provided by operating activities	510,897	405,755
Cash flows from investing activities
Acquisition of a business, net of cash acquired		(59,616)
Acquisition of real estate	(27,230)	(31,287)
Acquisition deposit		(22,050)
Net proceeds from sale of real estate investments	117,164	186,011
Investments in construction in progress	(61,991)	(98,187)
Proceeds from direct financing lease and related trust	15,220	88,730
Placement of mortgage loans	(59,922)	(14,739)
Collection of mortgage principal	4,005	43,379
Investments in unconsolidated joint ventures	(2,175)
Distributions from unconsolidated joint ventures in excess of earnings	2,852	8,075
Capital improvements to real estate investments	(27,018)	(39,540)
Receipts from insurance proceeds	346	6,878
Investments in other investments	(116,462)	(68,260)
Proceeds from other investments	99,239	72,137
Net cash (used in) provided by investing activities	(55,972)	71,531
Cash flows from financing activities
Proceeds from credit facility borrowings	939,466	887,000
Payments on credit facility borrowings	(893,000)	(1,485,100)
Noncontrolling members' contributions to consolidated joint venture		228
Receipts of other long-term borrowings		494,985
Payments of other long-term borrowings	(18,329)	(100,000)
Payments of financing related costs	(896)	(4,054)
Receipts from dividend reinvestment plan	3,747	91,845
Payments for exercised options and restricted stock	(4,148)	(3,848)
Net proceeds from issuance of common stock	1,788	107,044
Dividends paid	(459,743)	(417,252)
Distributions to Omega OP Unit Holders	(16,413)	(17,086)
Net cash used in financing activities	(447,528)	(446,238)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(662)	(487)
Increase in cash, cash equivalents and restricted cash	6,735	30,561
Cash, cash equivalents and restricted cash at beginning of period	33,380	11,671
Cash, cash equivalents and restricted cash at end of period	40,115	42,232
Omega OP
Cash flows from operating activities
Net (loss) income	100,471	290,801
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	247,301	221,185
Impairment on real estate properties	47,210	13,220
(Recovery) impairment on direct financing leases	(1,076)	7,700
Provision for credit losses	33,577
Provision for rental income	144,502	10,970
Interest - amortization of deferred financing costs	7,384	6,753
Accretion of direct financing leases	18	6
Stock-based compensation expense	14,380	11,519
Gain on assets sold - net	(13,932)	(52,803)
Amortization of acquired in-place leases - net	(8,460)	(4,673)
Effective yield receivable on mortgage notes	(433)	(258)
Interest paid-in-kind	(5,789)	(5,269)
Loss from unconsolidated joint ventures	153
Change in operating assets and liabilities - net:
Contractual receivables	5,359	(156)
Straight-line rent receivables	(16,112)	(35,592)
Lease inducements	(23,391)	(27,353)
Other operating assets and liabilities	(20,265)	(30,295)
Net cash provided by operating activities	510,897	405,755
Cash flows from investing activities
Acquisition of a business, net of cash acquired		(59,616)
Acquisition of real estate	(27,230)	(31,287)
Acquisition deposit		(22,050)
Net proceeds from sale of real estate investments	117,164	186,011
Investments in construction in progress	(61,991)	(98,187)
Proceeds from direct financing lease and related trust	15,220	88,730
Placement of mortgage loans	(59,922)	(14,739)
Collection of mortgage principal	4,005	43,379
Investments in unconsolidated joint ventures	(2,175)
Distributions from unconsolidated joint ventures in excess of earnings	2,852	8,075
Capital improvements to real estate investments	(27,018)	(39,540)
Receipts from insurance proceeds	346	6,878
Investments in other investments	(116,462)	(68,260)
Proceeds from other investments	99,239	72,137
Net cash (used in) provided by investing activities	(55,972)	71,531
Cash flows from financing activities
Repayments of secured borrowings	(18,329)
Proceeds from intercompany loans payable from Omega	939,466	1,381,985
Repayment of intercompany loans payable to Omega	(893,000)	(1,585,100)
Noncontrolling members' contributions to consolidated joint venture		228
Equity contributions from general partners	1,387	195,041
Payments of financing related costs	(896)	(4,054)
Distributions to general partners	(459,743)	(417,252)
Distributions to limited partners	(16,413)	(17,086)
Net cash used in financing activities	(447,528)	(446,238)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(662)	(487)
Increase in cash, cash equivalents and restricted cash	6,735	30,561
Cash, cash equivalents and restricted cash at beginning of period	33,380	11,671
Cash, cash equivalents and restricted cash at end of period	$ 40,115	$ 42,232

BASIS OF PRESENTATION AND SIGNI

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2020
Basis of Presentation and Significant Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview and Organization Omega Healthcare Investors, Inc. (“Omega”) was incorporated in the State of Maryland on March 31, 1992 and has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes. Omega is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega’s assets are owned directly or indirectly by, and all of Omega’s operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (“Omega OP”). Omega OP was formed as a limited partnership and organized in the State of Delaware on October 24, 2014. Unless stated otherwise or the context otherwise requires, the terms the “Company,” “we,” “our” and “us” means Omega and Omega OP, collectively. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”), assisted living facilities (“ALFs”), and to a lesser extent, independent living facilities (“ILFs”), rehabilitation and acute care facilities (“specialty facilities”) and medical office buildings (“MOBs”). Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the operators (we use the term “operator” to refer to our tenants, mortgagors and their affiliates who manage and/or operate our properties) to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor. Our other investment income derives from fixed and variable rate loans to our operators and/or their principals to fund working capital and capital expenditures. These loans, which may be either unsecured or secured by the collateral of the borrower, are classified as other investments. Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the Partnership Agreement. As of September 30, 2020, Omega owned approximately 97% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and investors owned approximately 3% of the outstanding Omega OP Units. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our latest Annual Report on Form 10-K Omega’s consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP, (iii) all direct and indirect wholly owned subsidiaries of Omega and (iv) other entities in which Omega or Omega OP has a majority voting interest and control. All intercompany transactions and balances have been eliminated in consolidation, and Omega’s net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Omega OP’s consolidated financial statements include the accounts of (i) Omega OP, (ii) all direct and indirect wholly owned subsidiaries of Omega OP and (iii) other entities in which Omega OP has a majority voting interest and control. All intercompany transactions and balances have been eliminated in consolidation, and Omega OP’s net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Risks and Uncertainties The Company is subject to certain risks and uncertainties affecting the healthcare industry, including those stemming from the novel coronavirus (“COVID-19”) global pandemic described below, which has disproportionately impacted the senior care sector, as well as, those stemming from healthcare legislation and changing regulation by federal, state and local governments, including those driven by the COVID-19 pandemic. Additionally, we are subject to risks and uncertainties as a result of changes affecting operators of nursing home facilities due to the actions of governmental agencies and insurers to limit the rising cost of healthcare services. The COVID-19 pandemic has led governments and other authorities in the U.S., U.K. and around the world to impose measures intended to control its spread, including but not limited to, the mandated use of personal protective equipment, restrictions on freedom of movement and business operations such as travel bans, border closings, business closures, quarantines and shelter-in-place orders, etc. A range of government restrictions remain in place along with continuing uncertainty around the potential duration of the pandemic. As of October 22, 2020, approximately half of our facilities have reported one or more positive cases of COVID-19 among the residents and/or operator employee populations. Many of our operators have reported incurring significant cost increases as a result of the COVID-19 pandemic, with dramatic increases for facilities with positive cases. We believe these increases primarily stem from elevated labor costs, including increased use of overtime and bonus pay, as well as a significant increase in both the cost and usage of personal protective equipment, testing equipment and processes and supplies. In terms of occupancy levels, many of our operators have reported experiencing declines, in part due to the elimination or suspension of elective hospital procedures, fewer discharges from hospitals to SNFs and higher hospital readmittances from SNFs. To the extent government support is not sufficient or timely to offset these impacts, or to the extent these trends continue or accelerate and are not offset by additional government relief that is sufficient or timely, the operating results of our operators are likely to be adversely affected, some may be unwilling or unable to pay their contractual obligations to us in full or on a timely basis and we may be unable to restructure such obligations on terms as favorable to us as those currently in place. Even if operators are able to avail themselves of government relief to offset some of these costs, they may face challenges in complying with the terms and conditions of government support and may face longer-term adverse impacts to their personnel and business operations from the pandemic, including potential patient litigation and decreased demand for their services. The extent of the COVID-19 pandemic’s effect on our and our operators’ operational and financial performance will depend on future developments, including the ultimate duration, spread and intensity of the outbreak, which may depend on factors such as the development and implementation of an effective vaccine and treatments for COVID-19, government funds and other support for the senior care sector and the efficacy of other policies and measures that may mitigate the impact of the pandemic, all of which are uncertain and difficult to predict. Due to these uncertainties, we are not able at this time to estimate the effect of these factors on our business, but the adverse impact on our business, results of operations, financial condition and cash flows could be material. Variable Interest Entities GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affects the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. Our variable interests in VIEs may be in the form of equity ownership, leases, guarantees and/or loans with our operators. We analyze our agreements and investments to determine whether our operators or unconsolidated joint ventures are VIEs and, if so, whether we are the primary beneficiary. We consolidate a VIE when we determine that we are its primary beneficiary. We identify the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Factors considered in determining whether we are the primary beneficiary of an entity include: (i) our voting rights, if any; (ii) our involvement in day-to-day capital and operating decisions; (iii) our risk and reward sharing; (iv) the financial condition of the operator or joint venture and (iv) our representation on the VIE’s board of directors. We perform this analysis on an ongoing basis. As of September 30, 2020, we have not consolidated any VIEs, as we do not have the power to direct the activities of any VIEs that most significantly impact their economic performance and we do not have the obligation to absorb losses or receive benefits of the VIEs that could be significant to the entity. Real Estate Investments and Depreciation The costs of significant improvements, renovations and replacements, including interest are capitalized. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are charged to operations as they are incurred. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from 20 eight three Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand and highly liquid investments with a maturity date of three months or less when purchased. These investments are stated at cost, which approximates fair value. The majority of our cash, cash equivalents and restricted cash are held at major commercial banks. Certain cash account balances exceed FDIC insurance limits of $250,000 per account and, as a result, there is a concentration of credit risk related to amounts in excess of the insurance limits. We regularly monitor the financial stability of these financial institutions and believe that we are not exposed to any significant credit risk in cash, cash equivalents or restricted cash. Restricted Cash Restricted cash consists primarily of liquidity deposits escrowed for tenant obligations required by us pursuant to certain contractual terms and other deposits required by the U.S. Department of Housing and Urban Development (“HUD”) in connection with our mortgage borrowings guaranteed by HUD. Real Estate Investment Impairment Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance including the current payment status of contractual obligations and expectations of the ability to meet future contractual obligations, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to management’s estimate of future undiscounted cash flows of the underlying facilities. The estimated future undiscounted cash flows are generally based on the related lease which relates to one or more properties and may include cash flows from the eventual disposition of the asset. In some instances, there may be various potential outcomes for a real estate investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess the recoverability are probability-weighted based on management’s best estimates as of the date of evaluation. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. Additionally, our evaluation of fair value may consider valuing the property as a nursing home or other healthcare facility as well as alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property as well as the fair value of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment to our assets in a future period that could be material to Omega’s results of operations. For the three months ended September 30, 2020 and 2019, we recognized impairment on real estate properties of approximately $28.1 million and $3.8 million, respectively. For the nine months ended September 30, 2020 and 2019, we recognized impairment on real estate properties of approximately $43.7 million and $9.5 million, respectively. In July 2020, we executed a Forbearance and Transition Agreement with Daybreak Venture LLC (“Daybreak”) which, among other things, set forth the parties’ plan to sell or re-lease the Daybreak portfolio (which plan contemplated the potential sale of 28 facilities currently leased to Daybreak to a non-Omega party for $100 million), and the Company’s agreement to forbear from exercising certain default remedies during the transition period. During the third quarter of 2020, discussions terminated on the contemplated sale transaction for $100 million, and in October 2020 the Forbearance and Transition Agreement was amended and restated to continue the forbearance. The Company is in negotiations with other third-party operators to re-lease these 28 facilities, along with three additional facilities. Further, the Company expects to re-lease or sell one additional Daybreak facility with a net book value of $0.1 million either in connection with or separate from these transactions. As of September 30, 2020, the 31 facilities subject to current re-lease negotiations have a net book value of approximately $147 million. We evaluated the facilities for impairment as of September 30, 2020 and concluded that the facilities were not impaired, as we believe that our expected annual nominal cash flows from re-leasing these facilities exceed our current net book value of the 31 facilities. To the extent certain of these 31 facilities are not re-leased to a third-party operator and are instead identified for sale, we may be required to record an impairment to the extent the sales price for a facility is less than its net book value. On May 26, 2020, we executed an agreement to sell an acute care hospital located in Nevada to an unrelated third-party for $56.5 million. The agreement provided that the sale was subject to a 60-day due diligence period which expired in July 2020. During the second quarter of 2020, we recorded an impairment of approximately $2.2 million related to this facility to reduce its net book value to its fair value less costs to sell of approximately $55.3 million and reclassified the facility to assets held for sale. In July 2020, we agreed with the third-party buyer to lower the purchase price to approximately $49.0 million. The reduction in the purchase price resulted in an additional impairment of approximately $7.4 million in July 2020, and the facility was subsequently sold in September 2020. Allowance for Losses on Mortgages, Other Investments and Direct Financing Leases The allowances for losses on mortgage notes receivable, other investments and direct financing leases (collectively, our “loans”) are maintained at a level believed adequate to absorb potential losses. The determination of the allowances is based on a quarterly evaluation of these loans, including general economic conditions and estimated collectability of loan payments. We evaluate the collectability of our loans receivable based on a combination of factors, including, but not limited to, delinquency status, financial strength of the borrower and guarantors and the value of the underlying collateral. If such factors indicate that there is greater risk of loan charge-offs, additional allowances or placement on non-accrual status may be required. A loan is impaired when, based on current information and events, it is probable that we will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreements. Consistent with this definition, all loans on non-accrual status may be deemed impaired. To the extent circumstances improve and the risk of collectability is diminished, we will return these loans to full accrual status. When management identifies a loan impairment, the loan is written down to the present value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the loan is written down to the fair value of the underlying collateral. We may base our valuation on a loan’s observable market price, if any, or the fair value of collateral, net of sales costs, if the repayment of the loan is expected to be provided solely by the sale of the collateral. We account for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We generally utilize the cost-recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impaired loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows expected under the loan or direct financing lease and/or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the book value of the loans or direct financing leases. Under the cost-recovery method, we apply cash received against the outstanding loan balance or direct financing lease prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the terms of the agreement. As of September 30, 2020 and December 31, 2019, we had $61.0 million and $5.1 million, respectively, of reserves on our loans. For additional information see “Accounting Pronouncements Adopted in 2020,” Note 3 – Direct Financing Leases, Note 4 – Mortgage Notes Receivable, and Note 5 – Other Investments. Goodwill Impairment We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a significant decline in real estate valuations, current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance or a significant decline in the value of our market capitalization, to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount. On an annual basis during the fourth quarter of each fiscal year, or on an interim basis if we conclude it is more likely than not that the fair value of the reporting unit is less than its carrying value, we perform a two-step goodwill impairment test to identify potential impairment and measure the amount of impairment we will recognize, if any. Earnings Per Share/Unit The computation of basic earnings per share/unit (“EPS” or “EPU”) is computed by dividing net (loss) income available to common stockholders/Omega OP Unit holders by the weighted-average number of shares of common stock/Omega OP Units outstanding during the relevant period. Diluted EPS/EPU is computed using the treasury stock method, which is net (loss) income divided by the total weighted-average number of common outstanding shares/Omega OP Units plus the effect of dilutive common equivalent shares/units during the respective period. Dilutive common shares/Omega OP Units reflect the assumed issuance of additional common shares pursuant to certain of our share-based compensation plans, including restricted stock and profit interest units, performance restricted stock and profit interest units, the assumed issuance of additional shares related to Omega OP Units held by outside investors. Dilutive Omega OP Units reflect the assumed issuance of additional Omega OP Units pursuant to certain of our share-based compensation plans, including, restricted stock and profit interest units, performance restricted stock and profit interest units. To the extent we have a net loss, potential common shares/units are not included in the computation of diluted earnings per share as the effect would be an antidilutive per share amount. Noncontrolling Interests Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity or owners’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors and interests in a consolidated real estate joint venture not fully owned by Omega. The noncontrolling interest for Omega OP represents outside investors interests in a consolidated real estate joint venture not fully owned by Omega OP. Foreign Operations The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). For our consolidated subsidiaries whose functional currency is not the USD, we translate their financial statements into the USD. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in Omega OP’s owners’ equity and Omega’s accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interests, if applicable. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature in which case the adjustments are included in Omega OP’s owners’ equity and Omega’s AOCL and a proportionate amount of gain or loss is allocated to noncontrolling interests, if applicable. Derivative Instruments Cash flow hedges During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with our related assertions. Omega recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which is determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated in qualifying cash flow hedging relationships, the gain or loss on the derivative is recognized in Omega OP’s owners’ equity and Omega’s AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, if applicable. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized liabilities or assets on the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At September 30, 2020 and December 31, 2019, the fair value of certain qualifying cash flow hedges was $12.0 million and $3.7 million, respectively, and are included in accrued expenses and other liabilities on our Consolidated Balance Sheets (see Note 19 – Subsequent Events). At September 30, 2020, the fair value of certain qualifying cash flow hedges was $6.6 million and is included in other assets on our Consolidated Balance Sheets (see Note 14 – Borrowing Activities and Arrangements). Net investment hedge We are exposed to fluctuations in the GBP against its functional currency, the USD, relating to its investments in healthcare-related investments located in the U.K. The Company uses a nonderivative, GBP-denominated term loan and line of credit to manage its exposure to fluctuations in the GBP-USD exchange rate. The foreign currency transaction gain or loss on the nonderivative hedging instrument that is designated and qualifies as a net investment hedge is reported in Omega OP’s owners’ equity and Omega’s AOCL in our Consolidated Balance Sheets. Contractual Receivables and Other Receivables and Lease Inducements Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception, modification, or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term. We assess the probability of collecting substantially all payments under our leases based on several factors, including, among other things, payment history of the lessee, the financial strength of the lessee and any guarantors, historical operations and operating trends, current and future economic conditions and expectations of performance (which includes known substantial doubt about an operator’s ability to continue as a going concern). If our evaluation of these factors indicates it is probable that we will be unable to collect substantially all rents, we place that operator on a cash basis and limit our rental income to the lesser of lease income on a straight-line basis plus variable rents when they become accruable or cash collected. As a result of placing an operator on a cash basis, we may recognize a charge to rental income for any contractual rent receivable, straight-line rent receivable and lease inducements. If we change our conclusion regarding the probability of collecting rent payments required by a lessee, we may recognize an adjustment to rental income in the period we make a change to our prior conclusion. On a quarterly basis, and more frequently as appropriate, we review our contractual interest receivables, effective yield interest receivables and direct financing lease receivables to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement, if any. For a loan recognized on an effective yield basis or a direct financing lease, we generally provide an allowance for effective interest or income from direct financing leases when certain conditions or indicators of adverse collectability are present. If these accounts receivable balances are subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. A summary of our net receivables by type is as follows: September 30, December 31, 2020 2019 (in thousands) Contractual receivables –

PROPERTIES AND INVESTMENTS

PROPERTIES AND INVESTMENTS	9 Months Ended
PROPERTIES AND INVESTMENTS	Sep. 30, 2020
PROPERTIES AND INVESTMENTS [Abstract]
PROPERTIES AND INVESTMENTS	NOTE 2 – PROPERTIES AND INVESTMENTS Leased Property A summary of our investments in real estate properties subject to operating leases is as follows: September 30, December 31, 2020 2019 (in thousands) Buildings $ 7,027,766 $ 7,056,106 Land 880,498 901,246 Furniture and equipment 528,324 515,421 Site improvements 303,978 287,655 Construction in progress 39,396 225,566 Total real estate investments 8,779,962 8,985,994 Less accumulated depreciation (1,974,038) (1,787,425) Real estate investments – net $ 6,805,924 $ 7,198,569 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (in thousands) Rental income – operating leases $ 81,424 $ 199,193 $ 517,384 $ 579,621 Variable lease income – operating leases 1,802 3,277 8,874 9,843 Total lease income $ 83,226 $ 202,470 $ 526,258 $ 589,464 Number of Total Building & Site Furniture Initial Facilities Country/ Investment Land Improvements & Equipment Annual Period SNF ALF Specialty MOB State (in millions) Cash Yield (1) Q1 — 2 — — UK $ 12.1 $ 3.6 $ 8.0 $ 0.5 8.00 % Q1 1 — — — IN 7.0 0.7 5.8 0.5 9.50 % Q2 1 — — — OH 6.9 0.8 5.5 0.6 9.50 % Total 2 2 — — $ 26.0 $ 5.1 $ 19.3 $ 1.6 (1) The initial annual cash yield reflects the initial annual cash rent divided by the purchase price. MedEquities Merger On May 17, 2019, Omega and Omega OP completed their merger with MedEquities Realty Trust, Inc. (“MedEquities”) and its subsidiary operating partnership and the general partner of its subsidiary operating partnership. Pursuant to the Agreement and Plan of Merger, as amended by the First Amendment to the Agreement and Plan of Merger, dated March 26, 2019, (the “Merger Agreement”) Omega acquired MedEquities and MedEquities was merged with and into Omega (the “Merger”) at the effective time of the Merger with Omega continuing as the surviving company. In accordance with the Merger Agreement, each share of MedEquities common stock issued and outstanding immediately prior thereto was converted into the right to receive (i) 0.235 of a share of Omega common stock plus the right to receive cash in lieu of any fractional shares of Omega common stock, and (ii) an amount in cash equal to $2.00 (the “Cash Consideration”). In connection with the MedEquities Merger, we issued approximately 7.5 million shares of Omega common stock and paid approximately $63.7 million of cash consideration to former MedEquities stockholders. We borrowed approximately $350 million under our existing senior unsecured revolving credit facility to fund the cash consideration and the repayment of MedEquities’ previously outstanding debt. As a result of the MedEquities Merger, we acquired 33 facilities subject to operating leases, four mortgages, three other investments and an Our purchase price allocation was finalized during the second quarter of 2020, with no material adjustments recorded. The following table highlights the final fair value of the assets acquired and liabilities assumed on May 17, 2019: (in thousands) Fair value of net assets acquired: Real estate investments $ 440,690 Mortgage notes receivable 108,097 Other investments 19,192 Investment in unconsolidated joint venture 73,834 Cash 4,067 Contractual receivables 1,002 Other assets (1) 7,698 Total investments 654,580 Debt (285,100) Accrued expenses and other liabilities (2) (23,931) Fair value of net assets acquired $ 345,549 (1) Includes approximately $2.5 million in above market lease assets. (2) Includes approximately $1.1 million in below market lease liabilities. Pro Forma Acquisition Results The following unaudited pro forma information presents consolidated financial information as if the MedEquities Merger occurred on January 1, 2019. In the opinion of management, all significant, necessary adjustments to reflect the effect of the merger have been made. Pro Forma Nine Months Ended September 30, 2019 Pro forma revenues $ 703,650 Pro forma net income $ 301,074 Earnings per share – diluted: Net income – as reported $ 1.32 Net income – pro forma $ 1.33 Asset Sales and Impairments During the first quarter of 2020, we sold six facilities subject to operating leases for approximately $18.1 million in net cash proceeds, recognizing a net gain of approximately $1.8 million. In addition, we recorded impairments on three facilities of approximately $3.6 million (one was subsequently reclassified to assets held for sale). During the second quarter of 2020, we sold 15 facilities (also see Note 4 – Mortgages Notes Receivable) subject to operating leases and one facility subject to a direct financing lease for approximately $38.0 million in net cash proceeds, recognizing a net gain of approximately $12.8 million. In addition, we recorded impairments on 10 facilities of approximately $12.0 million (two were subsequently reclassified to assets held for sale). During the third quarter of 2020, we sold six facilities and a parcel of land subject to operating leases for approximately $61.0 million in net cash proceeds, recognizing a net loss of approximately $0.7 million. In addition, we recorded impairments on seven facilities of approximately $28.1 million (six were subsequently reclassified to assets held for sale during the third quarter of 2020). Our impairments for the third quarter of 2020 were offset by approximately $3.5 million of insurance proceeds related to a facility that was previously destroyed and impaired. Our recorded impairments were primarily the result of decisions to exit certain non-strategic facilities and/or operators. We reduced the net book value of the impaired facilities to their estimated fair values or, with respect to the facilities reclassified to held for sale, to their estimated fair values less costs to sell. To estimate the fair value of the facilities, we utilized a market approach which considered binding sale agreements (a Level 1 input) and/or non-binding offers from unrelated third parties and/or broker quotes (a Level 3 input).

DIRECT FINANCING LEASES

DIRECT FINANCING LEASES	9 Months Ended
DIRECT FINANCING LEASES	Sep. 30, 2020
Direct Financing Leases [Abstract]
DIRECT FINANCING LEASES	NOTE 3 – DIRECT FINANCING LEASES The components of investments in direct financing leases consist of the following: September 30, December 31, 2020 2019 (in thousands) Minimum lease payments receivable $ 26,217 $ 27,227 Less unearned income (14,747) (15,522) Investment in direct financing leases 11,470 11,705 Less allowance for credit losses on direct financing leases (612) (217) Investment in direct financing leases – net $ 10,858 $ 11,488 Properties subject to direct financing leases 1 2 Number of direct financing leases 1 2 In June 2020, we received approximately $14.9 million from the Orianna Health Systems Distribution Trust (the “Trust”) as part of its final liquidation. As of December 31, 2019, our remaining receivable was approximately $14.1 million which was recorded in other assets on our Consolidated Balance Sheets. Approximately $0.8 million of the overall proceeds of $14.9 million were recorded in recovery (impairment) of direct financing leases. During the third quarter of 2020, we received additional proceeds of approximately $0.3 million from the Trust, which were recorded in recovery (impairment) of direct financing leases on our Consolidated Statements of Operations. In March 2019, we received updated information from the Trust indicating diminished collectability of the accounts receivable owed to us. As a result, we recorded an additional $7.7 million allowance during the three months ended March 31, 2019.

MORTGAGE NOTES RECEIVABLE

MORTGAGE NOTES RECEIVABLE	9 Months Ended
MORTGAGE NOTES RECEIVABLE	Sep. 30, 2020
Mortgage Notes Receivable [Abstract]
MORTGAGE NOTES RECEIVABLE	NOTE 4 – MORTGAGE NOTES RECEIVABLE As of September 30, 2020, mortgage notes receivable relate to ten fixed rate mortgage notes on 64 facilities. The mortgage notes are secured by first mortgage liens on the borrowers’ underlying real estate and personal property. The mortgage notes receivable relate to facilities located in eight states that are operated by seven independent healthcare operating companies. We monitor compliance with the terms of our mortgages and when necessary have initiated collection, foreclosure and other proceedings with respect to certain outstanding mortgage notes. The principal amounts outstanding of mortgage notes receivable, net of allowances, were as follows: September 30, December 31, 2020 2019 (in thousands) Mortgage note due 2027; interest at 10.59% $ 112,500 $ 112,500 Mortgage notes due 2029; interest at 10.52% (1) 672,364 526,520 Other mortgage notes outstanding (2) 136,860 139,448 Mortgage notes receivable, gross 921,724 778,468 Allowance for credit losses on mortgage notes receivable (29,185) (4,905) Total mortgages — net $ 892,539 $ 773,563 (1) Approximates the weighted average interest rate on 47 facilities as of September 30, 2020. Two notes totaling approximately $28.6 million are construction mortgages with maturities in 2021. Two mortgage notes totaling $43.2 million mature in 2021 and the remaining loan balance matures in 2029 . (2) Other mortgages outstanding have a weighted average interest rate of 9.40% per annum as of September 30, 2020 and maturity dates through 2028 . $672 Million Mortgage Notes due 2029 On May 1, 2020, we amended our initial $415 million amortizing master mortgage (the “Master Mortgage”) with Ciena Healthcare (“Ciena”) to (i) increase the interest rate on the Master Mortgage to 10.67% per annum and (ii) add an additional $83.5 million mortgage note related to eight SNFs and one ALF located in Michigan. These nine facilities were formerly leased to Ciena and were sold to Ciena in a noncash transaction that closed on May 1, 2020 and we retained the first mortgage. In connection with this sale, we recorded a loss of $3.6 million related to the write-off of the nine facilities’ straight-line rent receivable. The mortgage note matures on June 30, 2029 and bears an initial annual interest rate of 10.31% which increases each year by 2%. As of September 30, 2020, the outstanding principal balance of this mortgage note is approximately $83.4 million. In June 2020, we entered into a loan agreement with subsidiaries of Ciena to provide $43.2 million of mortgage notes related to two SNFs located in Ohio. The mortgage notes mature on June 30, 2021 and bear an initial annual interest rate of 9.5%. As of September 30, 2020, the outstanding principal balance of these mortgage notes is approximately $43.2 million. As of September 30, 2020, our total outstanding mortgage notes receivable with Ciena total $672.4 million.

OTHER INVESTMENTS

OTHER INVESTMENTS	9 Months Ended
OTHER INVESTMENTS	Sep. 30, 2020
Other Investments [Abstract]
OTHER INVESTMENTS	NOTE 5 – OTHER INVESTMENTS A summary of our other investments is as follows: September 30, December 31, 2020 2019 (in thousands) Other investment notes due 2021; interest at 13.11% (1) $ 81,948 $ 77,087 Other investment notes due 2021-2025; interest at 8.25% (1) 62,187 58,687 Other investment note due 2023; interest at 12.00% 49,908 52,213 Other investment notes due 2030; interest at 7.00% 132,148 65,000 Other investment notes outstanding (2) 169,504 166,241 Total other investments, gross 495,695 419,228 Allowance for credit losses on other investments (31,192) — Total other investments - net $ 464,503 $ 419,228 (1) Approximate weighted average interest rate as of September 30, 2020. (2) Other investment notes have a weighted average interest rate of 7.92% as of September 30, 2020 and maturity dates through 2028 . Other Investment Notes due 2021 Other Investment Notes due 2021-2025 On September 30, 2016, we acquired and amended a term loan of approximately $37.0 million with Agemo. A $5.0 million tranche of the term loan that bore interest at 13% per annum was repaid in August 2017. The remaining $32.0 million tranche of the term loan (the “$32.0 million term loan”) bears interest at 9% per annum and matures on December 31, 2024. The $32.0 million term loan and the $1.7 million term loan (discussed below) are secured by a security interest in certain collateral of Agemo. On November 5, 2019, we provided Agemo a $1.7 million term loan (which was added to the $32.0 million term loan) that bears interest at a fixed rate of 9% per annum and was initially scheduled to mature on March 31, 2020. On February 10, 2020, we extended the maturity of this loan to January 1, 2021. During the third quarter of 2020, the Company concluded that both the $32.0 million term loan and $1.7 million term loan were impaired, based in part on our consideration of information the Company received from the operator regarding substantial doubt as to its ability to continue as a going concern. We recorded a provision for credit loss of $24.4 million to reduce the carrying value of these loans to the fair value of the underlying collateral, which was limited to our $9.3 million letter of credit (a Level 1 input). We also fully reserved approximately $3.8 million of contractual interest receivable related to the $32.0 million term loan (see Note 1 – Basis of Presentation and Significant Accounting Policies). As of September 30, 2020, approximately $9.3 million is outstanding on these term loans. On September 1, 2020, we placed both the $32.0 million and the $1.7 million term loans on a cash basis for purposes of revenue recognition. On May 7, 2018, the Company provided Agemo a $25.0 million secured working capital loan bearing interest at 7% per annum and matures on April 30, 2025. The working capital loan is primarily secured by a collateral package that includes a second lien on the accounts receivable of the borrowers. The proceeds of the working capital loan were used to pay operating expenses, settlement payments, fees, taxes and other costs approved by the Company. As of September 30, 2020, approximately $25.0 million is outstanding on this working capital loan. During the third quarter of 2020, no incremental provision for credit loss was recorded for this loan given the underlying collateral value. On February 28, 2020, we provided an affiliate of Agemo a $3.5 million term loan bearing interest at a fixed rate of 10% per annum (with the interest paid-in-kind) and matures on February 28, 2021. As of September 30, 2020, $3.5 million is outstanding on this term loan. During the third quarter of 2020, no incremental provision for credit loss was recorded for this loan given the underlying collateral value. At September 30, 2020, the total carrying value of our loans with Agemo and its affiliates, net of allowances for credit losses, is approximately $37.8 million. Other Investment Notes due 2030 Other Investment Notes Outstanding On April 17, 2020, we provided a $17.6 million unsecured loan to a subsidiary of Second Spring Healthcare Investments (an entity in which we have an approximate 15% ownership interest, see Note 7 – Investment in Joint Ventures). The loan bears interest at the greater of the prime interest rate or 3-month LIBOR plus 2.75% per annum and is due on demand. As of September 30, 2020, the loan bears interest at 3.25% per annum and has a total outstanding balance of $17.6 million.

VARIABLE INTEREST ENTITIES

VARIABLE INTEREST ENTITIES	9 Months Ended
VARIABLE INTEREST ENTITIES	Sep. 30, 2020
Variable Interest Entities [Abstract]
VARIABLE INTEREST ENTITIES	NOTE 6 – VARIABLE INTEREST ENTITIES As of September 30, 2020 and December 31, 2019, Agemo is a VIE. As of September 30, 2020, Maplewood is also a VIE. Below is a summary of our assets, liabilities and collateral associated with these operators as of September 30, 2020 and December 31, 2019: September 30, 2020 December 31, 2019 Agemo Maplewood Agemo (in thousands) (in thousands) Assets Real estate investments – net $ 375,641 $ 746,956 $ 403,389 Other investments 37,753 132,148 58,687 Contractual receivables 641 771 18,113 Straight-line rent receivables — (61,207) 46,247 Lease inducement — 71,006 6,810 Subtotal 414,035 889,674 533,246 Liabilities Net in-place lease liability — (337) — Contingent liability — (43,915) — Subtotal — (44,252) — Collateral Letters of credit (9,253) — (9,253) Personal guarantee (8,000) (40,000) (8,000) Other collateral (375,641) (746,956) (403,389) Subtotal (392,894) (786,956) (420,642) Maximum exposure to loss $ 21,141 $ 58,466 $ 112,604 In determining our maximum exposure to loss from the VIE, we considered the underlying carrying value of the real estate subject to leases with the operator and other collateral, if any, supporting our other investments, which may include accounts receivable, security deposits, letters of credit or personal guarantees, if any, as well as other liabilities recognized with respect to these operators. See Note 5 – Other Investments regarding the terms of the other investments with Agemo and Maplewood. The table below reflects our total revenues from Agemo and Maplewood for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, Nine Months Ended September 30, 2020 2020 2019 2019 2020 2020 2019 2019 Agemo Maplewood Agemo Maplewood Agemo Maplewood Agemo Maplewood (in thousands) Revenue Rental income (1) $ (63,128) $ 13,199 $ 15,145 $ 10,337 $ (33,026) $ 33,381 $ 45,473 $ 28,804 Other investment income 1,059 1,979 1,168 1,215 3,597 4,833 3,295 3,606 Total (2) $ (62,069) $ 15,178 $ 16,313 $ 11,552 $ (29,429) $ 38,214 $ 48,768 $ 32,410 (1) The rental income related to Agemo for the three and nine months ended September 30, 2020, reflects the write-off of approximately $75.3 million of contractual rent receivable, straight-line rent receivable and lease inducements (see Note 1 – Basis of Presentation and Significant Accounting Policies). (2) For the three months ended September 30, 2020 and 2019, we received cash from Agemo of approximately $13.4 million and $13.5 million, respectively, pursuant to our lease and other investment agreements. For the nine months ended September 30, 2020 and 2019, we received cash from Agemo of approximately $40.1 million and $39.7 million, respectively, pursuant to our lease and other investment agreements. For the three months ended September 30, 2020 and 2019, we received cash rental income and other investment income from Maplewood of approximately $17.5 million and $11.4 million, respectively. For the nine months ended September 30, 2020 and 2019, we received cash rental income and other investment income from Maplewood of approximately $51.4 million and $31.7 million, respectively.

INVESTMENTS IN JOINT VENTURES

INVESTMENTS IN JOINT VENTURES	9 Months Ended
INVESTMENTS IN JOINT VENTURES	Sep. 30, 2020
INVESTMENTS IN JOINT VENTURES [Abstract]
INVESTMENTS IN JOINT VENTURES	NOTE 7 – INVESTMENTS IN JOINT VENTURES Unconsolidated Joint Ventures Carrying Amount Ownership Initial Investment Initial Facility Facilities at September 30, December 31, Entity (1) % Date Investment (2) Type 9/30/2020 2020 2019 Second Spring Healthcare Investments (3) 15% 11/1/2016 $ 50,032 SNF 23 $ 20,386 $ 22,504 Lakeway Realty, L.L.C. 51% 5/17/2019 73,834 Specialty facility 1 72,585 73,273 Cindat Joint Venture 49% 12/18/2019 105,687 ALF 67 103,052 103,976 OMG Senior Housing, LLC 50% 12/6/2019 — ILF 1 — — OH CHS SNP, Inc. 9% 12/20/2019 450 N/A N/A 191 131 $ 230,003 $ 196,214 $ 199,884 (1) These entities and their subsidiaries are not consolidated by the Company because it does not control, through voting rights or other means, the joint venture. (2) Our initial investment includes our transaction costs, if any. (3) The Company made a loan of $17.6 million to the venture which is included in other investments. See Note 5 – Other Investments. Three Months Ended September 30, Nine Months Ended September 30, Entity 2020 2019 2020 2019 (in thousands) Second Spring Healthcare Investments $ 1,666 $ 7,832 $ 2,947 $ 9,139 Lakeway Realty, L.L.C. 637 596 1,860 889 Cindat Joint Venture (398) — 493 — OMG Senior Housing, LLC (108) — (387) — OH CHS SNP, Inc. (105) — (259) — Total $ 1,692 $ 8,428 $ 4,654 $ 10,028 Asset Management Fees We receive asset management fees from certain joint ventures for services provided. For the three months ended September 30, 2020 and 2019, we recognized approximately $0.3 million and $0.2 million, respectively of asset management fees. For the nine months ended September 30, 2020 and 2019, we recognized approximately $1.0 million and $0.7 million, respectively of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statements of Operations.

ASSETS HELD FOR SALE

ASSETS HELD FOR SALE	9 Months Ended
ASSETS HELD FOR SALE	Sep. 30, 2020
Assets Held for Sale [Abstract]
ASSETS HELD FOR SALE	NOTE 8 – ASSETS HELD FOR SALE The following is a summary of our assets held for sale: Properties Held For Sale Number of Net Book Value Properties (in thousands) December 31, 2019 6 $ 4,922 Properties sold (1) (4) (4,341) Properties added (2) 6 23,544 March 31, 2020 8 24,125 Properties sold (1) (5) (19,910) Properties added (2) 3 66,301 June 30, 2020 6 70,516 Properties sold (1) (4) (66,560) Properties added (2) 11 31,965 September 30, 2020 (3) 13 $ 35,921 (1) In the first quarter of 2020, we sold four facilities for approximately $4.2 million in net cash proceeds recognizing a net loss on sale of approximately $0.5 million. In the second quarter of 2020, we sold five facilities for approximately $38.4 million in net cash proceeds recognizing a net gain on sale of approximately $16.7 million. In the third quarter of 2020, we sold four facilities and a parcel of land for approximately $60.7 million in net cash proceeds recognizing a net loss on sale of approximately $1.0 million. During the third quarter of 2020, we recorded a $7.4 million impairment on one facility to reduce its net book value to its fair value less cost to sell. (2) In the first quarter of 2020, we recorded approximately $1.9 million of impairment expense to reduce one facility’s book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale. In the second quarter of 2020, we recorded approximately $2.6 million of impairment expense to reduce two facilities’ book value to their estimated fair value less costs to sell before they were reclassified to assets held for sale. In the third quarter of 2020, we recorded approximately $24.2 million of impairment expense to reduce six facilities’ book value to their estimated fair value less costs to sell before they were reclassified to assets held for sale. (3) We plan to sell the facilities classified as assets held for sale at September 30, 2020 within the next twelve months.

INTANGIBLES

INTANGIBLES	9 Months Ended
INTANGIBLES	Sep. 30, 2020
Intangibles [Abstract]
INTANGIBLES	NOTE 9 – INTANGIBLES The following is a summary of our intangibles as of September 30, 2020 and December 31, 2019: September 30, December 31, 2020 2019 (in thousands) Assets: Goodwill $ 644,084 $ 644,415 Above market leases $ 22,822 $ 49,240 Accumulated amortization (20,526) (21,227) Net intangible assets $ 2,296 $ 28,013 Liabilities: Below market leases $ 140,744 $ 147,292 Accumulated amortization (94,914) (87,154) Net intangible liabilities $ 45,830 $ 60,138 Above market leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income. For the three months ended September 30, 2020 and 2019, our net amortization related to intangibles was $3.7 million and $1.3 million, respectively. For the nine months ended September 30, 2020 and 2019, our net amortization related to intangibles was $8.5 million and $4.7 million, respectively. The estimated net amortization related to these intangibles for the remainder of 2020 and the subsequent four years is as follows: remainder of 2020 – $2.7 million; 2021 – $6.1 million; 2022 – $5.8 million; 2023 – $5.6 million and 2024 – $5.4 million. As of September 30, 2020, the weighted average remaining amortization period of above market lease assets is nine years and below market lease liabilities is approximately eight years. The following is a summary of our goodwill as of September 30, 2020: (in thousands) Balance as of December 31, 2019 $ 644,415 Less: foreign currency translation (331) Balance as of September 30, 2020 $ 644,084

CONCENTRATION OF RISK

CONCENTRATION OF RISK	9 Months Ended
CONCENTRATION OF RISK	Sep. 30, 2020
Concentration of Risk [Abstract]
CONCENTRATION OF RISK	NOTE 10 – CONCENTRATION OF RISK As of September 30, 2020, our portfolio of real estate investments consisted of 976 healthcare facilities, located in 40 states and the U.K. and operated by 69 third-party operators. Our investment in these facilities, net of impairments and allowances, totaled approximately $9.7 billion at September 30, 2020, with approximately 97% of our real estate investments related to healthcare facilities. Our portfolio is made up of (i) 755 SNFs, 114 ALFs, 28 specialty facilities, two medical office buildings, (ii) fixed rate mortgages on 57 SNFs, three ALFs and four specialty facilities, and (iii) 13 facilities that are held for sale. At September 30, 2020, we also held other investments of approximately $464.5 million, consisting primarily of secured loans to third-party operators of our facilities and $196.2 million of investments in five unconsolidated joint ventures. At September 30, 2020 we had investments with one operator/or manager that exceeded 10% of our total investments: Ciena Healthcare (“Ciena”). Ciena also generated approximately 11% of our total revenues for the three and nine months ended September 30, 2020. Ciena generated approximately 11% of our total revenues for the three and nine months ended September 30, 2019. At September 30, 2020, the three states in which we had our highest concentration of investments were Florida (14%), Texas (9%) and Michigan (7%).

STOCKHOLDERS'_OWNERS' EQUITY

STOCKHOLDERS'/OWNERS' EQUITY	9 Months Ended
STOCKHOLDERS'/OWNERS' EQUITY	Sep. 30, 2020
Stockholders' / Owners' Equity [Abstract]
STOCKHOLDERS'/OWNERS' EQUITY	NOTE 11 – STOCKHOLDERS’/OWNERS’ EQUITY $200 Million Stock Repurchase Program On March 20, 2020, Omega’s Board of Directors authorized the repurchase of up to $200 million of its outstanding common stock from time to time over the twelve months ending March 20, 2021. We are authorized to repurchase shares of our common stock in open market and privately negotiated transactions or in any other manner as determined by Omega’s management and in accordance with applicable law. The timing and amount of stock repurchases will be determined, in management’s discretion, based on a variety of factors, including but not limited to market conditions, other capital management needs and opportunities, and corporate and regulatory considerations. Omega has no obligation to repurchase any amount of its common stock, and such repurchases, if any, may be discontinued at any time. Omega did not repurchase any of its outstanding common stock during the nine months ended September 30, 2020. Dividends The Board of Directors has declared common stock dividends as set forth below: Record Payment Dividend per Date Date Common Share January 31, 2020 February 14, 2020 $ 0.67 April 30, 2020 May 15, 2020 $ 0.67 July 31, 2020 August 14, 2020 $ 0.67 November 2, 2020 November 16, 2020 $ 0.67 On the same dates listed above, Omega OP Unit holders received the same distributions per unit as those paid to the common stockholders of Omega. $500 Million Equity Shelf Program For the three months ended September 30, 2020, no shares were issued under our $500 Million Equity Shelf Program. For the three months ended September 30, 2019, we issued approximately 0.1 million shares of our common stock at an average price of $33.91 per share, net of issuance costs, generating net proceeds of $4.2 million under our $500 Million Equity Shelf Program. For the nine months ended September 30, 2020 and 2019, we issued approximately 49 thousand and 3.1 million, respectively, shares of our common stock at an average price of $34.64 per share and $34.78 per share, respectively, net of issuance costs, generating net proceeds of $1.7 million and $107.0 million, respectively, under our $500 Million Equity Shelf Program. Dividend Reinvestment and Common Stock Purchase Plan On March 23, 2020, we announced that we suspended our Dividend Reinvestment and Common Stock Purchase Plan. For the three months ended September 30, 2020, no shares were issued under our Dividend Reinvestment and Common Stock Purchase Plan. For the three months ended September 30, 2019, we issued approximately 1.0 million shares of our common stock at an average price of $37.87 per share through our Dividend Reinvestment and Common Stock Purchase Plan for gross proceeds of approximately $37.7 million. For the nine months ended September 30, 2020 and 2019, we issued approximately 90 thousand and 2.5 million, respectively, shares of our common stock at an average price of $41.80 per share and $37.06 per share, respectively, through our Dividend Reinvestment and Common Stock Purchase Plan for gross proceeds of approximately $3.7 million and $91.8 million, respectively. Accumulated Other Comprehensive Loss The following is a summary of our accumulated other comprehensive loss, net of tax where applicable: As of and for the As of and for the Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands) Foreign Currency Translation: Beginning balance $ (68,795) $ (49,715) $ (35,100) $ (47,704) Translation loss 21,808 (12,015) (11,818) (13,857) Realized gain (loss) 19 23 (50) (146) Ending balance (46,968) (61,707) (46,968) (61,707) Derivative Instruments: Cash flow hedges: Beginning balance (9,699) (4,093) (2,369) 3,994 Unrealized gain (loss) 7,223 (26) 1,401 (8,765) Realized (loss) gain (1) (1,500) 195 (3,008) 847 Ending balance (3,976) (3,924) (3,976) (3,924) Net investment hedge: Beginning balance 9,533 790 (4,420) 70 Unrealized gain (9,953) 4,040 4,000 4,760 Ending balance (420) 4,830 (420) 4,830 Total accumulated other comprehensive loss for Omega OP (2) (51,364) (60,801) (51,364) (60,801) Add: portion included in noncontrolling interest 2,263 2,529 2,263 2,529 Total accumulated other comprehensive loss for Omega $ (49,101) $ (58,272) $ (49,101) $ (58,272) (1) Recorded in interest expense on the Consolidated Statements of Operations. (2) These amounts are included in Owners’ Equity.

TAXES

TAXES	9 Months Ended
TAXES	Sep. 30, 2020
Taxes [Abstract]
TAXES	NOTE 12 – TAXES Since our inception, Omega has elected to be taxed as a REIT under the applicable provisions of the Internal Revenue Code (“Code”). A REIT is generally not subject to federal income tax on that portion of its REIT taxable income which is distributed to its stockholders, provided that at least 90% of such taxable income is distributed each taxable year and certain other requirements are met, including asset and income tests. So long as we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected to treat certain of our active subsidiaries as TRSs. Our domestic TRSs are subject to federal, state and local income taxes at the applicable corporate rates. Our foreign TSRs are subject to foreign income taxes. As of September 30, 2020, one of our TRSs that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss (“NOL”) carry-forward of approximately $5.7 million. Up to 100% of the NOL carry-forwards arising in taxable years ending prior to January 1, 2018, may be used to reduce taxable income for any taxable year during the eligible carry-forward period. Changes made by the Tax Cuts and Jobs Act of 2017 (the “2017 Act”) limited the amount of taxable income that may be offset by a NOL carryforward to 80% of taxable income to the extent the NOL originated in tax years beginning after December 31, 2017 (the “80% Limitation”). Our NOL carry-forward was fully reserved as of September 30, 2020, with a valuation allowance due to uncertainties regarding realization. Under current law, our NOL carry-forwards generated up through December 31, 2017 may be carried forward for no more than 20 years, and our NOL carry-forwards generated in our taxable years ended December 31, 2019 and December 31, 2018 may be carried forward indefinitely. However, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) modified the NOL carryback rules and deferred the application for the NOL carry-forward rules. The CARES Act, which was signed into law on March 27, 2020, modified the NOL carry-forward rules applicable to certain of the NOL carry-forwards possessed by our TRSs. First, the CARES Act defers the application of the 80% Limitation to our TRSs until their taxable years ended December 31, 2021, in addition to modifying the computation of the 80% Limitation. Additionally, the CARES Act permits the carryback of NOLs generated by our TRSs in 2018, 2019, and 2020 for up to five years to offset taxable income reported in any of those prior taxable years and recover income taxes paid in such prior taxable years. Other provisions of the CARES Act may also impact the computation of taxable income by any of our TRSs or Omega and Omega OP. The modifications to the NOL carryback rules do not permit the carryback of an NOL by a REIT and, thus, will not impact Omega. We do not anticipate that such changes will materially impact the computation of Omega’s taxable income, or the taxable income of any Omega entity, including our TRSs. We also do not expect that Omega or any Omega entity, including our TRSs, will realize a material tax benefit as a result of the changes to the provisions of the Code made by the CARES Act. For the three months ended September 30, 2020 and 2019, we recorded approximately $0.2 million and $0.3 million, respectively, of state and local income tax provisions. For the nine months ended September 30, 2020 and 2019, we recorded approximately $0.8 million and $0.7 million, respectively, of state and local income tax provisions. For the three months ended September 30, 2020 and 2019, we recorded approximately $0.5 million and $0.2 million, respectively, of tax provisions for foreign income taxes. For the nine months ended September 30, 2020 and 2019, we recorded approximately $1.8 million and $1.3 million, respectively, of tax provisions for foreign income taxes. The expenses were included in income tax expense on our Consolidated Statements of Operations.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2020
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	NOTE 13 – STOCK-BASED COMPENSATION The following is a summary of our stock-based compensation expense for the three and nine months ended September 30, 2020 and 2019, respectively. Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands) Stock-based compensation expense $ 5,122 $ 2,921 $ 14,380 $ 11,031 Time Based Restricted Equity Awards Restricted stock, restricted stock units (“RSUs”) and profits interest units (“PIUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of service or a change in control of the Company. Prior to vesting, ownership of the shares/units cannot be transferred. The restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. PIUs accrue distributions, which are equivalent to dividend equivalents, but have no voting rights. Once vested, each RSU is settled by the issuance of one share of Omega common stock and each PIU is settled by the issuance of one partnership unit in Omega OP (“Omega OP Unit”), subject to certain conditions. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. The PIUs are valued using a Monte Carlo model to estimate fair value. We expense the cost of these awards ratably over their vesting period. We awarded 20,215 RSUs and 102,565 profit interest units to employees on January 1, 2020. Performance-Based Restricted Equity Awards Performance-based restricted equity awards include performance restricted stock units (“PRSUs”) and PIUs. PRSUs and PIUs are subject to forfeiture if the performance requirements are not achieved or if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. The PRSUs awarded in March 2016, January 2017, January 2018, and January 2019 and the PIUs awarded in March 2016, January 2017, January 2018, January 2019 and January 2020 have varying degrees of performance requirements to achieve vesting, and each PRSU and PIU award represents the right to a variable number of shares of common stock or partnership units. Each PIU once earned is convertible into one Omega OP Unit in Omega OP, subject to certain conditions. The vesting requirements are based on either the (i) total shareholder return (“TSR”) of Omega or (ii) Omega’s TSR relative to other real estate investment trusts in the FTSE NAREIT Equity Health Care Index for awards granted in or after 2016 (both “Relative TSR”). We expense the cost of these awards ratably over their service period. Prior to vesting and the distribution of shares or Omega OP Units, ownership of the PRSUs or PIUs cannot be transferred. Dividends on the PRSUs are accrued and only paid to the extent the applicable performance requirements are met. While each PIU is unearned, the employee receives a partnership distribution equal to 10% of the quarterly approved regular periodic distributions per Omega OP Unit. The remaining partnership distributions (which in the case of normal periodic distributions is equal to the total approved quarterly dividend on Omega’s common stock) on the PIUs accumulate, and if the PIUs are earned, the accumulated distributions are paid. We used a Monte Carlo model to estimate the fair value for the PRSUs and PIUs granted to the employees. The number of shares or units earned under the TSR PRSUs or PIUs depends generally on the level of achievement of Omega’s TSR over the indicated performance period. We awarded 680,038 TSR PIUs to employees on January 1, 2020. The number of shares or units earned under the Relative TSR PRSUs or PIUs depends generally on the level of achievement of Omega’s TSR relative to other real estate investment trusts in the FTSE NAREIT Equity Health Care Index TSR over the performance period indicated. We awarded 528,499 Relative TSR PIUs to employees on January 1, 2020.

BORROWING ARRANGEMENTS

BORROWING ARRANGEMENTS	9 Months Ended
BORROWING ARRANGEMENTS	Sep. 30, 2020
BORROWING ARRANGEMENTS [Abstract]
BORROWING ACTIVITIES AND ARRANGEMENTS	NOTE 14 – BORROWING ACTIVITIES AND ARRANGEMENTS The following is a summary of our borrowings: Annual Interest Rate as of September 30, September 30, December 31, Maturity 2020 2020 2019 (in thousands) Secured borrowings: HUD mortgages (1)(5) 2046-2052 3.01 % $ 369,076 $ 387,405 Term loan (2)(5) 2021 3.25 % 2,275 2,275 371,351 389,680 Unsecured borrowings: Revolving line of credit (3) 2021 1.34 % 170,667 125,000 U.S. term loan 2022 1.59 % 350,000 350,000 Sterling term loan (4) 2022 1.50 % 129,280 132,480 Omega OP term loan (5) 2022 3.29 % 75,000 75,000 2015 term loan 2022 3.80 % 250,000 250,000 Deferred financing costs – net (6) (1,946) (2,742) Total term loans – net 802,334 804,738 2023 notes 2023 4.375 % 700,000 700,000 2024 notes 2024 4.950 % 400,000 400,000 2025 notes 2025 4.500 % 400,000 400,000 2026 notes 2026 5.250 % 600,000 600,000 2027 notes 2027 4.500 % 700,000 700,000 2028 notes 2028 4.750 % 550,000 550,000 2029 notes 2029 3.625 % 500,000 500,000 Subordinated debt 2021 9.000 % 20,000 13,541 Discount – net (20,571) (23,041) Deferred financing costs – net (20,820) (23,778) Total senior notes and other unsecured borrowings – net 3,828,609 3,816,722 Total unsecured borrowings – net 4,801,610 4,746,460 Total secured and unsecured borrowings – net (7) $ 5,172,961 $ 5,136,140 (1) Reflects the weighted average annual contractual interest rate on the mortgages at September 30, 2020; secured by real estate assets with a net carrying value of $577.6 million as of September 30, 2020. (2) Borrowing is the debt of a consolidated joint venture. (3) During the first quarter of 2020, we drew approximately $300 million on our existing $1.25 billion revolving credit facility as a precautionary measure due to the COVID-19 outbreak. This borrowing was included in cash and cash equivalents on our Consolidated Balance Sheets as of March 31, 2020. We repaid this $300 million borrowing in June 2020. (4) Actual borrowing in British Pounds Sterling and remeasured to USD. (5) Omega OP or wholly owned subsidiaries of Omega OP are the obligor on these borrowings. (6) Includes $0.2 million of net deferred financing costs related to the Omega OP term loan as of September 30, 2020. (7) All borrowings are direct borrowings of Omega unless otherwise noted. HUD Mortgage Loan Payoffs On August 26, 2020, we paid approximately $13.7 million to retire two mortgage loans guaranteed by HUD. The loans were assumed as part of an acquisition in 2019, and had an average interest rate of 3.08% per annum with maturities in 2051 and 2052. The payoff included a $0.9 million prepayment fee which is included in interest – refinancing costs on our Consolidated Statements of Operations. Subordinated Debt $400 Million Forward Starting Swaps On March 27, 2020, we entered into five forward starting swaps totaling $400 million. We designated the forward starting swaps as cash flow hedges of interest rate risk associated with interest payments on a forecasted issuance of long-term debt, initially expected to occur within the next five years. The swaps are effective on August 1, 2023 and expire on August 1, 2033 and were issued at a fixed rate of approximately 0.8675%. In October 2020, we issued $700 million aggregate principal amount of our 3.375% Senior Notes due 2031 and discontinued hedge accounting. Amounts reported in accumulated other comprehensive loss related to these discontinued cash flow hedging relationships will be reclassified to interest expense as interest payments are made on the Company’s debt. Simultaneously, we re-designated these swaps in new cash flow hedging relationships of interest rate risk associated with interest payments on another forecasted issuance of long-term debt. We are hedging our exposure to the variability in future cash flows for forecasted transactions over a maximum period of 46 months (excluding forecasted transactions related to the payment of variable interest on existing financial instruments). Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of September 30, 2020 and December 31, 2019, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings. Omega OP, the guarantor of Parent’s outstanding senior notes, does not directly own any substantive assets other than its interest in non-guarantor subsidiaries.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended
FINANCIAL INSTRUMENTS	Sep. 30, 2020
Financial Instruments [Abstract]
FINANCIAL INSTRUMENTS	NOTE 15 – FINANCIAL INSTRUMENTS The net carrying amount of cash and cash equivalents, restricted cash, contractual receivables, other assets and accrued expenses and other liabilities reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (Level 1). At September 30, 2020 and December 31, 2019, the net carrying amounts and fair values of our other financial instruments were as follows: September 30, 2020 December 31, 2019 Carrying Fair Carrying Fair Amount Value Amount Value (in thousands) Assets: Investments in direct financing leases – net $ 10,858 $ 10,858 $ 11,488 $ 11,488 Mortgage notes receivable – net 892,539 920,800 773,563 819,083 Other investments – net 464,503 468,694 419,228 412,934 Total $ 1,367,900 $ 1,400,352 $ 1,204,279 $ 1,243,505 Liabilities: Revolving line of credit $ 170,667 $ 170,667 $ 125,000 $ 125,000 Term loan 2,275 2,275 2,275 2,275 U.S. term loan 349,226 350,000 348,878 350,000 Sterling term loan 128,989 129,280 132,059 132,480 Omega OP term loan 74,837 75,000 74,763 75,000 2015 term loan 249,282 250,000 249,038 250,000 4.375% notes due 2023 – net 696,688 756,678 695,812 749,693 4.95% notes due 2024 – net 396,461 431,497 395,702 442,327 4.50% notes due 2025 – net 396,734 427,411 396,163 430,529 5.25% notes due 2026 – net 596,261 659,994 595,732 675,078 4.50% notes due 2027 – net 690,543 757,945 689,445 759,475 4.75% notes due 2028 – net 542,647 606,329 541,891 602,967 3.625% notes due 2029 – net 489,170 507,158 488,263 500,792 HUD mortgages – net 369,076 419,925 387,405 379,866 Subordinated debt – net 20,105 21,828 13,714 15,253 Total $ 5,172,961 $ 5,565,987 $ 5,136,140 $ 5,490,735 Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies in our Annual Report on Form 10-K The following methods and assumptions were used in estimating fair value disclosures for financial instruments. ● Direct financing leases: The fair value of the investments in direct financing leases are estimated using a discounted cash flow analysis, using interest rates being offered for similar leases to borrowers with similar credit ratings (Level 3). ● Mortgage notes receivable: The fair value of the mortgage notes receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). ● Other investments: Other investments are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). ● Revolving line of credit, secured borrowing and term loans: The fair value of our borrowings under variable rate agreements are estimated using a present value technique based on expected cash flows discounted using the current market rates (Level 3). ● Senior notes and subordinated debt: The fair value of our borrowings under fixed rate agreements are estimated using a present value technique based on inputs from trading activity provided by a third-party (Level 2). ● HUD mortgages: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2020
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 16 – COMMITMENTS AND CONTINGENCIES Litigation On November 16, 2017, a purported securities class action complaint captioned Dror Gronich v. Omega Healthcare Investors, Inc., C. Taylor Pickett, Robert O. Stephenson, and Daniel J. Booth Steve Klein v. Omega Healthcare Investors, Inc., C. Taylor Pickett, Robert O. Stephenson, and Daniel J. Booth Pursuant to a Scheduling Order entered by the District Court, lead plaintiff Setzer and additional plaintiff Earl Holtzman filed a Consolidated Amended Class Action Complaint on May 25, 2018 (the “Securities Class Action”). The Securities Class Action purports to be a class action brought on behalf of shareholders who acquired the Company’s securities between May 3, 2017 and October 31, 2017. The Securities Class Action alleges that the defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by making materially false and/or misleading statements, and by failing to disclose material adverse facts about the Company’s business, operations, and prospects, including the financial and operating results of one of the Company’s operators, the ability of such operator to make timely rent payments, and the impairment of certain of the Company’s leases and the uncollectibility of certain receivables. The Securities Class Action, which purports to assert claims for violations of Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder, as well as Section 20(a) of the Exchange Act, seeks an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief. The Company and the officers named in the Securities Class Action filed a Motion to Dismiss on July 17, 2018. On March 25, 2019, the District Court entered an order dismissing with prejudice all claims against all defendants. Plaintiffs appealed the order to the United States Court of Appeals for the Second Circuit and the Court of Appeals heard oral argument on November 13, 2019. On August 3, 2020, the United States Court of Appeals for the Second Circuit issued a ruling reversing the District Court’s order of dismissal and remanding the case to the District Court for further proceedings. Pursuant to an agreed upon Stipulation, Plaintiffs filed a second amended complaint on August 28, 2020. The second amended complaint extends the class period to include shareholders who acquired the Company’s securities between February 8, 2017 and October 31, 2017. Pursuant to an agreed upon Stipulation and Order, the motion to dismiss the second amended complaint is due to be filed on November 24, 2020. On August 22, 2018, Stourbridge Investments LLC, a purported stockholder of the Company, filed a derivative action purportedly on behalf of the Company in the United States District Court for the Southern District of New York against the current directors of the Company as well as certain officers alleging violations of Section 14(a) of the Securities Exchange Act of 1934 and state-law claims including breach of fiduciary duty. Stourbridge Investments LLC v. Callen et al., On January 30, 2019, Swan filed a derivative action in the Baltimore City Circuit Court of Maryland, purportedly on behalf of the Company against certain current and former directors of the Company as well as certain officers, asserting claims for breach of fiduciary duty, waste of corporate assets and unjust enrichment. Swan v. Pickett, et al., Bradley and Smith v. Callen, et al. Swan Other In September 2016, MedEquities received a Civil Investigative Demand (“CID”) from the U.S. Department of Justice (“DOJ”), which indicates that it is conducting an investigation regarding alleged violations of the False Claims Act, Stark Law and Anti-Kickback Statute in connection with claims that may have been submitted to Medicare and other federal payors for services rendered to patients at Lakeway Regional Medical Center (the “Lakeway Hospital”) or by providers with financial relationships with Lakeway Hospital. As a result of the acquisition of MedEquities, the Company owns a 51% interest in an unconsolidated partnership that owns the Lakeway Hospital (Lakeway Realty, L.L.C.). The CID requested certain documents and information related to the acquisition and ownership of the Lakeway Hospital through Lakeway Realty, L.L.C. The Company has learned that the DOJ is investigating MedEquities’ conduct in connection with its investigation of financial relationships related to the Lakeway Hospital, including allegations by the DOJ that these relationships violate and continue to violate the Anti-Kickback Statute and, as a result, related claims submitted to federal payors violated and continue to violate the False Claims Act. The Company is cooperating fully with the DOJ in connection with the CID and has produced all of the information that has been requested to date. On September 29, 2020 the Department of Justice announced it had reached a settlement of a False Claims Act case with Lakeway Regional Medical Center wherein Lakeway Regional Medical Center agreed to pay $1.1 million for inducing certain physicians to refer patients by offering a low risk and high return investment in the form of a joint venture to purchase and then lease back the hospital to Lakeway Regional Medical Center. A MedEquities subsidiary was a party to this transaction but was not included in settlement discussions. As of November 2, 2020, the documents relating to the settlement were not publicly available. The Company believes that the acquisition, ownership and leasing of the Lakeway Hospital through Lakeway Realty, L.L.C. was and is in compliance with all applicable laws. However, due to the uncertainties surrounding this matter and its ultimate outcome, we are unable to determine whether it is probable that any loss has been incurred. In addition, we are subject to various other legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations. Indemnification Agreements In connection with certain facility transitions, we have agreed to indemnify certain operators in certain events. As of September 30, 2020, our maximum funding commitment under these indemnification agreements was approximately $11.5 million. Claims under these indemnification agreements may be made within 18 months to 72 months of the transition date. These indemnification agreements were provided to certain operators in connection with facility transitions and generally would be applicable in the event that the prior operators do not perform under their transition agreements. The Company does not expect to fund a material amount under these indemnification agreements. Commitments We have committed to fund the construction of new leased and mortgaged facilities, capital improvements and other commitments. We expect the funding of these commitments to be completed over the next several years. Our remaining commitments at September 30, 2020, are outlined in the table below (in thousands): Total commitments $ 562,262 Amounts funded to date (1) (467,141) Remaining commitments (2) $ 95,121 (1) Includes finance costs. (2) This amount excludes our remaining commitments to fund under our other investments of approximately $109.3 million.

(LOSS) EARNINGS PER SHARE_UNIT

(LOSS) EARNINGS PER SHARE/UNIT	9 Months Ended
(LOSS) EARNINGS PER SHARE/UNIT	Sep. 30, 2020
(LOSS) Earnings per Share/Unit [Abstract]
(LOSS) EARNINGS PER SHARE/UNIT	NOTE 17 – (LOSS) EARNINGS PER SHARE/UNIT The following tables set forth the computation of basic and diluted earnings per share/unit: Omega Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands, except per share amounts) Numerator: Net (loss) income $ (93,768) $ 142,948 $ 100,471 $ 290,801 Add/deduct: net loss (income) attributable to noncontrolling interests 2,477 (4,208) (2,540) (9,218) Net (loss) income available to common stockholders/Omega OP Unit holders $ (91,291) $ 138,740 $ 97,931 $ 281,583 Denominator: Denominator for basic earnings per share 227,507 217,818 227,393 211,315 Effect of dilutive securities: Common stock equivalents — 1,754 1,065 1,678 Net forward share contract — 319 — 106 Noncontrolling interest – Omega OP Units 6,168 6,622 6,078 7,072 Denominator for diluted earnings per share/unit 233,675 226,513 234,536 220,171 Earnings per share/unit - basic: Net (loss) income available to common stockholders/Omega OP Unit holders $ (0.40) $ 0.64 $ 0.43 $ 1.33 Earnings per share/unit – diluted: Net (loss) income (1) $ (0.40) $ 0.63 $ 0.43 $ 1.32 (1) For the three months ended September 30, 2020, approximately 904 potential common shares/units are not included in the computation of diluted earnings per share as a net loss exists and therefore the effect would be an antidilutive per share amount. Omega OP Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands, except per share amounts) Numerator: Net (loss) income $ (93,768) $ 142,948 $ 100,471 $ 290,801 Add: net loss attributable to noncontrolling interests 3 9 9 9 Net (loss) income available to Omega OP Unit holders $ (93,765) $ 142,957 $ 100,480 $ 290,810 Denominator: Denominator for basic earnings per unit 233,675 224,440 233,471 218,387 Effect of dilutive securities: Omega OP Unit equivalents — 1,754 1,065 1,678 Net forward share contract — 319 — 106 Denominator for diluted earnings per unit 233,675 226,513 234,536 220,171 Earnings per unit - basic: Net (loss) income available to Omega OP Unit holders $ (0.40) $ 0.64 $ 0.43 $ 1.33 Earnings per unit - diluted: Net (loss) income (1) $ (0.40) $ 0.63 $ 0.43 $ 1.32 (1) For the three months ended September 30, 2020, approximately 904 potential common shares/units are not included in the computation of diluted earnings per share as a net loss exists and therefore the effect would be an antidilutive per share amount.

SUPPLEMENTAL DISCLOSURE TO CONS

SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS	9 Months Ended
	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS	NOTE 18 – SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS The following are supplemental disclosures to the consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019: Nine Months Ended September 30, 2020 2019 (in thousands) Reconciliation of cash and cash equivalents and restricted cash: Cash and cash equivalents $ 35,951 $ 40,860 Restricted cash 4,164 1,372 Cash, cash equivalents and restricted cash at end of period $ 40,115 $ 42,232 Supplemental information: Interest paid during the period, net of amounts capitalized $ 174,247 $ 170,045 Taxes paid during the period $ 5,493 $ 3,510 Non cash investing activities Non cash acquisition of a business (see Note 2) $ — $ (566,966) Non cash acquisition of real estate (see Note 2) — (143,174) Non cash proceeds from sale of real estate investments (see Note 4) 83,910 — Non cash placement of mortgages (see Note 4) (86,936) — Non cash collection of mortgage principal — 11,874 Non cash investment in other investments (see Note 5) (121,139) (25,925) Non cash proceeds from other investments (see Note 5) 68,025 149,542 Non cash proceeds from direct financing lease — 4,970 Initial non cash right of use asset - ground leases — 5,593 Initial non cash lease liability - ground leases — (5,593) Non cash financing activities Debt assumed in merger (see Note 2) $ — $ 285,100 Stock exchanged in merger (see Note 2) — 281,865 Non cash borrowing of other long-term borrowings 6,459 — Change in fair value of cash flow hedges (1,637) (9,316) Remeasurement of debt denominated in a foreign currency (4,000) (4,760)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2020
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 19 – SUBSEQUENT EVENTS On November 1, 2020, we acquired seven facilities from an unrelated third-party for $78 million. The seven facilities consist of six SNFs and one ALF representing 876 operating beds located in Virginia, were simultaneously added to an existing operator’s triple net master lease with initial annual contractual cash rent of $7.4 million. We used the net proceeds from the 2031 Senior Notes offering to repay the outstanding balance on our U.S. term loan and 2015 term loan and partially paydown the Omega OP term loan and revolving line of credit

BASIS OF PRESENTATION AND SIG_2

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policy)	9 Months Ended
	Sep. 30, 2020
Basis of Presentation and Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our latest Annual Report on Form 10-K Omega’s consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP, (iii) all direct and indirect wholly owned subsidiaries of Omega and (iv) other entities in which Omega or Omega OP has a majority voting interest and control. All intercompany transactions and balances have been eliminated in consolidation, and Omega’s net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Omega OP’s consolidated financial statements include the accounts of (i) Omega OP, (ii) all direct and indirect wholly owned subsidiaries of Omega OP and (iii) other entities in which Omega OP has a majority voting interest and control. All intercompany transactions and balances have been eliminated in consolidation, and Omega OP’s net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to certain risks and uncertainties affecting the healthcare industry, including those stemming from the novel coronavirus (“COVID-19”) global pandemic described below, which has disproportionately impacted the senior care sector, as well as, those stemming from healthcare legislation and changing regulation by federal, state and local governments, including those driven by the COVID-19 pandemic. Additionally, we are subject to risks and uncertainties as a result of changes affecting operators of nursing home facilities due to the actions of governmental agencies and insurers to limit the rising cost of healthcare services. The COVID-19 pandemic has led governments and other authorities in the U.S., U.K. and around the world to impose measures intended to control its spread, including but not limited to, the mandated use of personal protective equipment, restrictions on freedom of movement and business operations such as travel bans, border closings, business closures, quarantines and shelter-in-place orders, etc. A range of government restrictions remain in place along with continuing uncertainty around the potential duration of the pandemic. As of October 22, 2020, approximately half of our facilities have reported one or more positive cases of COVID-19 among the residents and/or operator employee populations. Many of our operators have reported incurring significant cost increases as a result of the COVID-19 pandemic, with dramatic increases for facilities with positive cases. We believe these increases primarily stem from elevated labor costs, including increased use of overtime and bonus pay, as well as a significant increase in both the cost and usage of personal protective equipment, testing equipment and processes and supplies. In terms of occupancy levels, many of our operators have reported experiencing declines, in part due to the elimination or suspension of elective hospital procedures, fewer discharges from hospitals to SNFs and higher hospital readmittances from SNFs. To the extent government support is not sufficient or timely to offset these impacts, or to the extent these trends continue or accelerate and are not offset by additional government relief that is sufficient or timely, the operating results of our operators are likely to be adversely affected, some may be unwilling or unable to pay their contractual obligations to us in full or on a timely basis and we may be unable to restructure such obligations on terms as favorable to us as those currently in place. Even if operators are able to avail themselves of government relief to offset some of these costs, they may face challenges in complying with the terms and conditions of government support and may face longer-term adverse impacts to their personnel and business operations from the pandemic, including potential patient litigation and decreased demand for their services. The extent of the COVID-19 pandemic’s effect on our and our operators’ operational and financial performance will depend on future developments, including the ultimate duration, spread and intensity of the outbreak, which may depend on factors such as the development and implementation of an effective vaccine and treatments for COVID-19, government funds and other support for the senior care sector and the efficacy of other policies and measures that may mitigate the impact of the pandemic, all of which are uncertain and difficult to predict. Due to these uncertainties, we are not able at this time to estimate the effect of these factors on our business, but the adverse impact on our business, results of operations, financial condition and cash flows could be material.
Variable Interest Entities	Variable Interest Entities GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affects the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. Our variable interests in VIEs may be in the form of equity ownership, leases, guarantees and/or loans with our operators. We analyze our agreements and investments to determine whether our operators or unconsolidated joint ventures are VIEs and, if so, whether we are the primary beneficiary. We consolidate a VIE when we determine that we are its primary beneficiary. We identify the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Factors considered in determining whether we are the primary beneficiary of an entity include: (i) our voting rights, if any; (ii) our involvement in day-to-day capital and operating decisions; (iii) our risk and reward sharing; (iv) the financial condition of the operator or joint venture and (iv) our representation on the VIE’s board of directors. We perform this analysis on an ongoing basis. As of September 30, 2020, we have not consolidated any VIEs, as we do not have the power to direct the activities of any VIEs that most significantly impact their economic performance and we do not have the obligation to absorb losses or receive benefits of the VIEs that could be significant to the entity.
Real Estate Investments and Depreciation	Real Estate Investments and Depreciation The costs of significant improvements, renovations and replacements, including interest are capitalized. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are charged to operations as they are incurred. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from 20 eight three
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand and highly liquid investments with a maturity date of three months or less when purchased. These investments are stated at cost, which approximates fair value. The majority of our cash, cash equivalents and restricted cash are held at major commercial banks. Certain cash account balances exceed FDIC insurance limits of $250,000 per account and, as a result, there is a concentration of credit risk related to amounts in excess of the insurance limits. We regularly monitor the financial stability of these financial institutions and believe that we are not exposed to any significant credit risk in cash, cash equivalents or restricted cash.
Restricted Cash	Restricted Cash Restricted cash consists primarily of liquidity deposits escrowed for tenant obligations required by us pursuant to certain contractual terms and other deposits required by the U.S. Department of Housing and Urban Development (“HUD”) in connection with our mortgage borrowings guaranteed by HUD.
Real Estate Investment Impairment	Real Estate Investment Impairment Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance including the current payment status of contractual obligations and expectations of the ability to meet future contractual obligations, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to management’s estimate of future undiscounted cash flows of the underlying facilities. The estimated future undiscounted cash flows are generally based on the related lease which relates to one or more properties and may include cash flows from the eventual disposition of the asset. In some instances, there may be various potential outcomes for a real estate investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess the recoverability are probability-weighted based on management’s best estimates as of the date of evaluation. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. Additionally, our evaluation of fair value may consider valuing the property as a nursing home or other healthcare facility as well as alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property as well as the fair value of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment to our assets in a future period that could be material to Omega’s results of operations. For the three months ended September 30, 2020 and 2019, we recognized impairment on real estate properties of approximately $28.1 million and $3.8 million, respectively. For the nine months ended September 30, 2020 and 2019, we recognized impairment on real estate properties of approximately $43.7 million and $9.5 million, respectively. In July 2020, we executed a Forbearance and Transition Agreement with Daybreak Venture LLC (“Daybreak”) which, among other things, set forth the parties’ plan to sell or re-lease the Daybreak portfolio (which plan contemplated the potential sale of 28 facilities currently leased to Daybreak to a non-Omega party for $100 million), and the Company’s agreement to forbear from exercising certain default remedies during the transition period. During the third quarter of 2020, discussions terminated on the contemplated sale transaction for $100 million, and in October 2020 the Forbearance and Transition Agreement was amended and restated to continue the forbearance. The Company is in negotiations with other third-party operators to re-lease these 28 facilities, along with three additional facilities. Further, the Company expects to re-lease or sell one additional Daybreak facility with a net book value of $0.1 million either in connection with or separate from these transactions. As of September 30, 2020, the 31 facilities subject to current re-lease negotiations have a net book value of approximately $147 million. We evaluated the facilities for impairment as of September 30, 2020 and concluded that the facilities were not impaired, as we believe that our expected annual nominal cash flows from re-leasing these facilities exceed our current net book value of the 31 facilities. To the extent certain of these 31 facilities are not re-leased to a third-party operator and are instead identified for sale, we may be required to record an impairment to the extent the sales price for a facility is less than its net book value. On May 26, 2020, we executed an agreement to sell an acute care hospital located in Nevada to an unrelated third-party for $56.5 million. The agreement provided that the sale was subject to a 60-day due diligence period which expired in July 2020. During the second quarter of 2020, we recorded an impairment of approximately $2.2 million related to this facility to reduce its net book value to its fair value less costs to sell of approximately $55.3 million and reclassified the facility to assets held for sale. In July 2020, we agreed with the third-party buyer to lower the purchase price to approximately $49.0 million. The reduction in the purchase price resulted in an additional impairment of approximately $7.4 million in July 2020, and the facility was subsequently sold in September 2020.
Allowance for Losses on Mortgages, Other Investments and Direct Financing Leases	Allowance for Losses on Mortgages, Other Investments and Direct Financing Leases The allowances for losses on mortgage notes receivable, other investments and direct financing leases (collectively, our “loans”) are maintained at a level believed adequate to absorb potential losses. The determination of the allowances is based on a quarterly evaluation of these loans, including general economic conditions and estimated collectability of loan payments. We evaluate the collectability of our loans receivable based on a combination of factors, including, but not limited to, delinquency status, financial strength of the borrower and guarantors and the value of the underlying collateral. If such factors indicate that there is greater risk of loan charge-offs, additional allowances or placement on non-accrual status may be required. A loan is impaired when, based on current information and events, it is probable that we will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreements. Consistent with this definition, all loans on non-accrual status may be deemed impaired. To the extent circumstances improve and the risk of collectability is diminished, we will return these loans to full accrual status. When management identifies a loan impairment, the loan is written down to the present value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the loan is written down to the fair value of the underlying collateral. We may base our valuation on a loan’s observable market price, if any, or the fair value of collateral, net of sales costs, if the repayment of the loan is expected to be provided solely by the sale of the collateral. We account for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We generally utilize the cost-recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impaired loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows expected under the loan or direct financing lease and/or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the book value of the loans or direct financing leases. Under the cost-recovery method, we apply cash received against the outstanding loan balance or direct financing lease prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the terms of the agreement. As of September 30, 2020 and December 31, 2019, we had $61.0 million and $5.1 million, respectively, of reserves on our loans. For additional information see “Accounting Pronouncements Adopted in 2020,” Note 3 – Direct Financing Leases, Note 4 – Mortgage Notes Receivable, and Note 5 – Other Investments.
Goodwill Impairment	Goodwill Impairment We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a significant decline in real estate valuations, current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance or a significant decline in the value of our market capitalization, to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount. On an annual basis during the fourth quarter of each fiscal year, or on an interim basis if we conclude it is more likely than not that the fair value of the reporting unit is less than its carrying value, we perform a two-step goodwill impairment test to identify potential impairment and measure the amount of impairment we will recognize, if any.
Earnings Per Share/Unit	Earnings Per Share/Unit The computation of basic earnings per share/unit (“EPS” or “EPU”) is computed by dividing net (loss) income available to common stockholders/Omega OP Unit holders by the weighted-average number of shares of common stock/Omega OP Units outstanding during the relevant period. Diluted EPS/EPU is computed using the treasury stock method, which is net (loss) income divided by the total weighted-average number of common outstanding shares/Omega OP Units plus the effect of dilutive common equivalent shares/units during the respective period. Dilutive common shares/Omega OP Units reflect the assumed issuance of additional common shares pursuant to certain of our share-based compensation plans, including restricted stock and profit interest units, performance restricted stock and profit interest units, the assumed issuance of additional shares related to Omega OP Units held by outside investors. Dilutive Omega OP Units reflect the assumed issuance of additional Omega OP Units pursuant to certain of our share-based compensation plans, including, restricted stock and profit interest units, performance restricted stock and profit interest units. To the extent we have a net loss, potential common shares/units are not included in the computation of diluted earnings per share as the effect would be an antidilutive per share amount.
Noncontrolling Interests	Noncontrolling Interests Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity or owners’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors and interests in a consolidated real estate joint venture not fully owned by Omega. The noncontrolling interest for Omega OP represents outside investors interests in a consolidated real estate joint venture not fully owned by Omega OP.
Foreign Operations	Foreign Operations The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). For our consolidated subsidiaries whose functional currency is not the USD, we translate their financial statements into the USD. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in Omega OP’s owners’ equity and Omega’s accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interests, if applicable. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature in which case the adjustments are included in Omega OP’s owners’ equity and Omega’s AOCL and a proportionate amount of gain or loss is allocated to noncontrolling interests, if applicable.
Derivative Instruments	Derivative Instruments Cash flow hedges During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with our related assertions. Omega recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which is determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated in qualifying cash flow hedging relationships, the gain or loss on the derivative is recognized in Omega OP’s owners’ equity and Omega’s AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, if applicable. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized liabilities or assets on the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At September 30, 2020 and December 31, 2019, the fair value of certain qualifying cash flow hedges was $12.0 million and $3.7 million, respectively, and are included in accrued expenses and other liabilities on our Consolidated Balance Sheets (see Note 19 – Subsequent Events). At September 30, 2020, the fair value of certain qualifying cash flow hedges was $6.6 million and is included in other assets on our Consolidated Balance Sheets (see Note 14 – Borrowing Activities and Arrangements). Net investment hedge We are exposed to fluctuations in the GBP against its functional currency, the USD, relating to its investments in healthcare-related investments located in the U.K. The Company uses a nonderivative, GBP-denominated term loan and line of credit to manage its exposure to fluctuations in the GBP-USD exchange rate. The foreign currency transaction gain or loss on the nonderivative hedging instrument that is designated and qualifies as a net investment hedge is reported in Omega OP’s owners’ equity and Omega’s AOCL in our Consolidated Balance Sheets.
Contractual Receivables and Other Receivables and Lease Inducements	Contractual Receivables and Other Receivables and Lease Inducements Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception, modification, or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term. We assess the probability of collecting substantially all payments under our leases based on several factors, including, among other things, payment history of the lessee, the financial strength of the lessee and any guarantors, historical operations and operating trends, current and future economic conditions and expectations of performance (which includes known substantial doubt about an operator’s ability to continue as a going concern). If our evaluation of these factors indicates it is probable that we will be unable to collect substantially all rents, we place that operator on a cash basis and limit our rental income to the lesser of lease income on a straight-line basis plus variable rents when they become accruable or cash collected. As a result of placing an operator on a cash basis, we may recognize a charge to rental income for any contractual rent receivable, straight-line rent receivable and lease inducements. If we change our conclusion regarding the probability of collecting rent payments required by a lessee, we may recognize an adjustment to rental income in the period we make a change to our prior conclusion. On a quarterly basis, and more frequently as appropriate, we review our contractual interest receivables, effective yield interest receivables and direct financing lease receivables to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement, if any. For a loan recognized on an effective yield basis or a direct financing lease, we generally provide an allowance for effective interest or income from direct financing leases when certain conditions or indicators of adverse collectability are present. If these accounts receivable balances are subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. A summary of our net receivables by type is as follows: September 30, December 31, 2020 2019 (in thousands) Contractual receivables – net $ 10,757 $ 27,122 Effective yield interest receivables $ 12,481 $ 12,914 Straight-line rent receivables 129,559 275,549 Lease inducements 84,373 92,628 Other receivables and lease inducements $ 226,413 $ 381,091 During the first quarter of 2020, we provided approximately $16.0 million of funding to four operators, which was accounted for as lease inducements. Of the $16.0 million, $12.9 million was funded to an operator for development and start-up related costs. During the second quarter of 2020, we provided approximately $12.9 million of funding to three operators, which was accounted for as lease inducements. Of the $12.9 million, $11.0 million was funded to an operator for development and start-up related costs. During the third quarter of 2020, we wrote-off approximately $142.3 million of contractual receivables, straight-line rent receivables, and lease inducements to rental income as a result of placing three operators on a cash basis resulting from a change in our evaluation of the collectability of future rent payments due under the respective lease agreements as we considered information the Company received from these three operators regarding substantial doubt as to their ability to continue as a going concern. Of the $142.3 million, $64.9 million related to Genesis Healthcare, Inc. (“Genesis”), $75.3 million related to Agemo Holdings, LLC (“Agemo”) and $2.1 million related to another operator which leases two facilities from the Company. During the third quarter of 2020, we also wrote-off approximately $1.0 million of straight-line rent receivable to rental income as a result of transitioning facilities to another existing operator. In addition, during the third quarter of 2020, we received a one-time rent payment of approximately $55.4 million from Maplewood Real Estate Holdings, LLC (“Maplewood”), in conjunction with the restructuring of its master lease and loans with Omega (see Note 5 – Other Investments). This payment was accounted for as an adjustment to straight-line rent receivables and is being amortized over the remaining term of the master lease.
Accounting Pronouncement Adopted in 2020	Accounting Pronouncements Adopted in 2020 In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326) (“ASU 2016-13”), which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for credit losses. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. ASU 2016-13 specifically excludes from its scope receivables arising from operating leases accounted for under Topic 842. We adopted ASU 2016-13 on January 1, 2020 using the modified retrospective approach and we recorded an initial $28.8 million allowance for expected credit losses with a corresponding adjustment to equity Transition Impact of Adopting Topic 326 Pre-adoption balance as of Impact of adopting Post-adoption balance as of Financial Statement Line Item December 31, 2019 Topic 326 January 1, 2020 (in thousands) Mortgage Notes Receivable $ 773,563 $ (21,386) $ 752,177 Investment in Direct Financing Leases 11,488 (611) 10,877 Other Investments 419,228 (6,688) 412,540 Off-Balance Sheet Commitments 20,777 (100) 20,677 Total $ 1,225,056 $ (28,785) $ 1,196,271 We elected to disaggregate our financial assets within the scope of Topic 326 based on the type of financial instrument. These segments were further disaggregated based on our internal credit ratings. We assess our internal credit ratings on a quarterly basis. Our internal credit ratings consider several factors including the collateral and/or security, the performance of borrowers underlying facilities, if applicable, available credit support (e.g., guarantees), borrowings with third parties, and other ancillary business ventures and real estate operations of the borrower. Our internal ratings range between 1 and 7. An internal rating of 1 reflects the lowest likelihood of loss and a 7 reflects the highest likelihood of loss. Amortized Cost Basis By Year of Origination and Credit Quality Indicator Rating Financial Statement Line Item 2020 2019 2018 2017 2016 2015 2014 & older Revolving Loans Balance as of September 30, 2020 (in thousands) 1 Mortgage Notes Receivable $ - $ - $ - $ - $ - $ 67,381 $ - $ - $ 67,381 2 Mortgage Notes Receivable 43,150 - - - - - - - 43,150 3 Mortgage Notes Receivable - - - - - - 35,964 - 35,964 4 Mortgage Notes Receivable 88,749 15,765 44,451 46,491 36,297 9,561 500,399 - 741,713 5 Mortgage Notes Receivable - - 19,000 305 - - 7,834 - 27,139 6 Mortgage Notes Receivable - - - - - - 6,377 - 6,377 Sub-total 131,899 15,765 63,451 46,796 36,297 76,942 550,574 - 921,724 3 Investment in Direct Financing Leases - - - - - 11,470 - - 11,470 Sub-total - - - - - 11,470 - - 11,470 1 Other Investments 17,556 - - - - - - - 17,556 2 Other Investments - - - - - 2,082 - 15,265 17,347 3 Other Investments - 23,237 32,283 - - 388 4,032 144,368 204,308 4 Other Investments 3,500 14,117 112,910 - 83,495 - - 5,000 219,022 5 Other Investments - 22,326 14,436 - - - - 700 37,462 Sub-total 21,056 59,680 159,629 - 83,495 2,470 4,032 165,333 495,695 Total $ 152,955 $ 75,445 $ 223,080 $ 46,796 $ 119,792 $ 90,882 $ 554,606 $ 165,333 $ 1,428,889 We have a limited history of incurred losses and consequently have elected to employ external data to perform our expected credit loss calculation. We have elected a probability of default (“PD”) and loss given default (“LGD”) methodology. Our model’s historic inputs consider PD and LGD data for residential care facilities published by the Federal Housing Administration (“FHA”) along with Standards & Poor’s one-year global corporate default rates. Our historical loss rates revert to historical averages after 36 periods. Our model’s current conditions and supportable forecasts consider internal credit ratings, current and projected U.S. unemployment rates published by the United States Bureau of Labor Statistics and the Federal Reserve Bank of St. Louis and the weighted average life to maturity of the underlying financial asset. Allowance for Credit Loss Segment Financial Statement Line Item Allowance for Credit Loss at December 31, 2019 Allowance for Credit Loss on January 1, 2020 Provision for Credit Loss for the three months ended September 30, 2020 Provision for Credit Loss for the nine months ended September 30, 2020 Allowance for Credit Loss as of September 30, 2020 (in thousands) Segment A-4 Mortgage Notes Receivable $ - $ 19,293 $ (415) $ 3,359 $ 22,652 Segment B-3 Mortgage Notes Receivable - 901 (11) (85) 816 Segment C-5 Mortgage Notes Receivable - 829 (66) (475) 354 Segment E-6 Mortgage Notes Receivable 4,905 363 25 (2) 5,266 Segment F-2 Mortgage Notes Receivable - - (36) 97 97 Sub-total 4,905 21,386 (503) 2,894 29,185 Segment A-3 Investment in Direct Financing Leases 217 611 6 1 612 Sub-total 217 611 6 1 612 Segment A-4 Other Investments - 3,158 23,574 22,748 25,906 Segment B-3 Other Investments - 1,434 2,911 2,499 3,933 Segment C-2 Other Investments - 195 (41) (112) 83 Segment D-5 Other Investments - 1,901 (86) (631) 1,270 Sub-total - 6,688 26,358 24,504 31,192 Segment A-4 Off-Balance Sheet Mortgage Commitments - 100 (36) (73) 27 Segment B-3 Off-Balance Sheet Note Commitments - - 2,389 2,389 2,389 Segment C-2 Off-Balance Sheet Note Commitments - - 16 16 16 Sub-total - 100 2,369 2,332 2,432 Total $ 5,122 $ 28,785 $ 28,230 $ 29,731 $ 63,421 As of September 30, 2020, $10.3 million of contractual interest receivable is recorded in contractual receivables – net on our Consolidated Balance Sheets. We have elected the practical expedient to exclude interest receivable from our allowance for credit losses. We write-off interest receivable to provision for credit losses in the period we determine the interest is no longer considered collectible. During the third quarter of 2020, we determined that interest receivable of $3.8 million (related to the Agemo term loans, see Note 5 – Other Investments) was no longer considered collectible. As such, we reserved approximately $3.8 million of interest receivable through the provision for credit losses during the three month period ended September 30, 2020. The $3.8 million reserve for interest receivable is excluded from the table above. On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future London Inter-bank Offered Rate (“LIBOR”) indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. We continue to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

BASIS OF PRESENTATION AND SIG_3

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2020
Basis of Presentation and Significant Accounting Policies [Abstract]
Schedule of Net Accounts Receivable	A summary of our net receivables by type is as follows: September 30, December 31, 2020 2019 (in thousands) Contractual receivables – net $ 10,757 $ 27,122 Effective yield interest receivables $ 12,481 $ 12,914 Straight-line rent receivables 129,559 275,549 Lease inducements 84,373 92,628 Other receivables and lease inducements $ 226,413 $ 381,091
Schedule of credit losses impact	Pre-adoption balance as of Impact of adopting Post-adoption balance as of Financial Statement Line Item December 31, 2019 Topic 326 January 1, 2020 (in thousands) Mortgage Notes Receivable $ 773,563 $ (21,386) $ 752,177 Investment in Direct Financing Leases 11,488 (611) 10,877 Other Investments 419,228 (6,688) 412,540 Off-Balance Sheet Commitments 20,777 (100) 20,677 Total $ 1,225,056 $ (28,785) $ 1,196,271
Schedule by segment balance by vintage and credit quality indicator	Rating Financial Statement Line Item 2020 2019 2018 2017 2016 2015 2014 & older Revolving Loans Balance as of September 30, 2020 (in thousands) 1 Mortgage Notes Receivable $ - $ - $ - $ - $ - $ 67,381 $ - $ - $ 67,381 2 Mortgage Notes Receivable 43,150 - - - - - - - 43,150 3 Mortgage Notes Receivable - - - - - - 35,964 - 35,964 4 Mortgage Notes Receivable 88,749 15,765 44,451 46,491 36,297 9,561 500,399 - 741,713 5 Mortgage Notes Receivable - - 19,000 305 - - 7,834 - 27,139 6 Mortgage Notes Receivable - - - - - - 6,377 - 6,377 Sub-total 131,899 15,765 63,451 46,796 36,297 76,942 550,574 - 921,724 3 Investment in Direct Financing Leases - - - - - 11,470 - - 11,470 Sub-total - - - - - 11,470 - - 11,470 1 Other Investments 17,556 - - - - - - - 17,556 2 Other Investments - - - - - 2,082 - 15,265 17,347 3 Other Investments - 23,237 32,283 - - 388 4,032 144,368 204,308 4 Other Investments 3,500 14,117 112,910 - 83,495 - - 5,000 219,022 5 Other Investments - 22,326 14,436 - - - - 700 37,462 Sub-total 21,056 59,680 159,629 - 83,495 2,470 4,032 165,333 495,695 Total $ 152,955 $ 75,445 $ 223,080 $ 46,796 $ 119,792 $ 90,882 $ 554,606 $ 165,333 $ 1,428,889
Schedule of expected credit loss	Segment Financial Statement Line Item Allowance for Credit Loss at December 31, 2019 Allowance for Credit Loss on January 1, 2020 Provision for Credit Loss for the three months ended September 30, 2020 Provision for Credit Loss for the nine months ended September 30, 2020 Allowance for Credit Loss as of September 30, 2020 (in thousands) Segment A-4 Mortgage Notes Receivable $ - $ 19,293 $ (415) $ 3,359 $ 22,652 Segment B-3 Mortgage Notes Receivable - 901 (11) (85) 816 Segment C-5 Mortgage Notes Receivable - 829 (66) (475) 354 Segment E-6 Mortgage Notes Receivable 4,905 363 25 (2) 5,266 Segment F-2 Mortgage Notes Receivable - - (36) 97 97 Sub-total 4,905 21,386 (503) 2,894 29,185 Segment A-3 Investment in Direct Financing Leases 217 611 6 1 612 Sub-total 217 611 6 1 612 Segment A-4 Other Investments - 3,158 23,574 22,748 25,906 Segment B-3 Other Investments - 1,434 2,911 2,499 3,933 Segment C-2 Other Investments - 195 (41) (112) 83 Segment D-5 Other Investments - 1,901 (86) (631) 1,270 Sub-total - 6,688 26,358 24,504 31,192 Segment A-4 Off-Balance Sheet Mortgage Commitments - 100 (36) (73) 27 Segment B-3 Off-Balance Sheet Note Commitments - - 2,389 2,389 2,389 Segment C-2 Off-Balance Sheet Note Commitments - - 16 16 16 Sub-total - 100 2,369 2,332 2,432 Total $ 5,122 $ 28,785 $ 28,230 $ 29,731 $ 63,421

PROPERTIES AND INVESTMENTS (Tab

PROPERTIES AND INVESTMENTS (Tables)	9 Months Ended
PROPERTIES AND INVESTMENTS (Tables)	Sep. 30, 2020
PROPERTIES AND INVESTMENTS [Abstract]
Schedule of Investment in Leased Real Estate Properties	A summary of our investments in real estate properties subject to operating leases is as follows: September 30, December 31, 2020 2019 (in thousands) Buildings $ 7,027,766 $ 7,056,106 Land 880,498 901,246 Furniture and equipment 528,324 515,421 Site improvements 303,978 287,655 Construction in progress 39,396 225,566 Total real estate investments 8,779,962 8,985,994 Less accumulated depreciation (1,974,038) (1,787,425) Real estate investments – net $ 6,805,924 $ 7,198,569
Schedule of operating lease income	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (in thousands) Rental income – operating leases $ 81,424 $ 199,193 $ 517,384 $ 579,621 Variable lease income – operating leases 1,802 3,277 8,874 9,843 Total lease income $ 83,226 $ 202,470 $ 526,258 $ 589,464
Schedule of Significant Acquisitions	Number of Total Building & Site Furniture Initial Facilities Country/ Investment Land Improvements & Equipment Annual Period SNF ALF Specialty MOB State (in millions) Cash Yield (1) Q1 — 2 — — UK $ 12.1 $ 3.6 $ 8.0 $ 0.5 8.00 % Q1 1 — — — IN 7.0 0.7 5.8 0.5 9.50 % Q2 1 — — — OH 6.9 0.8 5.5 0.6 9.50 % Total 2 2 — — $ 26.0 $ 5.1 $ 19.3 $ 1.6 (1) The initial annual cash yield reflects the initial annual cash rent divided by the purchase price.
Schedule of recognized identified assets acquired and liabilities assumed	Our purchase price allocation was finalized during the second quarter of 2020, with no material adjustments recorded. The following table highlights the final fair value of the assets acquired and liabilities assumed on May 17, 2019: (in thousands) Fair value of net assets acquired: Real estate investments $ 440,690 Mortgage notes receivable 108,097 Other investments 19,192 Investment in unconsolidated joint venture 73,834 Cash 4,067 Contractual receivables 1,002 Other assets (1) 7,698 Total investments 654,580 Debt (285,100) Accrued expenses and other liabilities (2) (23,931) Fair value of net assets acquired $ 345,549 (1) Includes approximately $2.5 million in above market lease assets. (2) Includes approximately $1.1 million in below market lease liabilities.
Schedule of pro forma information not indicative of future operations	Pro Forma Nine Months Ended September 30, 2019 Pro forma revenues $ 703,650 Pro forma net income $ 301,074 Earnings per share – diluted: Net income – as reported $ 1.32 Net income – pro forma $ 1.33

DIRECT FINANCING LEASES (Tables

DIRECT FINANCING LEASES (Tables)	9 Months Ended
DIRECT FINANCING LEASES (Tables)	Sep. 30, 2020
Direct Financing Leases [Abstract]
Schedule of Components of Investment in Direct Financing Leases	The components of investments in direct financing leases consist of the following: September 30, December 31, 2020 2019 (in thousands) Minimum lease payments receivable $ 26,217 $ 27,227 Less unearned income (14,747) (15,522) Investment in direct financing leases 11,470 11,705 Less allowance for credit losses on direct financing leases (612) (217) Investment in direct financing leases – net $ 10,858 $ 11,488 Properties subject to direct financing leases 1 2 Number of direct financing leases 1 2

MORTGAGE NOTES RECEIVABLE (Tabl

MORTGAGE NOTES RECEIVABLE (Tables)	9 Months Ended
MORTGAGE NOTES RECEIVABLE (Tables)	Sep. 30, 2020
Mortgage Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Schedule of Investments	The principal amounts outstanding of mortgage notes receivable, net of allowances, were as follows: September 30, December 31, 2020 2019 (in thousands) Mortgage note due 2027; interest at 10.59% $ 112,500 $ 112,500 Mortgage notes due 2029; interest at 10.52% (1) 672,364 526,520 Other mortgage notes outstanding (2) 136,860 139,448 Mortgage notes receivable, gross 921,724 778,468 Allowance for credit losses on mortgage notes receivable (29,185) (4,905) Total mortgages — net $ 892,539 $ 773,563 (1) Approximates the weighted average interest rate on 47 facilities as of September 30, 2020. Two notes totaling approximately $28.6 million are construction mortgages with maturities in 2021. Two mortgage notes totaling $43.2 million mature in 2021 and the remaining loan balance matures in 2029 . (2) Other mortgages outstanding have a weighted average interest rate of 9.40% per annum as of September 30, 2020 and maturity dates through 2028 .

OTHER INVESTMENTS (Tables)

OTHER INVESTMENTS (Tables)	9 Months Ended
OTHER INVESTMENTS (Tables)	Sep. 30, 2020
Other Investment Receivables [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Schedule of Investments	A summary of our other investments is as follows: September 30, December 31, 2020 2019 (in thousands) Other investment notes due 2021; interest at 13.11% (1) $ 81,948 $ 77,087 Other investment notes due 2021-2025; interest at 8.25% (1) 62,187 58,687 Other investment note due 2023; interest at 12.00% 49,908 52,213 Other investment notes due 2030; interest at 7.00% 132,148 65,000 Other investment notes outstanding (2) 169,504 166,241 Total other investments, gross 495,695 419,228 Allowance for credit losses on other investments (31,192) — Total other investments - net $ 464,503 $ 419,228 (1) Approximate weighted average interest rate as of September 30, 2020. (2) Other investment notes have a weighted average interest rate of 7.92% as of September 30, 2020 and maturity dates through 2028 .

VARIABLE INTEREST ENTITIES (Tab

VARIABLE INTEREST ENTITIES (Tables) - Agemo Holdings LLC	9 Months Ended
VARIABLE INTEREST ENTITIES (Tables) - Agemo Holdings LLC	Sep. 30, 2020
Schedule of Variable Interest Entities	September 30, 2020 December 31, 2019 Agemo Maplewood Agemo (in thousands) (in thousands) Assets Real estate investments – net $ 375,641 $ 746,956 $ 403,389 Other investments 37,753 132,148 58,687 Contractual receivables 641 771 18,113 Straight-line rent receivables — (61,207) 46,247 Lease inducement — 71,006 6,810 Subtotal 414,035 889,674 533,246 Liabilities Net in-place lease liability — (337) — Contingent liability — (43,915) — Subtotal — (44,252) — Collateral Letters of credit (9,253) — (9,253) Personal guarantee (8,000) (40,000) (8,000) Other collateral (375,641) (746,956) (403,389) Subtotal (392,894) (786,956) (420,642) Maximum exposure to loss $ 21,141 $ 58,466 $ 112,604
Schedule of Variable Interest Entities revenue	Three Months Ended September 30, Nine Months Ended September 30, 2020 2020 2019 2019 2020 2020 2019 2019 Agemo Maplewood Agemo Maplewood Agemo Maplewood Agemo Maplewood (in thousands) Revenue Rental income (1) $ (63,128) $ 13,199 $ 15,145 $ 10,337 $ (33,026) $ 33,381 $ 45,473 $ 28,804 Other investment income 1,059 1,979 1,168 1,215 3,597 4,833 3,295 3,606 Total (2) $ (62,069) $ 15,178 $ 16,313 $ 11,552 $ (29,429) $ 38,214 $ 48,768 $ 32,410 (1) The rental income related to Agemo for the three and nine months ended September 30, 2020, reflects the write-off of approximately $75.3 million of contractual rent receivable, straight-line rent receivable and lease inducements (see Note 1 – Basis of Presentation and Significant Accounting Policies). (2) For the three months ended September 30, 2020 and 2019, we received cash from Agemo of approximately $13.4 million and $13.5 million, respectively, pursuant to our lease and other investment agreements. For the nine months ended September 30, 2020 and 2019, we received cash from Agemo of approximately $40.1 million and $39.7 million, respectively, pursuant to our lease and other investment agreements. For the three months ended September 30, 2020 and 2019, we received cash rental income and other investment income from Maplewood of approximately $17.5 million and $11.4 million, respectively. For the nine months ended September 30, 2020 and 2019, we received cash rental income and other investment income from Maplewood of approximately $51.4 million and $31.7 million, respectively.

INVESTMENT IN JOINT VENTUREs (T

INVESTMENT IN JOINT VENTUREs (Tables)	9 Months Ended
INVESTMENT IN JOINT VENTUREs (Tables)	Sep. 30, 2020
INVESTMENTS IN JOINT VENTURES [Abstract]
Schedule of equity method investments	Carrying Amount Ownership Initial Investment Initial Facility Facilities at September 30, December 31, Entity (1) % Date Investment (2) Type 9/30/2020 2020 2019 Second Spring Healthcare Investments (3) 15% 11/1/2016 $ 50,032 SNF 23 $ 20,386 $ 22,504 Lakeway Realty, L.L.C. 51% 5/17/2019 73,834 Specialty facility 1 72,585 73,273 Cindat Joint Venture 49% 12/18/2019 105,687 ALF 67 103,052 103,976 OMG Senior Housing, LLC 50% 12/6/2019 — ILF 1 — — OH CHS SNP, Inc. 9% 12/20/2019 450 N/A N/A 191 131 $ 230,003 $ 196,214 $ 199,884 (1) These entities and their subsidiaries are not consolidated by the Company because it does not control, through voting rights or other means, the joint venture. (2) Our initial investment includes our transaction costs, if any. (3) The Company made a loan of $17.6 million to the venture which is included in other investments. See Note 5 – Other Investments. Three Months Ended September 30, Nine Months Ended September 30, Entity 2020 2019 2020 2019 (in thousands) Second Spring Healthcare Investments $ 1,666 $ 7,832 $ 2,947 $ 9,139 Lakeway Realty, L.L.C. 637 596 1,860 889 Cindat Joint Venture (398) — 493 — OMG Senior Housing, LLC (108) — (387) — OH CHS SNP, Inc. (105) — (259) — Total $ 1,692 $ 8,428 $ 4,654 $ 10,028

ASSETS HELD FOR SALE (Tables)

ASSETS HELD FOR SALE (Tables)	9 Months Ended
ASSETS HELD FOR SALE (Tables)	Sep. 30, 2020
Assets Held for Sale [Abstract]
Schedule of Properties Held-for-Sale	The following is a summary of our assets held for sale: Properties Held For Sale Number of Net Book Value Properties (in thousands) December 31, 2019 6 $ 4,922 Properties sold (1) (4) (4,341) Properties added (2) 6 23,544 March 31, 2020 8 24,125 Properties sold (1) (5) (19,910) Properties added (2) 3 66,301 June 30, 2020 6 70,516 Properties sold (1) (4) (66,560) Properties added (2) 11 31,965 September 30, 2020 (3) 13 $ 35,921 (1) In the first quarter of 2020, we sold four facilities for approximately $4.2 million in net cash proceeds recognizing a net loss on sale of approximately $0.5 million. In the second quarter of 2020, we sold five facilities for approximately $38.4 million in net cash proceeds recognizing a net gain on sale of approximately $16.7 million. In the third quarter of 2020, we sold four facilities and a parcel of land for approximately $60.7 million in net cash proceeds recognizing a net loss on sale of approximately $1.0 million. During the third quarter of 2020, we recorded a $7.4 million impairment on one facility to reduce its net book value to its fair value less cost to sell. (2) In the first quarter of 2020, we recorded approximately $1.9 million of impairment expense to reduce one facility’s book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale. In the second quarter of 2020, we recorded approximately $2.6 million of impairment expense to reduce two facilities’ book value to their estimated fair value less costs to sell before they were reclassified to assets held for sale. In the third quarter of 2020, we recorded approximately $24.2 million of impairment expense to reduce six facilities’ book value to their estimated fair value less costs to sell before they were reclassified to assets held for sale. (3) We plan to sell the facilities classified as assets held for sale at September 30, 2020 within the next twelve months.

INTANGIBLES (Tables)

INTANGIBLES (Tables)	9 Months Ended
INTANGIBLES (Tables)	Sep. 30, 2020
Intangibles [Abstract]
Schedule of Intangibles	The following is a summary of our intangibles as of September 30, 2020 and December 31, 2019: September 30, December 31, 2020 2019 (in thousands) Assets: Goodwill $ 644,084 $ 644,415 Above market leases $ 22,822 $ 49,240 Accumulated amortization (20,526) (21,227) Net intangible assets $ 2,296 $ 28,013 Liabilities: Below market leases $ 140,744 $ 147,292 Accumulated amortization (94,914) (87,154) Net intangible liabilities $ 45,830 $ 60,138
Schedule of Reconciliation of Goodwill	The following is a summary of our goodwill as of September 30, 2020: (in thousands) Balance as of December 31, 2019 $ 644,415 Less: foreign currency translation (331) Balance as of September 30, 2020 $ 644,084

STOCKHOLDERS'_OWNERS' EQUITY (T

STOCKHOLDERS'/OWNERS' EQUITY (Tables)	9 Months Ended
STOCKHOLDERS'/OWNERS' EQUITY (Tables)	Sep. 30, 2020
Stockholders' / Owners' Equity [Abstract]
Schedule of common stock dividends	The Board of Directors has declared common stock dividends as set forth below: Record Payment Dividend per Date Date Common Share January 31, 2020 February 14, 2020 $ 0.67 April 30, 2020 May 15, 2020 $ 0.67 July 31, 2020 August 14, 2020 $ 0.67 November 2, 2020 November 16, 2020 $ 0.67
Schedule of Accumulated Other Comprehensive Loss	The following is a summary of our accumulated other comprehensive loss, net of tax where applicable: As of and for the As of and for the Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands) Foreign Currency Translation: Beginning balance $ (68,795) $ (49,715) $ (35,100) $ (47,704) Translation loss 21,808 (12,015) (11,818) (13,857) Realized gain (loss) 19 23 (50) (146) Ending balance (46,968) (61,707) (46,968) (61,707) Derivative Instruments: Cash flow hedges: Beginning balance (9,699) (4,093) (2,369) 3,994 Unrealized gain (loss) 7,223 (26) 1,401 (8,765) Realized (loss) gain (1) (1,500) 195 (3,008) 847 Ending balance (3,976) (3,924) (3,976) (3,924) Net investment hedge: Beginning balance 9,533 790 (4,420) 70 Unrealized gain (9,953) 4,040 4,000 4,760 Ending balance (420) 4,830 (420) 4,830 Total accumulated other comprehensive loss for Omega OP (2) (51,364) (60,801) (51,364) (60,801) Add: portion included in noncontrolling interest 2,263 2,529 2,263 2,529 Total accumulated other comprehensive loss for Omega $ (49,101) $ (58,272) $ (49,101) $ (58,272) (1) Recorded in interest expense on the Consolidated Statements of Operations. (2) These amounts are included in Owners’ Equity.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2020
Stock-Based Compensation [Abstract]
Schedule of Stock-based Compensation Expense	The following is a summary of our stock-based compensation expense for the three and nine months ended September 30, 2020 and 2019, respectively. Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands) Stock-based compensation expense $ 5,122 $ 2,921 $ 14,380 $ 11,031

BORROWING ARRANGEMENTS (Tables)

BORROWING ARRANGEMENTS (Tables)	9 Months Ended
BORROWING ARRANGEMENTS (Tables)	Sep. 30, 2020
BORROWING ARRANGEMENTS [Abstract]
Schedule of Borrowings	The following is a summary of our borrowings: Annual Interest Rate as of September 30, September 30, December 31, Maturity 2020 2020 2019 (in thousands) Secured borrowings: HUD mortgages (1)(5) 2046-2052 3.01 % $ 369,076 $ 387,405 Term loan (2)(5) 2021 3.25 % 2,275 2,275 371,351 389,680 Unsecured borrowings: Revolving line of credit (3) 2021 1.34 % 170,667 125,000 U.S. term loan 2022 1.59 % 350,000 350,000 Sterling term loan (4) 2022 1.50 % 129,280 132,480 Omega OP term loan (5) 2022 3.29 % 75,000 75,000 2015 term loan 2022 3.80 % 250,000 250,000 Deferred financing costs – net (6) (1,946) (2,742) Total term loans – net 802,334 804,738 2023 notes 2023 4.375 % 700,000 700,000 2024 notes 2024 4.950 % 400,000 400,000 2025 notes 2025 4.500 % 400,000 400,000 2026 notes 2026 5.250 % 600,000 600,000 2027 notes 2027 4.500 % 700,000 700,000 2028 notes 2028 4.750 % 550,000 550,000 2029 notes 2029 3.625 % 500,000 500,000 Subordinated debt 2021 9.000 % 20,000 13,541 Discount – net (20,571) (23,041) Deferred financing costs – net (20,820) (23,778) Total senior notes and other unsecured borrowings – net 3,828,609 3,816,722 Total unsecured borrowings – net 4,801,610 4,746,460 Total secured and unsecured borrowings – net (7) $ 5,172,961 $ 5,136,140 (1) Reflects the weighted average annual contractual interest rate on the mortgages at September 30, 2020; secured by real estate assets with a net carrying value of $577.6 million as of September 30, 2020. (2) Borrowing is the debt of a consolidated joint venture. (3) During the first quarter of 2020, we drew approximately $300 million on our existing $1.25 billion revolving credit facility as a precautionary measure due to the COVID-19 outbreak. This borrowing was included in cash and cash equivalents on our Consolidated Balance Sheets as of March 31, 2020. We repaid this $300 million borrowing in June 2020. (4) Actual borrowing in British Pounds Sterling and remeasured to USD. (5) Omega OP or wholly owned subsidiaries of Omega OP are the obligor on these borrowings. (6) Includes $0.2 million of net deferred financing costs related to the Omega OP term loan as of September 30, 2020. (7) All borrowings are direct borrowings of Omega unless otherwise noted.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
FINANCIAL INSTRUMENTS (Tables)	Sep. 30, 2020
Financial Instruments [Abstract]
Schedule of Financial Instruments	At September 30, 2020 and December 31, 2019, the net carrying amounts and fair values of our other financial instruments were as follows: September 30, 2020 December 31, 2019 Carrying Fair Carrying Fair Amount Value Amount Value (in thousands) Assets: Investments in direct financing leases – net $ 10,858 $ 10,858 $ 11,488 $ 11,488 Mortgage notes receivable – net 892,539 920,800 773,563 819,083 Other investments – net 464,503 468,694 419,228 412,934 Total $ 1,367,900 $ 1,400,352 $ 1,204,279 $ 1,243,505 Liabilities: Revolving line of credit $ 170,667 $ 170,667 $ 125,000 $ 125,000 Term loan 2,275 2,275 2,275 2,275 U.S. term loan 349,226 350,000 348,878 350,000 Sterling term loan 128,989 129,280 132,059 132,480 Omega OP term loan 74,837 75,000 74,763 75,000 2015 term loan 249,282 250,000 249,038 250,000 4.375% notes due 2023 – net 696,688 756,678 695,812 749,693 4.95% notes due 2024 – net 396,461 431,497 395,702 442,327 4.50% notes due 2025 – net 396,734 427,411 396,163 430,529 5.25% notes due 2026 – net 596,261 659,994 595,732 675,078 4.50% notes due 2027 – net 690,543 757,945 689,445 759,475 4.75% notes due 2028 – net 542,647 606,329 541,891 602,967 3.625% notes due 2029 – net 489,170 507,158 488,263 500,792 HUD mortgages – net 369,076 419,925 387,405 379,866 Subordinated debt – net 20,105 21,828 13,714 15,253 Total $ 5,172,961 $ 5,565,987 $ 5,136,140 $ 5,490,735

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Sep. 30, 2020
COMMITMENTS AND CONTINGENCIES [Abstract]
Schedule of remaining commitments	Total commitments $ 562,262 Amounts funded to date (1) (467,141) Remaining commitments (2) $ 95,121 (1) Includes finance costs. (2) This amount excludes our remaining commitments to fund under our other investments of approximately $109.3 million.

(LOSS) EARNINGS PER SHARE_UNIT

(LOSS) EARNINGS PER SHARE/UNIT (Tables)	9 Months Ended
(LOSS) EARNINGS PER SHARE/UNIT (Tables)	Sep. 30, 2020
(LOSS) Earnings per Share/Unit [Abstract]
Schedule of Computation of Basic and Diluted Earnings per Share	The following tables set forth the computation of basic and diluted earnings per share/unit: Omega Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands, except per share amounts) Numerator: Net (loss) income $ (93,768) $ 142,948 $ 100,471 $ 290,801 Add/deduct: net loss (income) attributable to noncontrolling interests 2,477 (4,208) (2,540) (9,218) Net (loss) income available to common stockholders/Omega OP Unit holders $ (91,291) $ 138,740 $ 97,931 $ 281,583 Denominator: Denominator for basic earnings per share 227,507 217,818 227,393 211,315 Effect of dilutive securities: Common stock equivalents — 1,754 1,065 1,678 Net forward share contract — 319 — 106 Noncontrolling interest – Omega OP Units 6,168 6,622 6,078 7,072 Denominator for diluted earnings per share/unit 233,675 226,513 234,536 220,171 Earnings per share/unit - basic: Net (loss) income available to common stockholders/Omega OP Unit holders $ (0.40) $ 0.64 $ 0.43 $ 1.33 Earnings per share/unit – diluted: Net (loss) income (1) $ (0.40) $ 0.63 $ 0.43 $ 1.32 (1) For the three months ended September 30, 2020, approximately 904 potential common shares/units are not included in the computation of diluted earnings per share as a net loss exists and therefore the effect would be an antidilutive per share amount. Omega OP Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 (in thousands, except per share amounts) Numerator: Net (loss) income $ (93,768) $ 142,948 $ 100,471 $ 290,801 Add: net loss attributable to noncontrolling interests 3 9 9 9 Net (loss) income available to Omega OP Unit holders $ (93,765) $ 142,957 $ 100,480 $ 290,810 Denominator: Denominator for basic earnings per unit 233,675 224,440 233,471 218,387 Effect of dilutive securities: Omega OP Unit equivalents — 1,754 1,065 1,678 Net forward share contract — 319 — 106 Denominator for diluted earnings per unit 233,675 226,513 234,536 220,171 Earnings per unit - basic: Net (loss) income available to Omega OP Unit holders $ (0.40) $ 0.64 $ 0.43 $ 1.33 Earnings per unit - diluted: Net (loss) income (1) $ (0.40) $ 0.63 $ 0.43 $ 1.32 (1) For the three months ended September 30, 2020, approximately 904 potential common shares/units are not included in the computation of diluted earnings per share as a net loss exists and therefore the effect would be an antidilutive per share amount.

SUPPLEMENTAL DISCLOSURE TO CO_2

SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS (Tables)	9 Months Ended
	Sep. 30, 2020
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Schedule of Cash Flow Supplemental Disclosures	The following are supplemental disclosures to the consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019: Nine Months Ended September 30, 2020 2019 (in thousands) Reconciliation of cash and cash equivalents and restricted cash: Cash and cash equivalents $ 35,951 $ 40,860 Restricted cash 4,164 1,372 Cash, cash equivalents and restricted cash at end of period $ 40,115 $ 42,232 Supplemental information: Interest paid during the period, net of amounts capitalized $ 174,247 $ 170,045 Taxes paid during the period $ 5,493 $ 3,510 Non cash investing activities Non cash acquisition of a business (see Note 2) $ — $ (566,966) Non cash acquisition of real estate (see Note 2) — (143,174) Non cash proceeds from sale of real estate investments (see Note 4) 83,910 — Non cash placement of mortgages (see Note 4) (86,936) — Non cash collection of mortgage principal — 11,874 Non cash investment in other investments (see Note 5) (121,139) (25,925) Non cash proceeds from other investments (see Note 5) 68,025 149,542 Non cash proceeds from direct financing lease — 4,970 Initial non cash right of use asset - ground leases — 5,593 Initial non cash lease liability - ground leases — (5,593) Non cash financing activities Debt assumed in merger (see Note 2) $ — $ 285,100 Stock exchanged in merger (see Note 2) — 281,865 Non cash borrowing of other long-term borrowings 6,459 — Change in fair value of cash flow hedges (1,637) (9,316) Remeasurement of debt denominated in a foreign currency (4,000) (4,760)

BASIS OF PRESENTATION AND SIG_4

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Detail)	May 26, 2020USD ($)	Jul. 31, 2020USD ($)facility	Sep. 30, 2020USD ($)facility$ / shares	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)$ / shares	Sep. 30, 2020USD ($)facilitysegment$ / shares	Sep. 30, 2019USD ($)$ / shares	Jan. 01, 2020USD ($)	Dec. 31, 2019USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of reportable segment \| segment							1
Impairment on real estate properties			$ 28,105,000			$ 3,836,000	$ 43,732,000	$ 9,545,000
Loan loss reserves			61,000,000				61,000,000			$ 5,100,000
Cash, FDIC Insured Amount			250,000				250,000
Impairment of Real Estate			28,100,000			$ 3,800,000	$ 47,210,000	$ 13,220,000
Provision of of straight-line rent and contractual receivables			$ 142,300,000
Depreciation method							straight-line basis
Special cash dividend (per share) \| $ / shares			$ 0.67			$ 0.66	$ 2.01	$ 1.98
Rental income			$ 83,226,000			$ 202,470,000	$ 526,258,000	$ 589,464,000
Real estate tax expense			2,127,000			$ 3,921,000	9,448,000	$ 11,833,000
Retained earnings (accumulated deficit)			2,533,339,000				2,533,339,000			2,463,436,000
Lease inducements			84,373,000				84,373,000			92,628,000
Financing receivable, allowance for credit losses			63,421,000				63,421,000		$ 28,785,000
Accrued investment income receivable			$ 10,300,000				$ 10,300,000
Number of real estate properties \| facility			976				976
Proceeds from sale of property held-for-sale				$ 38,400,000	$ 4,200,000
Real estate investments - net			$ 6,805,924,000				$ 6,805,924,000			7,198,569,000
Interest receivable			12,481,000				12,481,000			12,914,000
Provision for Credit Losses			$ 28,230,000				$ 29,731,000
Facilities Intended To Sell Per Agreement [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of real estate properties \| facility		28
Facilities Intended To Sell Per Agreement [Member] \| Scenario, Plan [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Proceeds from sale of property held-for-sale		$ 100,000,000
Facilites Previously Intended to Sell now Intended to Re-lease [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of real estate properties \| facility			28				28
Facilities Intended To Re-lease [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of real estate properties \| facility			31				31
Real estate investments - net			$ 147,000,000				$ 147,000,000
Additional Facilities Intended To Re Lease [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of real estate properties \| facility			3				3
Additional Single Facility Intended To Re Lease Or Sell [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of real estate properties \| facility			1				1
Real estate investments - net			$ 100,000				$ 100,000
Acute Care Hospital [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Impairment on real estate properties							2,200,000
Proceeds from sale of property held-for-sale	$ 56,500,000	49,000,000					55,300,000
Due diligence period for property sale	60 days
Acute Care Hospital [Member] \| Scenario, Plan [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Impairment on real estate properties		$ 7,400,000
Facilities Being Transitioned To Other Operator [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Provision of of straight-line rent and contractual receivables			1,000,000
Contractual Receivable [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Provision for Credit Losses			3,800,000
Accounting Standards Update 2016-13 [Member] \| Restatement Adjustment [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Retained earnings (accumulated deficit)									(28,800,000)
Financing receivable, allowance for credit losses									$ 28,800,000
Cash Flow Hedging [Member] \| Other Assets [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Cash flow hedges recorded at fair value, asset			6,600,000				6,600,000
Cash Flow Hedging [Member] \| Accounts Payable and Accrued Liabilities [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Cash flow hedges recorded at fair value, liability			12,000,000				$ 12,000,000			$ 3,700,000
Omega Op Units [Member] \| Omega Healthcare Investors [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned							97.00%
Omega Op Units [Member] \| Other Investors
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned							3.00%
Genesis HealthCare
Basis Of Presentation And Significant Accounting Policies [Line Items]
Provision of of straight-line rent and contractual receivables			64,900,000
Provision for Credit Losses							$ 0
Agemo Holdings LLC
Basis Of Presentation And Significant Accounting Policies [Line Items]
Provision of of straight-line rent and contractual receivables			75,300,000
Building \| Minimum
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives							20 years
Building \| Maximum
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives							40 years
Site improvements \| Minimum
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives							8 years
Site improvements \| Maximum
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives							15 years
Furniture and Equipment \| Minimum
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives							3 years
Furniture and Equipment \| Maximum
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives							10 years
Existing Operator
Basis Of Presentation And Significant Accounting Policies [Line Items]
Provision of of straight-line rent and contractual receivables			2,100,000
Third Party Operator [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Rental income			55,400,000
Four Operators [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Lease inducements					16,000,000
One Of Four Operator Developing And Start Up Related [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Lease inducements					$ 12,900,000
Three Operators [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Lease inducements				12,900,000
One Of Three Operator Developing And Start Up Related [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Lease inducements				$ 11,000,000
Three Operators Placed On A Cash Basis [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Provision of of straight-line rent and contractual receivables			142,300,000
One Operators Placed On Cash Basis [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Interest receivable			$ 3,800,000				$ 3,800,000

BASIS OF PRESENTATION AND SIG_5

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of Net Accounts Receivable) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Basis of Presentation and Significant Accounting Policies [Abstract]
Contractual receivables - net	$ 10,757	$ 27,122
Effective yield interest receivables	12,481	12,914
Straight-line rent receivables	129,559	275,549
Lease inducements	84,373	92,628
Other receivables and lease inducements	$ 226,413	$ 381,091

BASIS OF PRESENTATION AND SIG_6

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of credit losses impact) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jan. 01, 2020	Dec. 31, 2019
Mortgage notes receivable - net	$ 892,539	$ 752,177	$ 773,563
Investments in direct financing leases - net	10,858	10,877	11,488
Other investments - net	$ 464,503	412,540	419,228
Off-Balance Sheet Commitments		20,677	20,777
Financing Receivable, Collectively Evaluated for Impairment		1,196,271	$ 1,225,056
Restatement Adjustment [Member] \| Accounting Standards Update 2016-13 [Member]
Mortgage notes receivable - net		(21,386)
Investments in direct financing leases - net		(611)
Other investments - net		(6,688)
Off-Balance Sheet Commitments		(100)
Financing Receivable, Collectively Evaluated for Impairment		$ (28,785)

BASIS OF PRESENTATION AND SIG_7

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule by segment balance by vintage and credit quality indicator) (Detail) $ in Thousands	Sep. 30, 2020USD ($)
2020	$ 152,955
2019	75,445
2018	223,080
2017	46,796
2016	119,792
2015	90,882
2014 & older	554,606
Revolving Loans	165,333
Total Balance at September 30, 2020	1,428,889
Mortgage Receivable [Member]
2020	131,899
2019	15,765
2018	63,451
2017	46,796
2016	36,297
2015	76,942
2014 & older	550,574
Total Balance at September 30, 2020	921,724
Mortgage Receivable [Member] \| Internal Credit Rating One [Member]
2015	67,381
Total Balance at September 30, 2020	67,381
Mortgage Receivable [Member] \| Internal Credit Rating Two [Member]
2020	43,150
Total Balance at September 30, 2020	43,150
Mortgage Receivable [Member] \| Internal Credit Rating Three [Member]
2014 & older	35,964
Total Balance at September 30, 2020	35,964
Mortgage Receivable [Member] \| Internal Credit Rating Four [Member]
2020	88,749
2019	15,765
2018	44,451
2017	46,491
2016	36,297
2015	9,561
2014 & older	500,399
Total Balance at September 30, 2020	741,713
Mortgage Receivable [Member] \| Internal Credit Rating Five [Member]
2018	19,000
2017	305
2014 & older	7,834
Total Balance at September 30, 2020	27,139
Mortgage Receivable [Member] \| Internal Credit Rating Six [Member]
2014 & older	6,377
Total Balance at September 30, 2020	6,377
Direct Financing Lease [Member]
2015	11,470
Total Balance at September 30, 2020	11,470
Direct Financing Lease [Member] \| Internal Credit Rating Three [Member]
2015	11,470
Total Balance at September 30, 2020	11,470
Other Investment Receivables [Member]
2020	21,056
2019	59,680
2018	159,629
2016	83,495
2015	2,470
2014 & older	4,032
Revolving Loans	165,333
Total Balance at September 30, 2020	495,695
Other Investment Receivables [Member] \| Internal Credit Rating One [Member]
2020	17,556
Total Balance at September 30, 2020	17,556
Other Investment Receivables [Member] \| Internal Credit Rating Two [Member]
2015	2,082
Revolving Loans	15,265
Total Balance at September 30, 2020	17,347
Other Investment Receivables [Member] \| Internal Credit Rating Three [Member]
2019	23,237
2018	32,283
2015	388
2014 & older	4,032
Revolving Loans	144,368
Total Balance at September 30, 2020	204,308
Other Investment Receivables [Member] \| Internal Credit Rating Four [Member]
2020	3,500
2019	14,117
2018	112,910
2016	83,495
Revolving Loans	5,000
Total Balance at September 30, 2020	219,022
Other Investment Receivables [Member] \| Internal Credit Rating Five [Member]
2019	22,326
2018	14,436
Revolving Loans	700
Total Balance at September 30, 2020	$ 37,462

BASIS OF PRESENTATION AND SIG_8

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of expected credit loss per segment) (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Jan. 01, 2020
ECL balance	$ 63,421	$ 63,421	$ 28,785
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	28,230	29,731
ECL Ending balance	63,421	63,421
Finance Leases Portfolio Segment [Member]
ECL balance	612	612	611
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	6	1
ECL Ending balance	612	612
Other Investment Financing Receivable Segment [Member]
ECL balance	31,192	31,192	6,688
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	26,358	24,504
ECL Ending balance	31,192	31,192
Off Balance Financing Receivable Segment [Member]
ECL balance	2,432	2,432	100
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	2,369	2,332
ECL Ending balance	2,432	2,432
Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance	29,185	29,185	21,386
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(503)	2,894
ECL Ending balance	29,185	29,185
Internal Credit Rating Two [Member] \| Other Investment Financing Receivable Segment [Member]
ECL balance	83	83	195
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(41)	(112)
ECL Ending balance	83	83
Internal Credit Rating Two [Member] \| Off Balance Sheet Financing Receivable Segment Note Commitment [Member]
ECL balance	16	16
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	16	16
ECL Ending balance	16	16
Internal Credit Rating Two [Member] \| Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance	97	97
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(36)	97
ECL Ending balance	97	97
Internal Credit Rating Three [Member] \| Other Investment Financing Receivable Segment [Member]
ECL balance	3,933	3,933	1,434
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	2,911	2,499
ECL Ending balance	3,933	3,933
Internal Credit Rating Three [Member] \| Off Balance Sheet Financing Receivable Segment Note Commitment [Member]
ECL balance	2,389	2,389
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	2,389	2,389
ECL Ending balance	2,389	2,389
Internal Credit Rating Three [Member] \| Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance	816	816	901
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(11)	(85)
ECL Ending balance	816	816
Internal Credit Rating Three [Member] \| Direct Financing Lease [Member] \| Finance Leases Portfolio Segment [Member]
ECL balance	612	612	611
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	6	1
ECL Ending balance	612	612
Internal Credit Rating Four [Member] \| Other Investment Financing Receivable Segment [Member]
ECL balance	25,906	25,906	3,158
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	23,574	22,748
ECL Ending balance	25,906	25,906
Internal Credit Rating Four [Member] \| Off Balance Sheet Financing Receivable Segment Mortgage Commitment [Member]
ECL balance	27	27	100
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(36)	(73)
ECL Ending balance	27	27
Internal Credit Rating Four [Member] \| Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance	22,652	22,652	19,293
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(415)	3,359
ECL Ending balance	22,652	22,652
Internal Credit Rating Five [Member] \| Other Investment Financing Receivable Segment [Member]
ECL balance	1,270	1,270	1,901
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(86)	(631)
ECL Ending balance	1,270	1,270
Internal Credit Rating Five [Member] \| Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance	354	354	829
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	(66)	(475)
ECL Ending balance	354	354
Internal Credit Rating Six [Member] \| Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance	5,266	5,266	$ 363
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Provision for Credit Losses	25	(2)
ECL Ending balance	$ 5,266	5,266
Previous Accounting Guidance [Member]
ECL balance		5,122
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
ECL Beginning balance		5,122
Previous Accounting Guidance [Member] \| Finance Leases Portfolio Segment [Member]
ECL balance		217
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
ECL Beginning balance		217
Previous Accounting Guidance [Member] \| Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance		4,905
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
ECL Beginning balance		4,905
Previous Accounting Guidance [Member] \| Internal Credit Rating Three [Member] \| Direct Financing Lease [Member] \| Finance Leases Portfolio Segment [Member]
ECL balance		217
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
ECL Beginning balance		217
Previous Accounting Guidance [Member] \| Internal Credit Rating Six [Member] \| Mortgage Receivable [Member] \| Commercial Real Estate Portfolio Segment [Member]
ECL balance		4,905
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
ECL Beginning balance		$ 4,905

PROPERTIES AND INVESTMENTS (Lea

PROPERTIES AND INVESTMENTS (Leased Property) (Narrative) (Detail)	Sep. 30, 2020facility
Number of real estate properties	976
Skilled Nursing Facilities \| Facilities Leased [Member]
Number of real estate properties	754
Assisted Living Facilities \| Facilities Leased [Member]
Number of real estate properties	114
Specialty \| Facilities Leased [Member]
Number of real estate properties	28
Medical Office Building \| Facilities Leased [Member]
Number of real estate properties	2

PROPERTIES AND INVESTMENTS (Sum

PROPERTIES AND INVESTMENTS (Summary of our investment in leased real estate properties) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 8,779,962	$ 8,985,994
Less accumulated depreciation	(1,974,038)	(1,787,425)
Real estate investments - net	6,805,924	7,198,569
Building
Property, Plant and Equipment [Line Items]
Total real estate investments	7,027,766	7,056,106
Land
Property, Plant and Equipment [Line Items]
Total real estate investments	880,498	901,246
Furniture and Equipment
Property, Plant and Equipment [Line Items]
Total real estate investments	528,324	515,421
Building And Site Improvements
Property, Plant and Equipment [Line Items]
Total real estate investments	303,978	287,655
Construction in Progress
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 39,396	$ 225,566

PROPERTIES AND INVESTMENTS (Sch

PROPERTIES AND INVESTMENTS (Schedule of operating lease income) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating Lease, Lease Income [Abstract]
Rental income - operating leases	$ 81,424	$ 199,193	$ 517,384	$ 579,621
Variable lease income - operating leases	1,802	3,277	8,874	9,843
Total lease income	$ 83,226	$ 202,470	$ 526,258	$ 589,464

PROPERTIES AND INVESTMENTS (S_2

PROPERTIES AND INVESTMENTS (Schedule of Significant Acquisitions) (Detail) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020USD ($)facilityproperty	Jun. 30, 2020USD ($)facility	Mar. 31, 2020USD ($)facility	Sep. 30, 2020USD ($)facilityproperty
Real Estate Properties [Line Items]
Number of real estate properties \| facility	976			976
Payments to acquire businesses, gross				$ 26
Ohio
Real Estate Properties [Line Items]
Payments to acquire businesses, gross		$ 6.9
Initial Annual Cash Yield (%)		9.50%
United Kingdom
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			$ 12.1
Initial Annual Cash Yield (%)			8.00%
Indiana
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			$ 7
Initial Annual Cash Yield (%)			9.50%
Skilled Nursing Facilities
Real Estate Properties [Line Items]
Number of real estate properties \| facility	755			755
Assisted Living Facilities
Real Estate Properties [Line Items]
Number of real estate properties \| facility	114			114
Specialty
Real Estate Properties [Line Items]
Number of real estate properties \| property	28			28
Medical Office Building
Real Estate Properties [Line Items]
Number of real estate properties \| facility	2			2
Land
Real Estate Properties [Line Items]
Payments to acquire businesses, gross	$ 1.3			$ 5.1
Land \| Ohio
Real Estate Properties [Line Items]
Payments to acquire businesses, gross		$ 0.8
Land \| United Kingdom
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			$ 3.6
Land \| Indiana
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			0.7
Furniture and Equipment
Real Estate Properties [Line Items]
Payments to acquire businesses, gross				1.6
Furniture and Equipment \| Ohio
Real Estate Properties [Line Items]
Payments to acquire businesses, gross		0.6
Furniture and Equipment \| United Kingdom
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			0.5
Furniture and Equipment \| Indiana
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			0.5
Building And Site Improvements
Real Estate Properties [Line Items]
Payments to acquire businesses, gross				$ 19.3
Building And Site Improvements \| Ohio
Real Estate Properties [Line Items]
Payments to acquire businesses, gross		$ 5.5
Building And Site Improvements \| United Kingdom
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			8
Building And Site Improvements \| Indiana
Real Estate Properties [Line Items]
Payments to acquire businesses, gross			$ 5.8
Facilities Acquired \| Skilled Nursing Facilities
Real Estate Properties [Line Items]
Number of real estate properties \| facility	2			2
Facilities Acquired \| Skilled Nursing Facilities \| Ohio
Real Estate Properties [Line Items]
Number of real estate properties \| facility		1
Facilities Acquired \| Skilled Nursing Facilities \| Indiana
Real Estate Properties [Line Items]
Number of real estate properties \| facility			1
Facilities Acquired \| Assisted Living Facilities
Real Estate Properties [Line Items]
Number of real estate properties \| facility	2			2
Facilities Acquired \| Assisted Living Facilities \| United Kingdom
Real Estate Properties [Line Items]
Number of real estate properties \| facility			2

PROPERTIES AND INVESTMENTS (Med

PROPERTIES AND INVESTMENTS (MedEquities Merger) (Narrative) (Detail) $ / shares in Units, $ in Thousands, shares in Millions	May 17, 2019USD ($)facilityloansecurity$ / sharesitemshares	Sep. 30, 2020USD ($)facilitystate$ / shares	Sep. 30, 2019USD ($)$ / shares	Sep. 30, 2020USD ($)facilitystate$ / shares	Sep. 30, 2019USD ($)$ / shares
Business Acquisition [Line Items]
Consideration				$ 26,000
Special cash dividend (per share) \| $ / shares		$ 0.67	$ 0.66	$ 2.01	$ 1.98
Number of real estate properties \| facility		976		976
Number of states \| state		40		40
Acquisition related costs		$ 36	$ 887	$ 62	$ 5,072
Revenues		$ 119,177	$ 233,195	$ 628,596	$ 682,162
MedEquities
Business Acquisition [Line Items]
Business combination acquirees' stockholders conversion ratio of acquirer's stock received	0.235
Business combination acquirees stockholder's additional cash amount per share received \| $ / shares	$ 2
Consideration	$ 63,700
Number of shares issued \| shares	7.5
Loan amount	$ 350,000
Mortgage loans on real estate, number of loans \| loan	4
Number of other investments acquired \| security	3
Number of unconsolidated joint ventures acquired \| item	1
Consideration	$ 346,000
Facilities Acquired \| MedEquities
Business Acquisition [Line Items]
Number of real estate properties \| facility	33

PROPERTIES AND INVESTMENTS (Pro

PROPERTIES AND INVESTMENTS (Pro Forma Acquisition Results) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings per share - diluted:
Net income - as reported	$ (0.40)	$ 0.63	$ 0.43	$ 1.32
Pro Forma [Member]
Business Acquisition, Pro Forma Information [Abstract]
Pro forma revenues				$ 703,650
Pro forma net income				$ 301,074
Earnings per share - diluted:
Net income - as reported				$ 1.32
Net income - pro forma				$ 1.33

PROPERTIES AND INVESTMENTS (Fai

PROPERTIES AND INVESTMENTS (Fair Value of Assets Acquired and Liabilities Assumed) (Detail) $ in Thousands	May 17, 2019USD ($)
PROPERTIES AND INVESTMENTS [Abstract]
Real estate investments	$ 440,690
Mortgage notes receivable	108,097
Other investments	19,192
Investment in unconsolidated joint venture	73,834
Cash	4,067
Contractual receivables	1,002
Other assets	7,698
Total investments	654,580
Borrowings / debt	(285,100)
Accrued expenses and other liabilities	(23,931)
Fair value of net assets acquired	345,549
Above market lease assets, acquired	2,500
Below market leases, assumed	$ 1,100

PROPERTIES AND INVESTMENTS (Ass

PROPERTIES AND INVESTMENTS (Asset Sales and Impairments) (Narrative) (Detail) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2020USD ($)facility	Jun. 30, 2020USD ($)facility	Mar. 31, 2020USD ($)facilityproperty	Sep. 30, 2020USD ($)facility	Sep. 30, 2019USD ($)
Number of real estate properties \| facility	976			976
Receipts from insurance proceeds				$ 346	$ 6,878
Insurance proceeds received that offset impairments	$ 3,500
Facilities Classified to Asset Held for Sale [Member]
Number of real estate properties \| facility	6	2	1	6
6 Facilities
Amount of gain (loss) from sale of facilities	$ (700)		$ 1,800
Total cash proceeds	$ 61,000		$ 18,100
6 Facilities \| Facilities Sold
Number of real estate properties	6		6	6
3 Facilities
Provision for impairment on real estate properties			$ 3,600
3 Facilities \| Facilities With Impairment Charges [Member]
Number of real estate properties \| facility			3
15 Facilities and 1 Facility Subject to Direct Financing Lease
Amount of gain (loss) from sale of facilities		$ 12,800
Total cash proceeds		$ 38,000
15 Facilities \| Facilities Sold
Number of real estate properties \| facility		15
1 Facility Subject to Direct Financing Lease \| Facilities Sold
Number of real estate properties \| facility		1
10 Facilities
Provision for impairment on real estate properties		$ 12,000
10 Facilities \| Facilities With Impairment Charges [Member]
Number of real estate properties \| facility		10
7 Facilities
Provision for impairment on real estate properties	$ 28,100
7 Facilities \| Facilities With Impairment Charges [Member]
Number of real estate properties \| facility	7			7

DIRECT FINANCING LEASES (Narrat

DIRECT FINANCING LEASES (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Proceeds from distribution of trust				$ 15,220	$ 88,730
Other assets		$ 71,261		71,261		$ 102,462
Recovery (impairment) on direct financing leases	$ 800	$ 324		$ 1,076	$ (7,700)
Distribution Trust [Member]
Proceeds from distribution of trust	$ 14,900
Orianna
Other assets						$ 14,100
Orianna \| Distribution Trust [Member]
Recovery (impairment) on direct financing leases			$ (7,700)

DIRECT FINANCING LEASES (Schedu

DIRECT FINANCING LEASES (Schedule of Components of Investment in Direct Financing Leases) (Detail) $ in Thousands	Sep. 30, 2020USD ($)propertyfacilitycontract	Jan. 01, 2020USD ($)	Dec. 31, 2019USD ($)contractproperty
Lessee, Lease, Description [Line Items]
Minimum lease payments receivable	$ 26,217		$ 27,227
Less unearned income	(14,747)		(15,522)
Investment in direct financing leases	11,470		11,705
Less allowance for expected credit losses on direct financing leases	(612)		(217)
Investment in direct financing leases - net	$ 10,858	$ 10,877	$ 11,488
Number of real estate properties \| facility	976
Number of direct financing leases \| contract	1		2
Facilities Subject to Direct Financing Leases [Member]
Lessee, Lease, Description [Line Items]
Number of real estate properties \| property	1		2

MORTGAGE NOTES RECEIVABLE (Narr

MORTGAGE NOTES RECEIVABLE (Narrative) (Detail)	9 Months Ended
MORTGAGE NOTES RECEIVABLE (Narrative) (Detail)	Sep. 30, 2020statefacilitypropertyitementity
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties	976
Number of fixed rate mortgage \| item	10
Number of states \| state	40
Skilled Nursing Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties	755
Assisted Living Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties	114
Facilities Under Fixed Rate Mortgage Loans [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties	64
Facilities Under Fixed Rate Mortgage Loans [Member] \| Skilled Nursing Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| property	57
Facilities Under Fixed Rate Mortgage Loans [Member] \| Assisted Living Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| property	3
Mortgage Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of states \| state	8
Number of independent healthcare operating companies operating under mortgage notes receivable \| entity	7

MORTGAGE NOTES RECEIVABLE (Sche

MORTGAGE NOTES RECEIVABLE (Schedule of Receivables) (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)facility	Dec. 31, 2019USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility	976
Mortgage Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 921,724	$ 778,468
Allowance for credit losses	(29,185)	(4,905)
Total mortgages - net	892,539	773,563
Mortgage Loans on Real Estate	892,539	773,563
Mortgage Receivable [Member] \| Mortgage Note Due 2027 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 112,500	112,500
Mortgage loans on real estate, interest rate	10.59%
Maturity year	2027
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 672,364	526,520
Mortgage loans on real estate, interest rate	10.52%
Maturity year	2029
Mortgage Receivable [Member] \| 2 Mortgage Notes Due Through 2021 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 43,200
Mortgage Receivable [Member] \| Other Mortgage Notes Member
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 136,860	$ 139,448
Maximum \| Other Mortgage Notes Member
Accounts, Notes, Loans and Financing Receivable [Line Items]
Maturity year	2028
Maximum \| Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Maturity year	2029
Weighted Average [Member] \| Other Mortgage Notes Member
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage loans on real estate, interest rate	9.40%
Construction Loans [Member] \| Mortgage Receivable [Member] \| 2 Mortgage Notes Due Through 2021 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 28,600
Facilities Used in Weighted Average Interest Rate [Member] \| Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility	47

MORTGAGE NOTES RECEIVABLE (Note

MORTGAGE NOTES RECEIVABLE (Notes Due 2029 Narrative) (Detail) $ in Thousands	May 01, 2020USD ($)facility	Jun. 30, 2020USD ($)facility	Sep. 30, 2020USD ($)facility	Dec. 31, 2019USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility			976
Skilled Nursing Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility			755
Assisted Living Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility			114
Michigan \| 9 Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Write-off of straight-line rent receivable	$ 3,600
Mortgage Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable			$ 921,724	$ 778,468
Mortgage notes receivable			892,539	773,563
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable			$ 672,364	$ 526,520
Maturity year			2029
Mortgage loans on real estate, interest rate			10.52%
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Ciena Healthcare
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable			$ 672,400
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Maturity year			2029
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Master Mortgage [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 415,000
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Amended Master Mortgage [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage loans on real estate, interest rate	10.67%
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Amended Master Mortgage [Member] \| 9 Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable	$ 83,500
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Amended Master Mortgage [Member] \| Assisted Living Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility	1
Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Amended Master Mortgage [Member] \| Michigan \| 9 Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable			$ 83,400
Mortgage loans on real estate, interest rate	10.31%
Percentage of mortgage loan interest rate increase per annum	2.00%
Mortgage loans on real estate, maturity date	Jun. 30, 2029
Mortgage Receivable [Member] \| Mortgage Note Due 2021 [Member] \| Ohio \| 2 Facilities \| Ciena Healthcare Subsidiaries [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage notes receivable		$ 43,200
Mortgage loans on real estate, interest rate		9.50%
Mortgage loans on real estate, maturity date		Jun. 30, 2021
Mortgage notes receivable-net			$ 43,200
Facilities Covered by Mortgage and Used as Collateral [Member] \| Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Amended Master Mortgage [Member] \| Michigan \| Skilled Nursing Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility	8
Facilities Covered by Mortgage and Used as Collateral [Member] \| Mortgage Receivable [Member] \| Mortgage Note Due 2021 [Member] \| Skilled Nursing Facilities \| Ciena Healthcare Subsidiaries [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility		2
Facilities Formerly Leased Now Sold [Member] \| Mortgage Receivable [Member] \| Mortgage Note Due 2029 [Member] \| Amended Master Mortgage [Member] \| Michigan \| 9 Facilities
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of real estate properties \| facility	9

OTHER INVESTMENTS (Schedule of

OTHER INVESTMENTS (Schedule of Receivables) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Jan. 01, 2020	Dec. 31, 2019
Schedule of Investments [Line Items]
Total other investments	$ 464,503	$ 412,540	$ 419,228
Other Investment Receivables [Member]
Schedule of Investments [Line Items]
Other investments, gross	495,695		419,228
Allowance for credit losses	(31,192)
Other Investment Note Due 2021
Schedule of Investments [Line Items]
Other investments, gross	$ 81,948		77,087
Maturity year	2021
Other Investment Note Due 2021 Through 2025 [Member]
Schedule of Investments [Line Items]
Other investments, gross	$ 62,187		58,687
Other Investment Note Due 2023 [Member]
Schedule of Investments [Line Items]
Other investments, gross	$ 49,908		52,213
Maturity year	2023
Other Investments Note Due 2030 [Member]
Schedule of Investments [Line Items]
Other investments, gross	$ 132,148		65,000
Maturity year	2030
Other Investment notes outstanding
Schedule of Investments [Line Items]
Other investments, gross	$ 169,504		$ 166,241
Maturity year	2028
Minimum \| Other Investment Note Due 2021 Through 2025 [Member]
Schedule of Investments [Line Items]
Maturity year	2021
Maximum \| Other Investment Note Due 2021 Through 2025 [Member]
Schedule of Investments [Line Items]
Maturity year	2025
Weighted Average [Member] \| Other Investment Note Due 2021
Schedule of Investments [Line Items]
Interest rate	13.11%
Weighted Average [Member] \| Other Investment Note Due 2021 Through 2025 [Member]
Schedule of Investments [Line Items]
Interest rate	8.25%
Weighted Average [Member] \| Other Investment Note Due 2023 [Member]
Schedule of Investments [Line Items]
Interest rate	12.00%
Weighted Average [Member] \| Other Investments Note Due 2030 [Member]
Schedule of Investments [Line Items]
Interest rate	7.00%
Weighted Average [Member] \| Other Investment notes outstanding
Schedule of Investments [Line Items]
Interest rate	7.92%

OTHER INVESTMENTS (Note Due 202

OTHER INVESTMENTS (Note Due 2021 Narrative) (Detail) - USD ($)	Jul. 29, 2016	Sep. 30, 2020	Sep. 30, 2020	Jan. 01, 2020	Dec. 31, 2019	May 09, 2019	Mar. 06, 2018	Feb. 22, 2018
Schedule of Investments [Line Items]
Other investments		$ 464,503,000	$ 464,503,000	$ 412,540,000	$ 419,228,000
Provision for Credit Losses		28,230,000	29,731,000
Other Investment Note Due 2021
Schedule of Investments [Line Items]
Other investments, gross		81,948,000	81,948,000		$ 77,087,000
Genesis HealthCare
Schedule of Investments [Line Items]
Provision for Credit Losses			0
Genesis HealthCare \| Other Investment Note Due 2021
Schedule of Investments [Line Items]
Other investments, gross		81,900,000	81,900,000
Other investments		63,800,000	63,800,000
Loans Receivable Fixed Rate								14.00%
Loans Receivable Interest Paid-In-Kind								9.00%
Genesis HealthCare \| Other Investment Note Due 2021 First Loan
Schedule of Investments [Line Items]
Financing receivable, face amount	$ 48,000,000
Investment Maturity Date	Jul. 29, 2020					Nov. 30, 2021
Genesis HealthCare \| Other Investment Note Due 2021 First Loan \| Eurodollar [Member]
Schedule of Investments [Line Items]
Debt instrument, interest rate, stated percentage	13.00%
Debt instrument base rate floor	$ 1
Genesis HealthCare \| Other Investment Note Due 2021 First Loan \| Alternative Base Rate [Member]
Schedule of Investments [Line Items]
Debt instrument, interest rate, stated percentage	12.00%
Debt instrument base rate floor	$ 2
Genesis HealthCare \| Other Investment Note Due 2021 Second Loan
Schedule of Investments [Line Items]
Financing receivable, face amount							$ 16,000,000
Other investments		$ 18,200,000	$ 18,200,000
Loans Receivable Fixed Rate							10.00%
Loans Receivable Interest Paid-In-Kind							5.00%
Investment Maturity Date						Nov. 30, 2021	Jul. 29, 2020
Genesis HealthCare \| Debt Instrument, Redemption, Period One [Member] \| Other Investment Note Due 2021
Schedule of Investments [Line Items]
Notes Receivable Principal Payment	250,000
Genesis HealthCare \| Debt Instrument, Redemption, Period Two [Member] \| Other Investment Note Due 2021
Schedule of Investments [Line Items]
Notes Receivable Principal Payment	$ 500,000

OTHER INVESTMENTS (Note Due 2_2

OTHER INVESTMENTS (Note Due 2021-2025 Narrative) (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2017	Sep. 30, 2020	Sep. 30, 2020	Feb. 28, 2020	Feb. 10, 2020	Dec. 31, 2019	Nov. 05, 2019	May 07, 2018	Sep. 30, 2016
Schedule of Investments [Line Items]
Provision for Credit Losses		$ 28,230,000	$ 29,731,000
Other Investment Note Due 2021 Through 2025 [Member]
Schedule of Investments [Line Items]
Other investments, gross		62,187,000	62,187,000			$ 58,687,000
Other Investment notes outstanding
Schedule of Investments [Line Items]
Other investments, gross		169,504,000	169,504,000			166,241,000
Mortgage Receivable [Member]
Schedule of Investments [Line Items]
Other investments, gross		921,724,000	921,724,000			$ 778,468,000
Agemo Holdings LLC
Schedule of Investments [Line Items]
Loans Receivable, Net		37,800,000	37,800,000
Agemo Holdings LLC \| Tranche Two [Member]
Schedule of Investments [Line Items]
Financing receivable, face amount									$ 32,000,000
Agemo Holdings LLC \| Other Investment Note Due 2021 Through 2025 [Member]
Schedule of Investments [Line Items]
Financing receivable, face amount							$ 1,700,000		37,000,000
Letter of Credit as collateral fair value		9,300,000	9,300,000
Provision for Credit Losses		24,400,000
Loans Receivable, Net		9,300,000	9,300,000
Agemo Holdings LLC \| Other Investment Note Due 2021 Through 2025 [Member] \| Tranche One [Member]
Schedule of Investments [Line Items]
Debt instrument, interest rate, stated percentage	13.00%
Proceeds from collection of notes receivable	$ 5,000,000
Agemo Holdings LLC \| Other Investment Note Due 2021 Through 2025 [Member] \| Tranche Two [Member]
Schedule of Investments [Line Items]
Financing receivable, face amount							32,000,000		$ 32,000,000
Investment Maturity Date									Dec. 31, 2024
Debt instrument, interest rate, stated percentage									9.00%
Provision for Credit Losses		3,800,000
Agemo Holdings LLC \| Other Investment Note Due 2021 Through 2025 Second Loan [Member]
Schedule of Investments [Line Items]
Financing receivable, face amount								$ 25,000,000
Investment Maturity Date								Apr. 30, 2025
Debt instrument, interest rate, stated percentage								7.00%
Other investments, gross		25,000,000	25,000,000
Provision for Credit Losses		0
Agemo Holdings LLC \| Other Investment Note Due 2021 Through 2025 Fourth Loan [Member]
Schedule of Investments [Line Items]
Financing receivable, face amount							$ 1,700,000
Investment Maturity Date					Jan. 1, 2021		Mar. 31, 2020
Debt instrument, interest rate, stated percentage							9.00%
Affiliate Agemo Holdings LLC [Member] \| Other Investment Note Due 2021 Through 2025 [Member]
Schedule of Investments [Line Items]
Financing receivable, face amount				$ 3,500,000
Investment Maturity Date				Feb. 28, 2021
Debt instrument, interest rate, stated percentage				10.00%
Other investments, gross		3,500,000	$ 3,500,000
Provision for Credit Losses		$ 0

OTHER INVESTMENTS (Notes Due 20

OTHER INVESTMENTS (Notes Due 2030 Narrative) (Detail) - USD ($) $ in Thousands	Jul. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2017	Dec. 31, 2015
Rental income		$ 83,226	$ 202,470	$ 526,258	$ 589,464
Maplewood Real Estate Holdings \| Other Investment Note Due2030 [Member]
Financing receivable, face amount	$ 220,500
Debt instrument, interest rate, stated percentage	7.00%
Other investments, gross	$ 132,100	$ 132,100		$ 132,100
Investment Maturity Date	Jun. 30, 2030
Rental income	$ 55,400
Maplewood Real Estate Holdings \| Secured Revolving Credit One [Member]
Financing receivable, face amount							$ 50,000
Debt instrument, interest rate, stated percentage							6.66%
Maplewood Real Estate Holdings \| Secured Revolving Credit Two [Member]
Financing receivable, face amount						$ 15,000
Debt instrument, interest rate, stated percentage						9.50%

OTHER INVESTMENTS (Other Invest

OTHER INVESTMENTS (Other Investment Note Narrative) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Apr. 17, 2020	Dec. 31, 2019
Other Investment Receivables [Member]
Other investments, gross	$ 495,695		$ 419,228
Other Investment notes outstanding
Other investments, gross	169,504		$ 166,241
Subsidiary of Second Spring Healthcare [Member]
Other investments, gross	$ 17,600
Subsidiary of Second Spring Healthcare [Member] \| Other Investment notes outstanding
Financing receivable, face amount		$ 17,600
Debt instrument, interest rate, stated percentage	3.25%	2.75%
Other investments, gross	$ 17,600
Ownership %	15.00%

VARIABLE INTEREST ENTITIES (Sch

VARIABLE INTEREST ENTITIES (Schedule of Variable Interest Entities) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Variable Interest Entity [Line Items]
Rental income	$ 83,226	$ 202,470	$ 526,258	$ 589,464
Other investment income	11,286	9,989	32,870	33,036
Total operating revenues	119,177	233,195	628,596	682,162
Provision of of straight-line rent and contractual receivables	142,300
Agemo Holdings LLC
Variable Interest Entity [Line Items]
Provision of of straight-line rent and contractual receivables	75,300
Maplewood Real Estate Holdings
Variable Interest Entity [Line Items]
Total operating revenues		11,552	38,214	32,410
Maplewood Real Estate Holdings \| Rental and Other Investment Income [Member]
Variable Interest Entity [Line Items]
Variable interest entity rental and other investment income		11,400	51,400	31,700
Maplewood Real Estate Holdings \| Rental Income [Member]
Variable Interest Entity [Line Items]
Rental income		10,337	33,381	28,804
Maplewood Real Estate Holdings \| Other Investment Income [Member]
Variable Interest Entity [Line Items]
Other investment income		1,215	4,833	3,606
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC
Variable Interest Entity [Line Items]
Assets subtotal	414,035		414,035		$ 533,246
Maximum exposure to loss	21,141		21,141		112,604
Revenue total	(62,069)	16,313	(29,429)	48,768
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Rental and Other Investment Income [Member]
Variable Interest Entity [Line Items]
Variable interest entity rental and other investment income	13,400	13,500	40,100	39,700
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Rental Income [Member]
Variable Interest Entity [Line Items]
Revenue total	(63,128)	15,145	(33,026)	45,473
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Other Investment Income [Member]
Variable Interest Entity [Line Items]
Revenue total	1,059	$ 1,168	3,597	$ 3,295
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Letters of credit
Variable Interest Entity [Line Items]
Liabilities subtotal	(9,253)		(9,253)		(9,253)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Personal Guarantee Collateral [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(8,000)		(8,000)		(8,000)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Other Collateral [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(375,641)		(375,641)		(403,389)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Collateral Pledged [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(392,894)		(392,894)		(420,642)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Real Estate Investments [Member]
Variable Interest Entity [Line Items]
Assets subtotal	375,641		375,641		403,389
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Other Investments [Member]
Variable Interest Entity [Line Items]
Assets subtotal	37,753		37,753		58,687
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Accounts Receivable [Member]
Variable Interest Entity [Line Items]
Assets subtotal	641		641		18,113
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Straight-Line Rent Receivables [Member]
Variable Interest Entity [Line Items]
Assets subtotal					46,247
Variable Interest Entity, Not Primary Beneficiary [Member] \| Agemo Holdings LLC \| Lease inducement [Member]
Variable Interest Entity [Line Items]
Assets subtotal					$ 6,810
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings
Variable Interest Entity [Line Items]
Assets subtotal	889,674		889,674
Liabilities subtotal	(44,252)		(44,252)
Maximum exposure to loss	58,466		58,466
Revenue total	15,178
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Rental and Other Investment Income [Member]
Variable Interest Entity [Line Items]
Variable interest entity rental and other investment income	17,500
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Rental Income [Member]
Variable Interest Entity [Line Items]
Revenue total	13,199
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Other Investment Income [Member]
Variable Interest Entity [Line Items]
Revenue total	1,979
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Personal Guarantee Collateral [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(40,000)		(40,000)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Other Collateral [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(746,956)		(746,956)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Collateral Pledged [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(786,956)		(786,956)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Real Estate Investments [Member]
Variable Interest Entity [Line Items]
Assets subtotal	746,956		746,956
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Other Investments [Member]
Variable Interest Entity [Line Items]
Assets subtotal	132,148		132,148
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Accounts Receivable [Member]
Variable Interest Entity [Line Items]
Assets subtotal	771		771
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Straight-Line Rent Receivables [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(61,207)		(61,207)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Lease inducement [Member]
Variable Interest Entity [Line Items]
Assets subtotal	71,006		71,006
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Net In Place Lease Liability [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	(337)		(337)
Variable Interest Entity, Not Primary Beneficiary [Member] \| Maplewood Real Estate Holdings \| Contingent Liability [Member]
Variable Interest Entity [Line Items]
Liabilities subtotal	$ (43,915)		$ (43,915)

INVESTMENT IN JOINT VENTUREs (S

INVESTMENT IN JOINT VENTUREs (Schedule of equity method investments) (Narrative) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)facilitycontractproperty	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)facilitycontractproperty	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Investments in unconsolidated joint ventures	$ 196,214		$ 196,214		$ 199,884
Number of real estate properties \| facility	976		976
Number of Operators \| contract	69		69
Income (loss) from unconsolidated joint ventures	$ 1,692	$ 8,428	$ 4,654	$ 10,028
Initial Investment			230,003
Assets management fees recognized	$ 300	200	$ 1,000	700
Skilled Nursing Facilities
Number of real estate properties \| facility	755		755
Specialty
Number of real estate properties \| property	28		28
Assisted Living Facilities
Number of real estate properties \| facility	114		114
Second Spring Healthcare Investments [Member]
Income (loss) from unconsolidated joint ventures	$ 1,666	7,832	$ 2,947	9,139
Second Spring Healthcare Investments [Member] \| Skilled Nursing Facilities
Ownership %	15.00%		15.00%
Initial Investment Date			Nov. 1, 2016
Investments in unconsolidated joint ventures	$ 20,386		$ 20,386		22,504
Number of real estate properties \| facility	23		23
Initial Investment			$ 50,032
Subsidiary of Second Spring Healthcare [Member]
Other investments, gross	$ 17,600		17,600
Lakeway Realty LLC [Member]
Income (loss) from unconsolidated joint ventures	$ 637	$ 596	$ 1,860	$ 889
Lakeway Realty LLC [Member] \| Specialty
Ownership %	51.00%		51.00%
Initial Investment Date			May 17, 2019
Investments in unconsolidated joint ventures	$ 72,585		$ 72,585		73,273
Number of real estate properties \| facility	1		1
Initial Investment			$ 73,834
Cindat Ice Portfolio JV GP Limited [Member]
Income (loss) from unconsolidated joint ventures	$ (398)		$ 493
Cindat Ice Portfolio JV GP Limited [Member] \| Assisted Living Facilities
Ownership %	49.00%		49.00%
Initial Investment Date			Dec. 18, 2019
Investments in unconsolidated joint ventures	$ 103,052		$ 103,052		103,976
Number of real estate properties \| facility	67		67
Initial Investment			$ 105,687
OMG Senior Housing LLC [Member]
Income (loss) from unconsolidated joint ventures	$ (108)		$ (387)
OMG Senior Housing LLC [Member] \| Independent Living Facilities [Member]
Ownership %	50.00%		50.00%
Initial Investment Date			Dec. 6, 2019
Number of real estate properties \| facility	1		1
OH CHS SNP Inc [Member]
Ownership %	9.00%		9.00%
Initial Investment Date			Dec. 20, 2019
Investments in unconsolidated joint ventures	$ 191		$ 191		$ 131
Income (loss) from unconsolidated joint ventures	$ (105)		(259)
Initial Investment			$ 450

ASSETS HELD FOR SALE (Schedule

ASSETS HELD FOR SALE (Schedule of Properties Held-for-Sale) (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2020USD ($)facilityproperty	Jun. 30, 2020USD ($)propertyfacility	Mar. 31, 2020USD ($)propertyfacility	Sep. 30, 2020USD ($)facilityproperty
Number Of Properties
Beginning Balance \| property	6	8	6	6
Properties sold \| property	(4)	(5)	(4)
Properties added \| property	11	3	6
Ending balance \| property	13	6	8	13
Net Book Value
Beginning Balance	$ 70,516	$ 24,125	$ 4,922	$ 4,922
Properties sold	(66,560)	(19,910)	(4,341)
Properties added	31,965	66,301	23,544
Ending balance	$ 35,921	70,516	24,125	$ 35,921
Net proceeds from sale of facilities held for sale		38,400	4,200
Gain (loss) from sale of facilities		16,700	(500)
Number of real estate properties \| facility	976			976
Impairment charges	$ 7,400		$ 1,900
Skilled Nursing Facilities
Net Book Value
Number of real estate properties \| facility	755			755
Assisted Living Facilities
Net Book Value
Number of real estate properties \| facility	114			114
2 Facilities
Net Book Value
Impairment charges		$ 2,600
6 Facilities
Net Book Value
Impairment charges	$ 24,200
4 Facilities and Parcel of Land [Member}
Net Book Value
Net proceeds from sale of facilities held for sale	60,700
Gain (loss) from sale of facilities	$ (1,000)
Facilities Sold \| 4 Facilities
Net Book Value
Number of real estate properties \| facility			4
Facilities Sold \| 5 Facilities
Net Book Value
Number of real estate properties \| facility		5
Facilities Sold \| 4 Facilities and Parcel of Land [Member}
Net Book Value
Number of real estate properties \| facility	4			4
Facilities With Impairment Charges [Member] \| 2 Facilities
Net Book Value
Number of real estate properties \| facility		2
Facilities With Impairment Charges [Member] \| 6 Facilities
Net Book Value
Number of real estate properties \| facility	6			6

INTANGIBLES (Narrative) (Detail

INTANGIBLES (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
INTANGIBLES (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net amortization of intangible assets	$ 3.7	$ 1.3	$ 8.5	$ 4.7
Remainder 2020	2.7		2.7
2021	6.1		6.1
2022	5.8		5.8
2023	5.6		5.6
2024	$ 5.4		$ 5.4
Below market leases, weighted average remaining amortization, period			8 years
Above market leases
Weighted average remaining amortization			9 years

INTANGIBLES (Schedule of Intang

INTANGIBLES (Schedule of Intangibles) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets:
Goodwill	$ 644,084	$ 644,415
Gross intangible assets	22,822	49,240
Accumulated amortization	(20,526)	(21,227)
Net intangible assets	2,296	28,013
Liabilities:
Below market leases	140,744	147,292
Accumulated amortization	(94,914)	(87,154)
Net intangible liabilities	$ 45,830	$ 60,138

INTANGIBLES (Schedule of Reconc

INTANGIBLES (Schedule of Reconciliation of Goodwill) (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Goodwill [Roll Forward]
Balance	$ 644,415
Less: foreign currency translation	(331)
Balance	$ 644,084

CONCENTRATION OF RISK (Narrativ

CONCENTRATION OF RISK (Narrative) (Detail) $ in Thousands	3 Months Ended		9 Months Ended
CONCENTRATION OF RISK (Narrative) (Detail) $ in Thousands	Sep. 30, 2020USD ($)facilitycontractpropertyitemstate	Sep. 30, 2019	Sep. 30, 2020USD ($)facilitycontractpropertyitemstate	Sep. 30, 2019	Jan. 01, 2020USD ($)	Dec. 31, 2019USD ($)
Concentration Risk [Line Items]
Number of real estate properties	976		976
Number of operators that met or exceeded ten percent threshold for revenues \| item	1		1
Number of states \| state	40		40
Number of operators \| contract	69		69
Gross investment in facilities, net of impairments and reserves for uncollectible loans \| $	$ 9,700,000		$ 9,700,000
Other investments \| $	464,503		464,503		$ 412,540	$ 419,228
Investment in unconsolidated joint venture \| $	$ 196,214		$ 196,214			$ 199,884
Number of unconsolidated joint ventures \| item	5		5
Five Unconsolidated Joint Venture [Member]
Concentration Risk [Line Items]
Investment in unconsolidated joint venture \| $	$ 196,200		$ 196,200
Geographic Concentration Risk [Member] \| Florida
Concentration Risk [Line Items]
Concentration percentage			14.00%
Geographic Concentration Risk [Member] \| Texas
Concentration Risk [Line Items]
Concentration percentage			9.00%
Geographic Concentration Risk [Member] \| Michigan
Concentration Risk [Line Items]
Concentration percentage			7.00%
Product Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration percentage			97.00%
Skilled Nursing Facilities
Concentration Risk [Line Items]
Number of real estate properties	755		755
Assisted Living Facilities
Concentration Risk [Line Items]
Number of real estate properties	114		114
Specialty
Concentration Risk [Line Items]
Number of real estate properties \| property	28		28
Medical Office Building
Concentration Risk [Line Items]
Number of real estate properties	2		2
Ciena Healthcare \| Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration percentage	11.00%	11.00%	11.00%	11.00%
Facilities Under Fixed Rate Mortgage Loans [Member]
Concentration Risk [Line Items]
Number of real estate properties	64		64
Facilities Under Fixed Rate Mortgage Loans [Member] \| Skilled Nursing Facilities
Concentration Risk [Line Items]
Number of real estate properties \| property	57		57
Facilities Under Fixed Rate Mortgage Loans [Member] \| Assisted Living Facilities
Concentration Risk [Line Items]
Number of real estate properties \| property	3		3
Facilities Under Fixed Rate Mortgage Loans [Member] \| Specialty
Concentration Risk [Line Items]
Number of real estate properties	4		4
Facilities Held for Sale or Closed [Member]
Concentration Risk [Line Items]
Number of real estate properties	13		13

STOCKHOLDERS'_OWNERS' EQUITY (C

STOCKHOLDERS'/OWNERS' EQUITY (Common Stock Repurchase) (Narrative) (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Mar. 20, 2020
Stockholders' / Owners' Equity [Abstract]
Stock repurchase program, authorized amount		$ 200
Stock repurchased during period, shares	0

STOCKHOLDERS'_OWNERS' EQUITY (S

STOCKHOLDERS'/OWNERS' EQUITY (Schedule of Common Stock Dividends) (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Dividends Payable [Line Items]
Common Stock, Dividends, Per Share, Declared	$ 0.67	$ 0.66	$ 2.01	$ 1.98
January 31, 2020
Dividends Payable [Line Items]
Dividends Declared, Date Of Record			Jan. 31, 2020
Dividends Payable, Date to be Paid			Feb. 14, 2020
Common Stock, Dividends, Per Share, Declared			$ 0.67
April 30, 2020
Dividends Payable [Line Items]
Dividends Declared, Date Of Record			Apr. 30, 2020
Dividends Payable, Date to be Paid			May 15, 2020
Common Stock, Dividends, Per Share, Declared			$ 0.67
July 31, 2020
Dividends Payable [Line Items]
Dividends Declared, Date Of Record			Jul. 31, 2020
Dividends Payable, Date to be Paid			Aug. 14, 2020
Common Stock, Dividends, Per Share, Declared			$ 0.67
November 2, 2020
Dividends Payable [Line Items]
Dividends Declared, Date Of Record			Nov. 2, 2020
Dividends Payable, Date to be Paid			Nov. 16, 2020
Common Stock, Dividends, Per Share, Declared			$ 0.67

STOCKHOLDERS'_OWNERS' EQUITY (E

STOCKHOLDERS'/OWNERS' EQUITY (Equity Shelf Program) (Narrative) (Detail) - $500 Million Equity Shelf Program - USD ($) $ / shares in Units, $ in Millions	Sep. 03, 2015	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Sales price, equity distribution agreement	$ 500
Issuance of common stock (in shares)		0	100,000	49,000	3,100,000
Average issue price per share			$ 33.91	$ 34.64	$ 34.78
Proceeds from issuance of common stock			$ 4.2	$ 1.7	$ 107

STOCKHOLDERS'_OWNERS' EQUITY (D

STOCKHOLDERS'/OWNERS' EQUITY (Dividend Reinvestment and Common Stock Purchase Plan) (Narrative) (Detail) - Dividend Reinvestment And Common Stock Purchase Plan - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Issuance of common stock (in shares)	0	1,000,000	90,000	2,500,000
Average issue price per share		$ 37.87	$ 41.80	$ 37.06
Net proceeds from issuance of common stock		$ 37.7	$ 3.7	$ 91.8

STOCKHOLDERS'_OWNERS' EQUITY _2

STOCKHOLDERS'/OWNERS' EQUITY (Schedule of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 4,167,392		$ 4,336,594
Balance , ending	3,938,414	$ 4,083,462	3,938,414	$ 4,083,462
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4,167,392	4,083,462	4,336,594	4,083,462	$ 3,938,414	$ 4,336,594	$ 4,083,462
Add: portion included in noncontrolling interest					(193,854)	(201,166)
Stockholders Equity/AOCI					3,744,560	4,135,428
Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(66,235)
Balance , ending	(49,101)	(58,272)	(49,101)	(58,272)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(49,101)	(58,272)	(49,101)	(58,272)	(49,101)		(58,272)
Omega OP \| Foreign Currency Translation [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(68,795)	(49,715)	(35,100)	(47,704)
Translation loss	21,808	(12,015)	(11,818)	(13,857)
Realized gain (loss)	19	23	(50)	(146)
Balance , ending	(46,968)	(61,707)	(46,968)	(61,707)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(46,968)	(61,707)	(46,968)	(61,707)	(46,968)	(35,100)	(61,707)
Omega OP \| Cash Flow Hedges [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(9,699)	(4,093)	(2,369)	3,994
Unrealized (loss) gain	7,223	(26)	1,401	(8,765)
Realized (loss) gain	(1,500)	195	(3,008)	847
Balance , ending	(3,976)	(3,924)	(3,976)	(3,924)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(3,976)	(3,924)	(3,976)	(3,924)	(3,976)	(2,369)	(3,924)
Omega OP \| Net Investment Hedge [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	9,533	790	(4,420)	70
Unrealized (loss) gain	(9,953)	4,040	4,000	4,760
Balance , ending	(420)	4,830	(420)	4,830
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(420)	4,830	(420)	4,830	(420)	$ (4,420)	4,830
Omega OP \| Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance , ending	(51,364)	(60,801)	(51,364)	(60,801)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ (51,364)	$ (60,801)	$ (51,364)	$ (60,801)	(51,364)		(60,801)
Add: portion included in noncontrolling interest					2,263		2,529
Stockholders Equity/AOCI					$ (49,101)		$ (58,272)

TAXES (Narrative) (Detail)

TAXES (Narrative) (Detail) $ in Millions	3 Months Ended		9 Months Ended
TAXES (Narrative) (Detail) $ in Millions	Sep. 30, 2020USD ($)subsidiary	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)subsidiary	Sep. 30, 2019USD ($)
Taxes [Line Items]
Percentage of minimum taxable income is distributed	90.00%		90.00%
Permitted ownership of a taxable REIT subsidiary ("TRS"), maximum percentage	100.00%		100.00%
Number of REIT subsidiaries \| subsidiary	1		1
Net operating loss carryforwards period			Under current law, our NOL carry-forwards generated up through December 31, 2017 may be carried forward for no more than 20 years, and our NOL carry-forwards generated in our taxable years ended December 31, 2019 and December 31, 2018 may be carried forward indefinitely.
Provision (benefit) for foreign income taxes	$ 0.5	$ 0.2	$ 1.8	$ 1.3
State and local income tax provision	0.2	$ 0.3	$ 0.8	$ 0.7
Number of TSRs subject to federal, state and local income taxes with net operating loss carryforwards \| subsidiary			1
Taxable REIT Subsidiaries [Member]
Taxes [Line Items]
Net operating loss carry-forward	$ 5.7		$ 5.7
Tax Years Prior to January 1 2018 [Member]
Taxes [Line Items]
Net operating loss percentage that can be used to reduce taxable income			100.00%

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jan. 01, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 5,122	$ 2,921	$ 14,380	$ 11,031
Percentage of operating partnership units distributions			10.00%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares awarded, other than options					20,215
Profit Interest Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares awarded, other than options					102,565
Relative TSR PIUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares awarded, other than options					528,499
TSR Profit Interest Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares awarded, other than options					680,038

STOCK-BASED COMPENSATION (Sched

STOCK-BASED COMPENSATION (Schedule of Stock-based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock-Based Compensation [Abstract]
Stock-based compensation expense	$ 5,122	$ 2,921	$ 14,380	$ 11,031

BORROWING ARRANGEMENTS (Schedul

BORROWING ARRANGEMENTS (Schedule of Borrowings) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Total secured borrowings - net			$ 371,351		$ 389,680
Revolving line of credit			170,667		125,000
Total term loans - net			802,334		804,738
Total senior notes and other unsecured borrowings - net			3,828,609		3,816,722
Total secured and unsecured borrowings - net			5,172,961		$ 5,136,140
Proceeds from lines of credit			939,466	$ 887,000
Repayments of Lines of Credit			893,000	$ 1,485,100
Hud Mortgage Assumed [Member]
Debt Instrument [Line Items]
Assets pleadged as collateral, fair value			577,600
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,250,000
Proceeds from lines of credit		$ 300,000
Repayments of Lines of Credit	$ 300,000
2017 Omega OP Term Loan Facility
Debt Instrument [Line Items]
Deferred financing costs - net			$ (200)
4.375% notes due 2023
Debt Instrument [Line Items]
Rate			4.375%		4.375%
4.95% notes due 2024
Debt Instrument [Line Items]
Rate			4.95%		4.95%
4.50% notes due 2025
Debt Instrument [Line Items]
Rate			4.50%		4.50%
5.25% notes due 2026
Debt Instrument [Line Items]
Rate			5.25%		5.25%
4.50% notes due 2027
Debt Instrument [Line Items]
Rate			4.50%		4.50%
4.75% notes due 2028
Debt Instrument [Line Items]
Rate			4.75%		4.75%
3.625% notes due 2029
Debt Instrument [Line Items]
Rate			3.625%		3.625%
Secured Debt [Member]
Debt Instrument [Line Items]
Total secured borrowings - net			$ 371,351		$ 389,680
Secured Debt [Member] \| Hud Mortgage Assumed [Member]
Debt Instrument [Line Items]
Rate			3.01%
Total secured borrowings - net			$ 369,076		387,405
Secured Debt [Member] \| Term Loan
Debt Instrument [Line Items]
Maturity			2021
Rate			3.25%
Total secured borrowings - net			$ 2,275		2,275
Unsecured Debt [Member]
Debt Instrument [Line Items]
Deferred financing costs - net			(20,820)		(23,778)
Total term loans - net			802,334		804,738
Discount - net			(20,571)		(23,041)
Total senior notes and other unsecured borrowings - net			3,828,609		3,816,722
Total unsecured borrowings - net			$ 4,801,610		4,746,460
Unsecured Debt [Member] \| Revolving Credit Facility
Debt Instrument [Line Items]
Maturity			2021
Rate			1.34%
Revolving line of credit			$ 170,667		125,000
Unsecured Debt [Member] \| Term Loan
Debt Instrument [Line Items]
Deferred financing costs - net			$ (1,946)		(2,742)
Unsecured Debt [Member] \| U.S. term loan
Debt Instrument [Line Items]
Maturity			2022
Rate			1.59%
Total term loans - net			$ 350,000		350,000
Unsecured Debt [Member] \| Sterling term loan
Debt Instrument [Line Items]
Maturity			2022
Rate			1.50%
Total term loans - net			$ 129,280		132,480
Unsecured Debt [Member] \| 2017 Omega OP Term Loan Facility
Debt Instrument [Line Items]
Maturity			2022
Rate			3.29%
Total term loans - net			$ 75,000		75,000
Unsecured Debt [Member] \| Amended 2015 Term Loan Facility
Debt Instrument [Line Items]
Maturity			2022
Rate			3.80%
Total term loans - net			$ 250,000		250,000
Unsecured Debt [Member] \| Subordinated debt
Debt Instrument [Line Items]
Maturity			2021
Rate			9.00%
Long-term debt, gross			$ 20,000		13,541
Senior Notes [Member] \| 4.375% notes due 2023
Debt Instrument [Line Items]
Maturity			2023
Rate			4.375%
Long-term debt, gross			$ 700,000		700,000
Senior Notes [Member] \| 4.95% notes due 2024
Debt Instrument [Line Items]
Maturity			2024
Rate			4.95%
Long-term debt, gross			$ 400,000		400,000
Senior Notes [Member] \| 4.50% notes due 2025
Debt Instrument [Line Items]
Maturity			2025
Rate			4.50%
Long-term debt, gross			$ 400,000		400,000
Senior Notes [Member] \| 5.25% notes due 2026
Debt Instrument [Line Items]
Maturity			2026
Rate			5.25%
Long-term debt, gross			$ 600,000		600,000
Senior Notes [Member] \| 4.50% notes due 2027
Debt Instrument [Line Items]
Maturity			2027
Rate			4.50%
Long-term debt, gross			$ 700,000		700,000
Senior Notes [Member] \| 4.75% notes due 2028
Debt Instrument [Line Items]
Maturity			2028
Rate			4.75%
Long-term debt, gross			$ 550,000		550,000
Senior Notes [Member] \| 3.625% notes due 2029
Debt Instrument [Line Items]
Maturity			2029
Rate			3.625%
Long-term debt, gross			$ 500,000		500,000
Omega OP
Debt Instrument [Line Items]
Total secured borrowings - net			371,351		389,680
Total term loans - net			$ 74,837		$ 74,763
Minimum \| Secured Debt [Member] \| Hud Mortgage Assumed [Member]
Debt Instrument [Line Items]
Maturity			2046
Maximum \| Secured Debt [Member] \| Hud Mortgage Assumed [Member]
Debt Instrument [Line Items]
Maturity			2052

BORROWING ARRANGEMENTS (HUD Mor

BORROWING ARRANGEMENTS (HUD Mortgage Loan Payoffs) (Details) $ in Thousands	Aug. 26, 2020USD ($)item	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)
Interest - refinancing costs		$ 896	$ 896
Two Hud Mortgages Assumed [Member] \| Secured Debt [Member]
Repayments of Secured Debt	$ 13,700
Long-term Debt, Weighted Average Interest Rate, over Time	3.08%
Interest - refinancing costs	$ 900
Number of assumed loans retired \| item	2
Hud Mortgage Assumed Maturity 2051 [Member] \| Secured Debt [Member]
Maturity	2051
Hud Mortgage Assumed Maturity 2052 [Member] \| Secured Debt [Member]
Maturity	2052

BORROWING ARRANGEMENTS (Forward

BORROWING ARRANGEMENTS (Forward Starting Swaps) (Details) $ in Millions	Mar. 27, 2020USD ($)contract	Oct. 31, 2020USD ($)	Sep. 30, 2020	Oct. 09, 2020USD ($)
Debt instrument, covenant description			Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of September 30, 2020 and December 31, 2019, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings. Omega OP, the guarantor of Parent’s outstanding senior notes, does not directly own any substantive assets other than its interest in non-guarantor subsidiaries.
Number of forward starting swaps entered into \| contract	5
Senior Notes Due 2031 \| Senior Notes [Member] \| Subsequent event
Debt instrument, face amount		$ 700		$ 700
Debt instrument, interest rate, stated percentage		3.375%		3.375%
Maturity		2031
Interest Rate Swap \| Cash Flow Hedging [Member]
Derivative, notional amount	$ 400
Derivative, effective date			Aug. 1, 2023
Derivative, inception Date			Mar. 27, 2020
Derivative, maturity Date			Aug. 1, 2033
Derivative forecasted issuance period on long term debt	5 years
Derivative, fixed interest rate	0.8675%
Derivative, maximum period	46 months

BORROWING ARRANGEMENTS (Subordi

BORROWING ARRANGEMENTS (Subordinated Debt) (Narrative) (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2019USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2010item	Jun. 30, 2010USD ($)
Subordinated debt \| Unsecured Debt [Member]
Long-term Debt, Gross	$ 13,541	$ 20,000
Debt instrument, interest rate, stated percentage		9.00%
Five Subordinated Debt Notes [Member]
Number of separate subordinated notes assumed \| item			5
Five Subordinated Debt Notes [Member] \| Unsecured Debt [Member]
Long-term Debt, Gross				$ 4,000
Debt instrument, interest rate, stated percentage				9.00%
Offset (reversed) assumed debt against unpaid rent	$ 6,500

FINANCIAL INSTRUMENTS (Schedule

FINANCIAL INSTRUMENTS (Schedule of Financial Instruments) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
4.375% notes due 2023
Liabilities:
Notes issued, interest rate	4.375%	4.375%
4.95% notes due 2024
Liabilities:
Notes issued, interest rate	4.95%	4.95%
4.50% notes due 2025
Liabilities:
Notes issued, interest rate	4.50%	4.50%
5.25% notes due 2026
Liabilities:
Notes issued, interest rate	5.25%	5.25%
4.50% notes due 2027
Liabilities:
Notes issued, interest rate	4.50%	4.50%
4.75% notes due 2028
Liabilities:
Notes issued, interest rate	4.75%	4.75%
3.625% notes due 2029
Liabilities:
Notes issued, interest rate	3.625%	3.625%
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Assets:
Investments in direct financing leases - net	$ 10,858	$ 11,488
Mortgage notes receivable - net	892,539	773,563
Other investments - net	464,503	419,228
Total	1,367,900	1,204,279
Liabilities:
Revolving line of credit	170,667	125,000
Secured borrowing	2,275	2,275
U.S. term loan	349,226	348,878
Sterling term loan	128,989	132,059
Omega OP term loan	74,837	74,763
2015 term loan	249,282	249,038
Subordinated debt - net	20,105	13,714
Total	5,172,961	5,136,140
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| 4.375% notes due 2023
Liabilities:
Notes Payable	696,688	695,812
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| 4.95% notes due 2024
Liabilities:
Notes Payable	396,461	395,702
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| 4.50% notes due 2025
Liabilities:
Notes Payable	396,734	396,163
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| 5.25% notes due 2026
Liabilities:
Notes Payable	596,261	595,732
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| 4.50% notes due 2027
Liabilities:
Notes Payable	690,543	689,445
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| 4.75% notes due 2028
Liabilities:
Notes Payable	542,647	541,891
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| 3.625% notes due 2029
Liabilities:
Notes Payable	489,170	488,263
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| Hud Mortgage Assumed [Member]
Liabilities:
HUD debt - net	369,076	387,405
Estimate Of Fair Value, Fair Value Disclosure [Member]
Assets:
Investments in direct financing leases - net	10,858	11,488
Mortgage notes receivable - net	920,800	819,083
Other investments - net	468,694	412,934
Total	1,400,352	1,243,505
Liabilities:
Revolving line of credit	170,667	125,000
Secured borrowing	2,275	2,275
U.S. term loan	350,000	350,000
Sterling term loan	129,280	132,480
Omega OP term loan	75,000	75,000
2015 term loan	250,000	250,000
Subordinated debt - net	21,828	15,253
Total	5,565,987	5,490,735
Estimate Of Fair Value, Fair Value Disclosure [Member] \| 4.375% notes due 2023
Liabilities:
Notes Payable	756,678	749,693
Estimate Of Fair Value, Fair Value Disclosure [Member] \| 4.95% notes due 2024
Liabilities:
Notes Payable	431,497	442,327
Estimate Of Fair Value, Fair Value Disclosure [Member] \| 4.50% notes due 2025
Liabilities:
Notes Payable	427,411	430,529
Estimate Of Fair Value, Fair Value Disclosure [Member] \| 5.25% notes due 2026
Liabilities:
Notes Payable	659,994	675,078
Estimate Of Fair Value, Fair Value Disclosure [Member] \| 4.50% notes due 2027
Liabilities:
Notes Payable	757,945	759,475
Estimate Of Fair Value, Fair Value Disclosure [Member] \| 4.75% notes due 2028
Liabilities:
Notes Payable	606,329	602,967
Estimate Of Fair Value, Fair Value Disclosure [Member] \| 3.625% notes due 2029
Liabilities:
Notes Payable	507,158	500,792
Estimate Of Fair Value, Fair Value Disclosure [Member] \| Hud Mortgage Assumed [Member]
Liabilities:
HUD debt - net	$ 419,925	$ 379,866

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands	Sep. 29, 2020	Sep. 30, 2020	May 17, 2019
Total commitments		$ 562,262
Indemnification Agreement [Member]
Total commitments		$ 11,500
Lakeway Realty LLC [Member]
Litigation settlement, amount awarded to other party	$ 1,100
Lakeway Realty LLC [Member] \| MedEquities
Equity Method Investment, Ownership Percentage			51.00%
Minimum \| Indemnification Agreement [Member]
Indemnification agreement occurrence period		18 months
Maximum \| Indemnification Agreement [Member]
Indemnification agreement occurrence period		72 months

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Schedule of remaining commitments) (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Total commitments	$ 562,262
Amounts funded to date	(467,141)
Remaining commitments	95,121
Other Investment Receivables [Member]
Remaining commitments	$ 109,300

(LOSS) EARNINGS PER SHARE_UNI_2

(LOSS) EARNINGS PER SHARE/UNIT (Schedule of Computation of Basic and Diluted Earnings per Share) (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net (loss) income	$ (93,768)	$ 142,948	$ 100,471	$ 290,801
Add/deduct: net loss (income) attributable to noncontrolling interests	2,477	(4,208)	(2,540)	(9,218)
Net (loss) income available to common stockholders/owners	$ (91,291)	$ 138,740	$ 97,931	$ 281,583
Denominator:
Denominator for basic earnings per share	227,507	217,818	227,393	211,315
Effect of dilutive securities:
Common stock equivalents		1,754	1,065	1,678
Net forward share contract		319		106
Noncontrolling interest - Omega OP Units	6,168	6,622	6,078	7,072
Denominator for diluted earnings per share	233,675	226,513	234,536	220,171
Earnings per share/unit - basic:
Net (loss) income available to common stockholders	$ (0.40)	$ 0.64	$ 0.43	$ 1.33
Net income (loss) per share
Net (loss) income	$ (0.40)	$ 0.63	$ 0.43	$ 1.32
Net income (loss) per unit
Potentially antidilutive shares excluded	904
Omega OP
Numerator:
Net (loss) income	$ (93,768)	$ 142,948	$ 100,471	$ 290,801
Add/deduct: net loss (income) attributable to noncontrolling interests	3	9	9	9
Net (loss) income available to common stockholders/owners	$ (93,765)	$ 142,957	$ 100,480	$ 290,810
Denominator:
Denominator for basic earnings per unit	233,675	224,440	233,471	218,387
Effect of dilutive securities:
Net forward share contract		319		106
Noncontrolling interest - Omega OP Units		1,754	1,065	1,678
Denominator for diluted earnings per unit	233,675	226,513	234,536	220,171
Earnings per share/unit - basic:
Net (loss) income available to owners'	$ (0.40)	$ 0.64	$ 0.43	$ 1.33
Net income (loss) per unit
Net (loss) income	$ (0.40)	$ 0.63	$ 0.43	$ 1.32
Potentially antidilutive shares excluded	904

SUPPLEMENTAL DISCLOSURE TO CO_3

SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	$ 35,951	$ 40,860	$ 24,117
Restricted cash	4,164	1,372	9,263
Cash, cash equivalents and restricted cash at end of period	40,115	42,232	$ 33,380	$ 11,671
Supplemental Information:
Interest paid during the period, net of amounts capitalized	174,247	170,045
Taxes paid during the period	5,493	3,510
Non cash investing activities
Non cash acquisition of a business (see Note 2)		(566,966)
Non cash acquisition of real estate (see Note 2)		(143,174)
Non cash proceeds from sale of real estate investments (See Note 4)	83,910
Non cash placement of mortgages (see Note 4)	(86,936)
Non cash collection of mortgage principal		11,874
Non cash investment in other investments (see Note 5)	(121,139)	(25,925)
Non cash proceeds from other investments (see Note 5)	68,025	149,542
Non cash proceeds from direct financing lease		4,970
Initial non cash right of use asset - ground leases		5,593
Initial non cash lease liability - ground leases		(5,593)
Non cash financing activities
Debt assumed in merger (see Note 2)		285,100
Stock exchanged in merger (see Note 2)		281,865
Non cash borrowing of other long-term borrowings	6,459
Change in fair value of cash flow hedges	(1,637)	(9,316)
Remeasurement of debt denominated in a foreign currency	$ (4,000)	$ (4,760)

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Detail) $ in Thousands	Nov. 01, 2020USD ($)facilityitem	Oct. 14, 2020USD ($)	Oct. 09, 2020USD ($)	Sep. 30, 2020USD ($)facility	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)facility	Sep. 30, 2019USD ($)	Oct. 31, 2020USD ($)
Number of real estate properties \| facility				976		976
Approximate purchase price						$ 26,000
Initial annual contractual cash rent				$ 81,424	$ 199,193	$ 517,384	$ 579,621
Subsequent event \| Facilities Acquired \| 7 Facilities
Number of real estate properties \| facility	7
Approximate purchase price	$ 78,000
Number of Operating Beds \| item	876
Initial annual contractual cash rent	$ 7,400
Senior Notes Due 2031 \| Senior Notes [Member]
Debt Instrument, Maturity Date						Feb. 1, 2031
Senior Notes Due 2031 \| Subsequent event \| Senior Notes [Member]
Aggregate principal amount			$ 700,000					$ 700,000
Interest rate			3.375%					3.375%
Percentage of issue price on face value of debt			98.249%
Net proceeds from issuance of notes			$ 680,500
Interest Rate Swap \| 2015 term loan and the Omega OP term loan \| Subsequent event
Notional amount		$ 275,000
Amount of swap agreement paid		$ 11,000
Skilled Nursing Facilities \| Subsequent event \| Facilities Acquired \| 7 Facilities
Number of real estate properties \| facility	6
Assisted Living Facilities \| Subsequent event \| Facilities Acquired \| 7 Facilities
Number of real estate properties \| facility	1